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ABSTRACT 
Recent guidelines for the management of stable coronary artery disease (CAD) and 
myocardial revascularisation emphasise the importance of the presence of ischaemia for 
guiding revascularisation. Cardiovascular Magnetic Resonance (CMR) perfusion imaging and 
fractional flow reserve (FFR) are two methods of physiological ischaemia assessment, one 
invasive and the other non-invasive.  
In order that the results are interpreted accurately, it is important to be aware of the 
limitations and advantages of each technique. These techniques measure different 
parameters so it is not uncommon that the two tests may lead to differing results in one 
patient. In addition, the extent and not just the presence of ischaemia are increasingly 
considered to be an important variable that needs to be considered. 
The aim of this thesis is to assess the similarities and differences in ischaemia assessment 
between the two tests, in particular in the assessment of ischaemic burden and also on 
specific clinical scenarios such as microvascular and multivessel disease. 
Firstly, a close correlation between the extent of ischaemia measured by CMR and the FFR 
value itself is demonstrated. FFR measurement has previously been used as an indicator of 
the presence of ischaemia alone and the relationship with ischaemic extent has never been 
proven. It is an interesting finding, which lends weight to the strategy of targeted 
revascularisation aiming for the greatest reduction in ischaemic burden. The FFR value itself 
as an indicator of ischaemic burden is also useful in centres that do not have access to 
sophisticated imaging techniques such as CMR. 
Secondly, another simple method of invasive estimation of ischaemic burden is 
demonstrated via the use of a functional jeopardy score. This is validated against CMR but is 
limited by a tendency to overestimate the extent of ischaemia. The use of the FFR value 
itself, as demonstrated in chapter 4, therefore offers better potential as a marker of 
ischaemic extent. 
Two examples of areas where there may be discrepant results are in patients with 
multivessel disease and patients with microvascular disease. A comparative analysis of the 
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diagnostic accuracy of these two tests in multivessel disease demonstrates reasonable 
concordance but does lead us to question which test is the diagnostic reference standard. In 
the discrepant cases, it is unclear whether CMR underestimates or FFR overestimates the 
number of perfusion territories. 
Finally, a novel method of non invasively differentiating between multivessel disease and 
microvascular disease is demonstrated, providing a feasible solution to this diagnostic 
dilemma.  Multivessel CAD and microvascular disease can be accurately distinguished using 
the novel concept of perfusion dephasing analysis, which analyses the spatio-temporal 
variability in the distribution of myocardial perfusion to the LV myocardium. An improved 
diagnostic algorithm of CMR is therefore proposed, including the analysis of the variance of 
time to peak signal intensity, the most accurate index for perfusion dephasing. This has the 
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Myocardial ischaemia as a consequence of coronary artery disease  (CAD) is a major cause of 
mortality and morbidity.  
There are many different methods of ischaemia assessment, which are the subject of intense 
research with the aim of improving assessment and guiding therapy. Recently, the use of 
ischaemic burden to target revascularisation is gaining interest as a therapeutic goal with the 
aim of providing prognostic benefit for the patient. 
Cardiovascular Magnetic Resonance (CMR) perfusion imaging is increasingly used as a 
method of ischaemia assessment due to its high diagnostic accuracy and potential for the 
measurement of ischaemic burden. However, not all centres have access to CMR perfusion 
imaging whilst most interventional practices increasingly use fractional flow reserve (FFR) for 
the assessment of ischaemia.  
This thesis seeks to further our understanding of the differences between CMR and FFR in 
the assessment of ischaemia and ischaemic burden and, in particular, the areas of 
discordance between the two methods. The ability to understand these differences allows 
the more appropriate selection of assessment method thus bringing us closer to our goal of 
improved patient care. 
The first part of this thesis focuses on the assessment of ischaemic burden. The second part 
concentrates on the areas of discrepancy between the two tests with a particular focus on 
microvascular and multivessel disease. 
 
Chapter 1 In the first chapter I review the evidence for the use of CMR and FFR for the 
physiological assessment of ischaemia. In particular I focus on the importance of using 
ischaemia and ischaemic burden to guide revascularisation. 
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Chapter 2  In this chapter, I describe the potential areas of discrepancy between the two 
diagnostic modalities. An understanding of these is vital for the appropriate interpretation of 
test results and subsequent decision making for the patient. 
 
Chapter 3  Describes the concept, design, and the rationale behind the MR-INFORM trial. 
This is a randomised-controlled trial comparing stress perfusion CMR with FFR to guide the 
management of patients with stable coronary artery disease. 
 
Chapter 4 In this chapter, I examine the correlation between FFR value and the extent of 
ischaemia measured by CMR. Although the FFR value provides a measure of the physiological 
significance of a stenosis, its relationship with ischaemic burden has never previously been 
described.  
 
Chapter 5 Describes the validation by CMR of an invasive method of measuring 
ischaemic   burden.   In   this   chapter   a   novel   “functional   jeopardy   score   “   is   described   and  
tested. This is particularly useful in centres, which do not have access to a non-invasive 
perfusion service. 
 
Chapter 6 Compares areas of discordance in patients with multivessel disease. It is 
recognised that there is a potential for discrepancy between invasive and non-invasive 
assessment of ischaemia in patients with multi-vessel disease. A comparison between CMR 
and FFR in this complex group of patients has never previously been done. 
 
Chapter 7 Focuses on a new method of differentiation between microvascular and 
multivessel disease by using dephasing analysis. A common diagnostic dilemma is the 
interpretation of widespread circumferential ischaemia, with patients with microvascular 
disease quite often being referred for angiography to rule out significant coronary disease. 
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Any technique that allows differentiation of these two different pathological entities will 
potentially affect patient management. 
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CHAPTER 1: INTRODUCTION 
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Coronary artery disease (CAD) remains a major cause of death and disability around the 
world. In patients with CAD, the accurate diagnosis and assessment of myocardial ischaemia 
is essential both for diagnostic and treatment purposes. Functional information on the 
significance of a coronary artery stenosis is increasingly used to decide on the management 
of patients with coronary artery disease (1). The importance of physiological lesion 
assessment has been acknowledged by the latest European Society of Cardiology (ESC) 
guidelines on myocardial revascularisation (2) (see Fig 1.1), which recommend that 
physiological assessment occur before consideration for revascularisation, especially for 
intermediate lesions. Revascularisation of lesions without functional significance can then be 
deferred if required. The European guidelines(2) have suggested the implementation of a 
multi-disciplinary heart team consisting of an imaging specialist, an interventionist, and a 
cardiac surgeon with the documentation of ischaemia using non-invasive imaging prior to 
making a decision. Additionally, the guidelines also highlight the importance not only on the 
presence of ischaemia, but also the extent of ischaemia i.e. ischaemic burden to be used to 
guide decision-making. 
Non-invasive imaging modalities that incorporate ischaemia assessment include perfusion 
imaging by single photon emission computed tomography (SPECT), stress echocardiography 
and cardiovascular magnetic resonance  (CMR) perfusion imaging. CMR perfusion imaging is 
a relative newcomer in the arena of diagnostic imaging. While most literature on non-
invasive assessment of ischaemia is based on SPECT, CMR has shown advantages such as 
higher spatial resolution (3, 4) and potentially better diagnostic accuracy (5) whilst avoiding 
the use of ionising radiation. 
Fractional Flow Reserve (FFR) is an invasive assessment of haemodynamically significant 
stenosis that is used in the catheterisation laboratory to guide revascularisation. The ESC 
guidelines(2) recommend FFR guided percutaneous intervention (PCI) when objective 
evidence of vessel related ischaemia has not been established prior to catheterisation.  
Whilst FFR is convenient and relatively easy to use, it gives an indication of the presence of 
ischaemia only, without any indication of its extent.  
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The ESC guidelines(2) also recommend that the heart team should agree on the indication for 
myocardial revascularisation. This includes documented ischaemia or FFR <0.80 for all lesions 
between 50- 90% or >10% ischaemia (see Fig 1.1) 
 
Fig 1.1:  European Society of Cardiology guidelines on myocardial revascularisation. (Adapted 
from (2)) 
 
While there is a significant body of literature on the accuracy of both CMR and FFR for the 
detection of CAD, there are limited data on their comparability in the assessment of different 
clinical scenarios such as multivessel disease and microvascular disease.. 
There are important differences in the two techniques that need to be understood in order 
to appreciate the strengths and limitations of each technique. 
 
1.1 OVERVIEW OF CMR PERFUSION IMAGING 
CMR itself has advantages over other forms of non-invasive imaging in that it allows a 
comprehensive examination of the heart including structure, function, perfusion and scar.  
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This is done without the use of ionising radiation and with sufficiently high resolution to 
delineate transmural differences of myocardial blood flow and scar.  
First pass myocardial perfusion imaging involves achieving maximal coronary vasodilatation, 
usually with intravenous adenosine, and imaging the first passage of a contrast bolus into the 
myocardium. Perfusion of contrast into the myocardium subtended by vessels with flow 
limiting CAD does not increase with stress as much as in myocardium supplied by normal 
vessels. In the clinical setting, this is analysed qualitatively as a defect in the contrast 
perfusion into the myocardial wall visible with stress but not at rest.  
In addition, semi- quantitative analyses such as the upslope of the myocardial time intensity 
curves have been used. Fully quantitative analysis allows the absolute quantification of 
myocardial blood flow (MBF) through the use of complex mathematical modelling. These 
techniques, however, remain within the research arena and are rarely used for clinical 
decision-making. 
 
1.1.1 CMR VALIDATION STUDIES 
Validation of CMR myocardial perfusion imaging has been performed in both animal and 
clinical studies. Initially important animal model studies(6) proved CMR superiority over 
SPECT for the identification of haemodynamically significant CAD. In a study by Lee et al (6), 
instrumented dogs had the circumflex artery partially occluded. Regional differences in flow, 
quantified using microspheres, were compared with CMR and SPECT imaging. The high 
spatial resolution of CMR enabled transmural flow to be evaluated in 3 to 5 layers across the 
myocardial wall. Reductions in subendocardial flow were visually apparent in CMR images. 
Endocardial-to-epicardial gradients in CMR flow increased progressively with stenosis 
severity, whereas transmural flow patterns in remote normally perfused myocardium 
remained normal. Flow reductions of <50% not identified by radionuclide imaging were 
apparent in CMR.  See Fig 1.2 
Additionally absolute quantification of myocardial blood flow by CMR perfusion is well 
validated against microspheres(7, 8). In a study by Christian et al(7), coronary artery 
occlusion was successfully performed in 16 animals. Fully quantitative (i.e. absolute) analysis 
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of myocardial blood flow (MBF) at CMR imaging correlated with microsphere MBF 
measurement (r = 0.95, P < .001) across the full range of blood flow rates encountered (from 
0 to >5.0 mL/min/g). Furthermore, close correlations were demonstrated in the endocardial 
and epicardial segments.  
Reproducibility of perfusion imaging has also been tested in a recent study published by 
Morton et al(9).  16 patients underwent high-resolution 3T perfusion imaging three times 
during a single day to evaluate interstudy reproducibility and the effects of diurnal variation.  
There was reasonable reproducibility of quantitative perfusion measures with a co-efficient 
of variation of 16, 26.8 and 23.95 (%) for global rest and stress perfusion and MPR 
respectively. The reproducibility of LV volumes and function was excellent. There were no 
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Fig 1.2:  CMR, SPECT and microsphere data during pharmacological vasodilatation in animals 
with no (top), moderate (middle) and severe (bottom) reduction in microsphere flow in the 
circumflex bed. Shown from left to right are (1) a single frame from the image stack; (2) CMR 
signal-intensity curves for 12 30-degree sectors (beginning at the most cranial image point 
and proceeding clockwise); (3) the corresponding 99mTc-sestamibi SPECT image; and (4) 
relative CMR curve areas, 99mTc-sestamibi count rates, and microsphere concentrations in 
each 30-degree sector. Peak flow reductions indicated by microspheres are ≥50% and 85%, 
respectively (lower 2 panels). CMR images show homogeneous myocardial contrast 
enhancement in the absence of stenosis, moderately reduced enhancement in the circumflex 
bed with moderate flow reduction, and markedly reduced enhancement with severe flow 
reduction. A transmural gradient in flow is visually apparent in both cases of flow reduction. 
CMR signal-intensity curves have nearly identical initial areas in the absence of stenosis. 
Areas in the circumflex distribution are reduced moderately and markedly with moderate 
and severe flow reductions, respectively. SPECT images show uniform signal intensity in the 
absence of flow reduction and in the presence of moderate flow reduction. A prominent 
perfusion defect is apparent with severe flow reduction. Relative CMR curve areas and 
microsphere concentrations correspond closely in all cases. SPECT count rates are 
homogeneous at rest and remain so with moderate flow reduction but show an 
approximately 50% peak reduction with severe flow reduction. Adapted from (6). 
The diagnostic accuracy of CMR perfusion imaging for the detection of functionally significant 
CAD has been tested in multiple studies with increasingly large patient populations (See table 
1.1).  There is now convincing outcome (10, 11) data as well as evidence from large 
prospective studies (5, 12-14).  
 
1.1.2 CMR OUTCOME STUDIES 
Two recent prospective studies, comparing CMR perfusion imaging with SPECT, have shown 
results favourable for CMR. MR-IMPACT I involved 234 patients at 18 centers and compared 
the results of CMR perfusion imaging with  SPECT,  having  QCA  ≥50  %  as  reference-standard 
(15). The results of this dose-finding study confirmed the high diagnostic accuracy of CMR 
and prompted the design of a second trial aiming to directly compare CMR perfusion imaging 
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and SPECT for detection of CAD, using a similar reference-standard (but this time with the 
inclusion of previous myocardial infarction but no significant stenosis on coronary 
angiography as a CAD equivalent). In the MR- IMPACT II trial(12), 533 patients were enrolled 
in 33 centers. The primary endpoint of CMR non-inferiority vs. SPECT was achieved for 
sensitivity but not specificity when using the perfusion data only, without information from 
LGE.  
CMR had higher sensitivity (75 % vs. 59 %, P=0.03) and lower specificity (59 % vs. 72 %, 
P=0.03). Global CMR perfusion imaging diagnostic performance was superior to SPECT for the 
entire population (465 patients) and in all pre- specified sub-groups such as patients with 
gated- and non- gated-SPECT, patients without prior myocardial infarction, patients with 
multi-vessel disease, both in men as well as women(16). Importantly, these results were 
found using just the CMR perfusion imaging component of the CMR protocol for the direct 
comparison against SPECT. In clinical practice, however, the functional evaluation of 
myocardial contractility and evaluation of myocardial fibrosis/scar are routinely performed as 
part of a comprehensive CMR protocol. Therefore, an even better performance of CMR 
might be expected when these components are integrated in a comprehensive evaluation. 
This was demonstrated in a recent paper published by Greenwood et al(5). They used a 
comprehensive CMR protocol in a 752 patient single centre study, and compared it to SPECT 
using coronary angiography as a reference standard. This is the largest CMR perfusion study 
published so far and demonstrated a sensitivity of 86 % and a sensitivity of 83%, whilst SPECT 
resulted in 66% and 83% (P<0.0001) respectively. 
A meta-analysis published by Hamon et al in 2010(14), involved a total population of 2456 
patients, and revealed a per-patient sensitivity and specificity of 89 % and 80 %, respectively. 
A further meta-analysis of 17, 901 patients showed an area under the curve (AUC) of 0.9055 
for CMR (17), which was similar to PET and superior to SPECT imaging. Nandalur et al (18) in 
another meta-analysis demonstrated a sensitivity, specificity and diagnostic accuracy were 
0.91 and 0.81 respectively. A more recent meta-analysis included 14 studies and 12178 
patients and specifically addressed prognosis in patients with a normal stress perfusion scan 
(19). In these patients, the negative predictive value for non-fatal myocardial infarction and 
cardiac death was 98.12% (95% CI 97.26-98.83). 
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Recent work is now focusing on novel methods of quantitative perfusion analysis to improve 
diagnostic accuracy(4, 20). Methods of CMR perfusion analysis continue to attract significant 
research interest.  As mentioned earlier, these include semi quantitative and fully 
quantitative methods aiming to express myocardial blood flow (MBF) as ml/mg/min. These 
methods, however, remain within the realm of research. 
 
1.2 OVERVIEW OF FRACTIONAL FLOW RESERVE  
The pressure derived fractional flow reserve allows invasive assessment of ischaemia done at 
the time of angiography and demonstrates the extent to which maximal myocardial flow is 
limited by the presence of an epicardial stenosis. FFR is the ratio of maximal myocardial 
blood flow achievable in the presence of an epicardial stenosis (Qs) to the maximal 
myocardial blood flow in the hypothetical case of a completely unobstructed coronary artery 
(Qn).  
FFR =  Qs/ Qn 
Assuming that microvascular and coronary collateral resistances are minimal and constant 
during maximal hyperaemia, FFR can be derived from simultaneous measurement of distal 
coronary, aortic and central venous pressures (Pd, Pa, Pv respectively), obviating the need to 
directly measure myocardial flow(21, 22).  
FFR = Qs/ Qn =  (Pd-Pv)/ (Pa-Pv) 
As an unobstructed epicardial coronary artery poses negligible resistance to flow, the normal 
value for FFR is 1.0 and values below 0.75 reliably predict reversible ischaemia (100% 
specificity) in patients with normal left ventricular functions. Therefore the FFR value of 0.75 
is used to distinguish significant from non-significant stenoses. 
1.2.1 FFR VALIDATION STUDIES 
The initial validation of the pressure-derived FFR was done with an epicardial coronary 
doppler probe in a dog model (21). Five dogs were acutely instrumented with an epicardial, 
coronary doppler flow velocity transducer. FFR was calculated from the pressure 
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measurements and compared with relative maximum coronary artery flow measured directly 
by the doppler flowmeter at three different levels of arterial pressure for each of 12 different 
severities of stenosis at each pressure level (See Fig 1.3). 
  
Fig 1.3. Plots of relation between (Pd-Pw)/(Pa/Pw)(pressure derived fractional coronary 
artery flow reserve) and Qs/Qn (directly measured fractional coronary artery flow reserve) at 
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different arterial pressures and different stenosis in the five experiments. Pa, mean aortic 
pressure; Pv, central venous pressure; Pw coronary wedge pressure. 
Pijls et al (23) validated FFR in humans with single vessel disease. They defined ischaemia as a 
positive result on any of three non-invasive tests done in all of 45 consecutive patients: 
thallium SPECT, stress echocardiography and standard exercise testing. They used this 
approach to guarantee a high sensitivity for the detection of any ischaemia. 
There were a significant number of negative SPECT and stress echo results at FFR values 
lower than 0.75 although in all patients myocardial ischaemia was demonstrated on one of 
the three tests used. In 21 of the 25 patients with an FFR of 0.75 or higher, all of the non-
invasive tests were negative. Of the remaining three patients, two had a positive exercise 
ECG and two had a positive thallium scan. In these three patients, the FFR method yielded 
false negative results, because evidence of inducible ischaemia was present despite an FFR of 
0.75 or higher. The authors argue that, according to sequential Bayesian considerations, the 
composite information from sequentially performed non-invasive tests has a diagnostic 
accuracy of almost 100%. An FFR < 0.75 yielded a specificity rate for detection of inducible 
ischaemia of 100%, a sensitivity of 88% and a diagnostic accuracy rate of 93% versus the gold 
standard of inducible ischaemia on one of three non-invasive tests.  
Reproducibility of FFR was tested performing pressure measurements under varying 
haemodynamic conditions(24). Thirteen patients referred for intervention underwent 
repeated measurements of FFR, CFR, and the hyperaemic flow versus pressure slope index 
(IHDVPS)  (the slope of the instantaneous hyperaemic diastolic coronary flow velocity-aortic 
pressure relation) at baseline, during atrial pacing (110 beats/min), during nitroprusside 
infusion for a drop in systolic blood pressure of 20 mm Hg, and during dobutamine infusion 
(10 microg/ kg/min). The coefficient of variation for FFR was found to be 4.8%, compared 
with 10.4% for CFR and 27.7% for IHDVPS. Similar numbers were found for pacing, 
hypotension, and dobutamine infusion. The reproducibility of FFR with moderate 
haemodynamic manipulations was found to be robust in these patients, however again this 
validation was done in patients with single-vessel coronary artery disease (CAD) and normal 
ventricles.  
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1.2.2 FFR OUTCOME TRIALS 
Although the initial results from the validation study done in humans (23) demonstrated a 
specificity of 100% and a sensitivity of 88%, subsequent studies have not confirmed such 
excellent results. A meta- analysis of FFR vs QCA and non-invasive imaging by Christou et al 
demonstrated a sensitivity and specificity of 76% and 76% of FFR compared with non-
invasive imaging in 31 studies (25). Overall concordances were 61% for lesions with diameter 
stenosis 30-70%, 67% for stenosis >70 % and 95% for stenosis less than 30%. The majority of 
the non-invasive tests were perfusion scintigraphy with some data available for dobutamine 
stress echocardiography. Compared to quantitative coronary angiography (QCA) alone, FFR 
had a sensitivity of 78% and a specificity of 51%. It is noteworthy that there was very poor 
concordance between FFR and QCA reflecting the significant difference between a purely 
anatomical and a physiological estimate of ischaemia. 
However, using FFR to guide revascularisation has been clearly demonstrated to impact on 
subsequent event rates in patients. The DEFER (FFR to determine appropriateness of 
Angioplasty in Moderate Coronary Stenosis) (26) trial showed clearly that in patients with 
functionally non-significant stenosis (FFR>0.75), the annual mortality or rate of myocardial 
infarction was less than 1%. 325 patients scheduled for angioplasty were randomised into 
three groups. If FFR was > 0.75, patients were randomly assigned to the deferral group or the 
PCI performance group. If FFR was < 0.75, PCI was performed as planned and patients were 
entered into a reference group. Overall, the event-free survival was not different between 
the deferred and performed groups (80% and 73%, respectively, p = 0.52), and both were 
significantly better than in the reference group (63%, p = 0.03). The composite rate of cardiac 
death and acute myocardial infarction in the deferred, performed, and reference groups was 
3.3%, 7.9%, and 15.7%, respectively (p = 0.21 for deferred vs. performed and p = 0.003 for 
reference vs. both of the deferred and performed groups. The percentage of patients free 
from chest pain on follow up was not different between the deferred and performed groups. 
Thereby concluding that it is safe to defer lesions with a negative FFR for up to five years  
(27)(See fig 1.4).  
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Fig 1.4: Data from the DEFER study: 5-year follow-up study. 
(Left) Event free survival curves for the DEFER, Perform, and reference groups.  
(Right) incidence of cardiac death/myocardial infarction (MI) for the three groups. Adapted 
from (28)  
Furthermore, the FAME trial (29) showed that in 1000 pts with angiographic multivessel 
disease, in whom the decision to stent was based on the FFR measurement alone (FFR 
<0.80), the rate of adverse events were decreased by 30% in the first year after FFR guided 
PCI in multivessel disease. In this randomised controlled trial, operators randomised all 
electively selected lesions for PCI into an angiography guided or PCI guided approach based 
on an FFR value of less than 0.80 demonstrated a one year event rate of 18.3 % in the 
angiography group, and 13.2% in the FFR group (p=0.02).  After 2 years, the advantage of FFR 
guidance of PCI in multivessel disease increased further with respect to lower mortality and 
myocardial infarction rates. This trial clearly demonstrates that diameter stenosis is not a 
good marker of significance of disease and that treatment should be guided according to 
functional evaluation. The reduction in event rates is likely to be related to fewer implanted 
stents having fewer procedure-related early and late stent complications. 
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Many of the earlier FFR and certainly most of the validation studies used an FFR value of 0.75 
or below as the threshold for significance. The newer studies all use a threshold of 0.80 
incorporating   the   traditional   “grey-zone”   between   0.75   and   0.8. The rationale behind this 
decision is not clearly stated and it does raise the question of whether the results of the 
initial validation trials show the same high diagnostic accuracy with the use of a different 
threshold for significance. 
The FAME 2 trial (30) is a prospective multicentre RCT comparing FFR guided PCI and medical 
therapy with medical therapy alone in lesions with an FFR result of less than 0.8. This trial 
enrolled 1220 patients but was halted early. Patients with stable CAD  (11% asymptomatic, 
16 % with silent ischaemia, 66 % with class 1- 2 symptoms) for whom PCI was being 
considered, had all stenoses assessed by FFR (76% had single vessel disease by FFR). The 
primary end point was a composite of death, myocardial infarction, or urgent 
revascularisation 
Recruitment for this trial was halted prematurely because of a significant between group 
difference in the percentage of patients who had a primary endpoint event  (4.3% vs 12.7%). 
This was largely driven by a difference in the rate of urgent revascularisation with 50 % of 
these patients having an unstable event. Neither the rate of death or the rate of myocardial 
infarction differed significantly between the two groups.  There  were  only  33  “hard  events”  
of which there were only 4 deaths  (3 in the OMT arm; 1  in  the  PCI  arm)  and  29  MI’s  (14 in 
the OMT arm; 15 in the PCI arm). Of note, the urgent revascularisation end-point was largely 
a clinical one and did not require objective evidence of either abnormal biomarkers or 
electrocardiographic ischaemia in all patients to meet this endpoint. Of the 56 unplanned 
hospitalisations resulting in urgent revascularisation, 29 (52%) were not accompanied by any 
objective findings of high-risk ischaemia or biomarker positivity. Due to the early 
termination, the effect of PCI on symptom reduction was not shown to be significant beyond 
6 months. It seems therefore that the benefit of PCI over OMT was not demonstrated in 
terms of hard events or symptoms, thereby again fuelling the controversy surrounding the 
advantages of PCI. 
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1.3 STUDIES OF DIRECT COMPARISON BETWEEN CMR AND FFR 
There have been a number of comparative studies between CMR and FFR, predominantly for 
the validation of CMR perfusion imaging against FFR for discrimination of the haemodynamic 
significance of intermediate stenosis (see table 1.1 for a list of comparative trials). In a 
population of 101 patients with suspected angina, Watkins et al reported an excellent per- 
patient sensitivity (95 %) and specificity (91 %) for detection  of  FFR  ≤0.75,  stating  that  CMR  
performance seems to be even higher than previously reported(31). Jogiya et al assessed 53 
patients with 3D whole heart perfusion CMR and FFR in vessels with > 50 % severity 
angiographically(32). The sensitivity, specificity, and diagnostic accuracy of CMR for the 
detection of CAD were 91%, 90% and 91% on a per patient basis.  Bettencourt et al 
confirmed these findings, reporting a per- patient sensitivity and specificity of 93 % and 87 % 
respectively, using the same FFR threshold as reference and values of 89 % and 88 % using an 
FFR threshold of 0.80 which is most commonly used in current clinical practice (33). Both 
studies showed better results in vessel- and patient- based analysis when the functional 
standard (FFR) was used as opposed to QCA, suggesting that the accuracy of CMR 
performance is underestimated when compared with an anatomical reference-standard. 
Further developments are continuously being reported in the field of CMR. Whole-heart 3D 
dynamic perfusion allows determination of the myocardial ischaemic burden holding the 
promise for better non-invasive therapeutic guidance and risk stratification. 
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Table 1.1: Major CMR, FFR and comparative trials 













Nagel et al(11) 2003 84 51 CXA≥75% 88 90 
Ishida et al(34) 2003 104 74 CXA≥70% 98 95 
Doyle et al(35) 2003 185 14 CXA≥70% 57 78 
Plein et al(36) 2004 68 82 CXA>70% 96 83 
Takase 
etal(37) 
2004 102 75 CXA>50% 93 85 
Giang et al(38) 2004 44 64 CXA≥70% 93 75 
Plein et al(39) 2005 82 72 CXA≥70% 88 74 
Klem et al(40) 2006 92 40 CXA≥70% 89 87 
Pilz et al(41) 2006 171 66 CXA>70% 96 83 
Merkle et 
al(42) 
2007 228 67 CXA>70% 96 72 
Schwitter et 
al(15) 
2008 225 76 CXA≥50% 85 67 
Gebker et 
al(43) 
2008 101 69 CXA≥50% 90 71 
Klem et al(40) 2006 92 27 CXA≥50% 89 87 
Klein et al(44) 2009 78 69 CXA>50% 67 88 




2010 62 66 CXA>50% 90 81 
Stolzmann et 
al(46) 
2011 65 60 CXA≥50% 78 88 
De Mello et 
al(47) 
2011 54 69 CXA≥70% 92 84 
Gebker et 
al(43) 
2012 78 69 CXA≥70% 92 83 
Schwitter et 
al(12) 
2012 425 49 CXA≥70% 67 61 
Greenwood et 
al(5) 
2012 752 39 CXA 86 83 
FFR studies  
Pijls et al(48) 1995 60  X ECG BCV 0.7
4 
De Bruyne et 
al(49) 
1995 60  X-ECG BCV 0.7
2 










1997 37  DSE BCV 0.6
8 



















2004 21  DSE n/a n/a 














De Bruyne et 
al(57) 
2001 57  MIBI-SPECT 
post MI 
82 87 
Samady et al 
(58) 
2006 48  MIBI-SPECT 
post MI 
88 93 
CMR vs FFR  
Rieber et 
al(59) 
2006 43 31 FFR ≤  0.75 93 57 
Costa et al(60) 2007 30 32 FFR ≤0.75 93 57 
Futamatsu et 
al(61) 
2007 30 32 FFR ≤0.75 93 57 




2009 101 77 FFR ≤0.75 95 91 
Kirschbaum et 
al(62) 
2011 50 43 FFR <0.80 97 60 
Lockie et 
al(63) 
2011 42 42 FFR ≤0.75 82 94 
Bettencourt et 
al(33) 
2012 103 44 FFR ≤0.80 89 88 
Bernhardt et 
al(64) 




2012 53 64 FFR ≤0.75 91 90 
Manka et 
al(65) 
2012 109 58 FFR ≤0.75 90 82 
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1.4 ASSESSMENT OF ISCHAEMIC BURDEN 
Whilst CMR and FFR may be accurate and reproducible measures of ischaemia, whether 
ischaemic extent is the important variable to be considered in decisions regarding 
revascularisation is now also being considered.  
Hachamovitch (66) assessed survival in 10 627 patients who had undergone clinical SPECT 
studies in a single US centre. Patients with no or mild baseline ischaemia had an improved 
prognosis with medical therapy compared with revascularisation, while conversely those 
with moderate-to-severe ischaemia had an improved prognosis with revascularisation. An 
ischaemic threshold of 10– 12.5% of myocardium differentiated patients who benefited from 
revascularisation from those who did not (fig 1.5). The relationship between % ischaemic 
myocardium and the log of the hazard ratio for revascularisation versus medical therapy 
based on this Cox model (fig 1.5) revealed that in the setting of no or mild amounts of 
inducible ischemia, patients undergoing medical therapy had a survival advantage over 
patients undergoing revascularisation. These 2 lines intersect at a value of approximately 
10% to 12.5% ischaemic myocardium, above which the survival benefit for revascularisation 
over medical therapy increases as a function of increasing amounts of inducible ischaemia. 
Even though these data are from a very large cohort and the conclusions are interesting, 
there are inherent limitations to the study as it was a non- randomised, retrospective 
observational study that used a propensity score to adjust for non-randomisation. 
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Figure 1.5: Relationship between myocardial ischaemia burden and the hazard ratio for 
cardiac death in patients treated with revascularisation (Revasc) versus medical therapy 
(Medical Rx). A threshold of 10-12% ischaemia burden defines those who appear to derive a 
prognostic benefit from revascularisation; adapted from (66). 
The landmark randomised controlled COURAGE trial (67) on the other hand concluded that 
there is no prognostic benefit from PCI in addition to optimal medical therapy as an initial 
treatment for stable CAD. This was despite the fact that the majority of participants had 
objective evidence of ischaemia at baseline, including 54% of patients with reversible defects 
on nuclear imaging. 
These data generated considerable controversy and led many to re-evaluate entirely the role 
of PCI in stable CAD. It seems paradoxical that there was no incremental benefit from PCI 
given that the presence of demonstrable ischaemia confers a worse prognosis.  Although 
there are a number of possible explanations for this, the most likely is because the study 
design favoured inclusion of lower risk patients with a lower burden of pre-treatment 
myocardial ischaemia. For example, patients with an exercise test positive in the first stage 
were excluded and only a third of patients in the PCI arm had a significant reduction of 
ischaemia following PCI. 
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In apparent contradiction to the main study, the nuclear substudy of the same trial (68) 
suggested that PCI might confer a prognostic benefit in patients with a significant ischaemic 
burden and improved patient selection may allow this benefit to be realised. 
In a more recent observational study by Hachamovitch et al (69), 13 969 patients who 
underwent adenosine or exercise SPECT, were identified and a percentage ischaemic 
myocardium and percentage fixed myocardium was calculated.  These patients were then 
followed up and those patients with a high ischaemic percentage and without prior 
myocardial infarction (MI) demonstrated a benefit from early revascularisation. This benefit 
was not evident in those patients with prior scarring. The survival of patients with minimal 
ischaemia was superior with medical therapy without early revascularisation.  
These studies form part of the emerging evidence that for patients to really derive prognostic 
benefit from revascularisation, an approach geared towards significant ischaemia reduction 
should be adopted. 
 
1.4.1 INVASIVE ASSESSMENT OF ISCHAEMIC BURDEN 
Both FFR and invasive angiography are limited in that they  don’t   allow  direct measures of 
ischaemic burden. 
To overcome this limitation several jeopardy scores have been developed and validated (70, 
71).  These scores are based on the location and anatomical severity of coronary lesions; 
however, they do not incorporate the functional significance of a stenosis.  
The APPROACH (72) anatomical score divides the left ventricle into regions according to 
pathological studies in humans evaluating the relative proportion of myocardium perfused by 
each coronary artery. In the modified version, the vessel dominance, site of occlusion and 
size of the major branches of the infarct related artery are taken into consideration.  
The BCIS score is a contemporary score(71, 73), derived from the Duke score. The Duke 
Jeopardy score is calculated by dividing the coronary tree into six segments of nearly equal 
myocardial perfusion (i.e. left anterior descending artery, major septal perforator, major 
diagonal branch, circumflex artery, major obtuse marginal artery and posterior descending 
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artery). A score of two is given for each significant lesion in a myocardial territory. The BCIS 
score allows for the classification of graft and left main stem disease by ascribing points to a 
left main lesion of >50% and to significant graft lesions. 
Although there are a number of different jeopardy scores, their use is mainly confined to 
research applications. 
 
1.4.2 CMR ASSESSMENT OF ISCHAEMIC BURDEN 
Most of the studies using ischaemic burden have traditionally used SPECT as the non-invasive 
imaging modality. There is some evidence(74) that the prognostic threshold for significant 
ischaemia applies to CMR also, but there are no direct  comparative trials related to this.  In 
preliminary analysis of 10 patients who underwent CMR and SPECT scanning, the mean 
percentage of inducible ischaemia was 7.3% (range 0-22.2%) for CMR and 10.3% for SPECT 
(range 0-25.0%). Overall there was no significant difference (P=0.47) (74) 
In a recent study, Jogiya et al measured ischaemic burden by visual analysis of CMR 
images(75) demonstrating good correlation with the Duke Jeopardy score (r=0.82). Morton 
et  al  showed  that  a  BCIS  score  ≥6  predicts  an  ischaemia  threshold  of  12%  on  CMR  with  high  
specificity (76). However, both of these studies have used an anatomical score, without 
correction for haemodynamic relevance and, as mentioned earlier, the concordance 
between anatomical severity and physiological evaluation by FFR is poor. 
Manka et al (65) used 3D perfusion technique to compare the FFR significant lesions with the 
volume of myocardial hypo-enhancement. They found that a cut off value of 4.4% ischaemic 
burden corresponding to a FFR threshold of 0.75 resulted in a sensitivity and specificity of 
86.5% and 86.3% respectively.  
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CHAPTER 2: AREAS OF DISCREPANCY BETWEEN CMR AND 
FFR 
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There are important fundamental differences in the measurement of ischaemia by CMR and 
FFR. FFR is primarily a method of vessel specific lesion assessment and CMR perfusion 
imaging focuses on the effect of a functionally significant stenosis on myocardial blood flow. 
CMR perfusion imaging gives an indication of Coronary Flow reserve (CFR), which reflects the 
combined impact of epicardial and microvascular resistance on limiting hyperaemic blood 
flow. Because of the different nature of assessment there are certain clinical scenarios in 
which the results of these two tests will differ.  
In this chapter, the areas of potential discrepancy will be reviewed. 
 
2.1 MICROVASCULAR DISEASE  
A common area that can cause discrepancy between the results of non-invasive and invasive 
tests is in coronary microvascular disease, in which functional and structural abnormalities of 
the coronary microvasculature can lead to microvascular ischaemia. 
Microvascular disease is defined as reduced coronary flow reserve in the absence of an 
epicardial stenosis and can be primary or secondary. Primary microvascular disease occurs in 
the absence of any other cardiac cause and the underlying disorder is thought to be due to 
vascular abnormalities of the endothelial cells, smooth muscle cells and the autonomic 
nervous system resulting in raised microvascular resistance. Secondary microvascular disease 
can occur due to conditions such as hypertension, hypercholesterolaemia, left ventricular 
hypertrophy and diabetes. Similar mechanisms are at play in patients with risk factors for 
CAD. Left ventricular hypertrophy is also thought to result in raised microvascular resistance 
due to increasing myocardial fibrosis. Furthermore, having epicardial coronary disease itself 
is associated with concomitant microvascular disease.  
 
2.1.1 CMR IN MICROVASCULAR DISEASE  
With CMR perfusion imaging, stress perfusion imaging relies on the difference between 
hyperaemic and baseline blood flow, the CFR. CFR reflects the combined impact of epicardial 
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and microvascular resistance on limiting hyperaemic flow, therefore conditions affecting 
myocardial and microvascular resistance such as age, left ventricular hypertrophy, diabetes 
mellitus, or myocardial infarction will affect the value of CFR, independent of epicardial 
coronary disease.  
It is therefore plausible that in patients with significant microvascular dysfunction, a 
perfusion defect demonstrating ischaemia may be visible in the absence of significant 
epicardial disease. This group of patients would be similar to the patient group studied by 
Meuwissen et al (77) in which FFR was > 0.75 but CFR was <2.0, reflecting higher 
microvascular resistance (see Fig 2.1). 
However, whether patients with microvascular disease and normal coronary arteries, do 
have myocardial ischaemia is heavily debated. This conflict is epitomised by SPECT perfusion 
data in patients with syndrome X, with some studies showing abnormal perfusion in the 
majority of these patients(78)and others showing no correlation between perfusion defects 
and CFR(79). 
The capability of CMR itself for detecting subendocardial ischaemia, in microvascular disease 
is also unclear, despite the superior spatial resolution. A study by Panting et al (80)showed 
that patients with angina and normal coronary angiography have a reduction in the ratio of 
subendocardial to subepicardial myocardial perfusion on CMR, suggesting ischaemia is the 
cause of symptoms in this patient group. However, Vermeltfoort (81) in a similar study 
design using CMR found no difference in subendocardial and subepicardial perfusion in 
response to adenosine. The reason for the contrasting findings is not clear but it has been 
suggested the findings seen in the Panting study may have been due to an artefact of the 
first pass sequence(82).  
Lanza et al (83) showed that dobutamine induced stress abnormalities in the left anterior 
descending artery (LAD) territory at peak stress in cardiac syndrome X (CSX) patients were 
associated with a reduced CFR in the LAD (measured by transthoracic echo doppler study) in 
response to adenosine suggesting microvascular dysfunction as an aetiology. 
In another study by Yilmaz et al (84) symptomatic patients with normal coronary arteries 
underwent CMR perfusion testing, coronary angiography and achetylcholine testing in 42 
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patients. They found that, during intracoronary acetylcholine testing, those patients with a 
reversible stress induced perfusion defect were more likely to have a coronary epicardial or 
microvascular vasoreaction (20/22). Those without a perfusion defect were less likely to have 
a reaction to acetylcholine (10/20). 
In contradistinction to the above study, a recent study by Karamitsos (85) et al, examined 18 
patients with CSX chest pain, abnormal exercise test, normal coronary angiogram without 
other causes of microvascular dysfunction and assessed oxygenation with a BOLD sequence 
and also quantified myocardial blood flow. There were no significant differences in MBF at 
stress, BOLD signal change and coronary flow reserve measurements in CSX patients and 
controls respectively. The only significant difference demonstrated between the two groups 
was that the group with syndrome X experienced more chest pain. This study is interesting as 
the patients are characterised very well however, rather than finding conclusive answers, it 
does add further fuel to the debate regarding this difficult patient group. 
  
2.1.2 FFR IN MICROVASCULAR DISEASE 
By definition, primary and secondary microvascular disease occur in the presence of normal 
coronary arteries. Therefore, in the absence of epicardial coronary stenosis, the FFR will be 
negative. 
However, consideration needs to be given to the assessment of epicardial disease in the 
presence of increased or variable microvascular resistance. For the accurate interpretation of 
FFR in this scenario it is important to recapitulate how FFR has been derived. 
 
FFR myo = Qs/Qn 
Which equates to the fraction of maximal flow to the myocardium in the presence of a 
stenosis (Qs) to the theoretical maximal flow in the same myocardial bed without a stenosis 
(Qn).  
According to Ohms law, Flow= pressure /resistance  (Q= P/R) 
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    FFR myo =Qs/Qn = (Ps/Rs)/ (Pn/Rn)  
Furthermore, Ps is defined as the measure mean pressure distal to a stenosis (Pd) minus 
mean venous pressure (Pv). Pv here is an estimate of residual myocardial capillary perfusion 
pressure. The same applies to Pn 
FFRmyo =  Qs/Qn =  (Pd-Pv)/r 
       (Pa-Pv)/r 
Also, during maximal hyperaemia, it is assumed that myocardial resistance of a stenotic bed, 
Rs, or a normal bed Rn would be minimal, constant and comparable. 
Therefore R cancels from the equation, and if venous pressure is assumed to be small then 
the equation approaches  
   FFRmyo =  Pd/Pa 
 
It is important to understand that the measurement of FFR is based on a number of 
assumptions such as myocardial resistance is negligible and constant and that venous 
pressure is small.  As mentioned earlier, most of the human FFR validation studies were done 
in patients with single vessel disease and normal ventricular function. In patients with more 
complex disease i.e. multivessel disease or with reduced ventricular function, microvascular 
resistance is more likely to be raised, inconstant or heterogeneous.  
Even in the absence of coronary narrowings, there is a huge variation in microvascular 
resistance between patients and even between coronary territories. In a study by Meuwissen 
et al (77), 150 lesions (between 40% and 70% diameter stenosis by visual stenosis) in 126 
patients were assessed with FFR and CFR. Agreement between outcomes of FFR and CFR, 
categorised at cut-off values of 0.75 and 2.0 respectively, was observed in 109 coronary 
lesions (73%).  In 27% of lesions there was a discrepancy between FFR and CFR (See Fig 2.1). 
In the group where FFR was >0.75 and CFR < 2.0, there was a significantly higher measured 
microvascular resistance (defined as the ratio of mean distal pressure to average peak blood 
flow velocity during maximal hyperaemia) (overall range 2.42±0.77 vs1.91±0.70 mmHg.cm-
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1.s-1). There also was a significant variability in the measured microvascular resistance 
(overall range 0.65 to 4.64 mmHg.cm-1.s-1).  This suggests that if microvascular resistance 
increases then CFR will decrease and FFR will increase despite an anatomically fixed stenosis. 
The variability in microvascular resistance exists across individuals and perfusion territories. 
This study challenges the notion that microvascular resistance is constant and negligible and 
emphasises the importance of combined pressure and flow velocity measurements to 
evaluate coronary lesion severity and microvascular involvement.  
 
 
Fig 2.1:  Scatterplot of FFR vs CFR (n=150). Data were categorized on basis of cut-off values. 
Group A had FFR<0.75 and CFR≥2.0; Group B had FFR ≥0.75 and CFR<2.0. Adapted from (77). 
 
The effect of varying microvascular resistance means that the assumptions underlying the 
calculation of FFR may not always be correct, and FFR may not be accurate when 
microvascular resistance is not constant and minimal. In these cases there may be significant 
discordance between CFR and FFR measurement. Although the population studied by 
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Meuwissen et al (77) was fairly diverse including patients with diabetes mellitus, 
hypertension, left ventricular hypertrophy and restenosis, it is interesting to surmise whether 
in patients with higher levels of comorbidity and diffuse disease, concordance is worse. If 
microvascular resistance is variable in the presence of diffuse coronary disease, distal 
coronary pressure in the stenotic bed is likely to be higher than that in the proximal bed that 
will lead to a higher FFR value, independent of stenosis severity. 
 Chameleau et al (86) investigated the effect of the severity of an epicardial stenosis on 
microvascular resistance in 27 patients with coronary artery disease and stable angina.  All 
patients had an angiographically normal coronary artery, an artery with an intermediate 
lesion, and an artery with a severe lesion: the latter was treated with angioplasty. The ratio 
of mean distal pressure to average peak blood velocity was used as an index of microvascular 
resistance. They demonstrated that there was a positive association between coronary lesion 
severity and variability of distal microvascular resistance that normalizes after angioplasty. 
Additionally, there was also heterogeneity of microvascular resistance between perfusion 
territories.  
This finding is further tested in a study by De Luca et al(87) who used increasing doses of 
intracoronary vasodilator and assessed the effect of progressive vasodilatation on FFR. FFR 
was assessed in 50 intermediate lesions in 46 patients with increasing doses of adenosine up 
to 720Ug administered as intracoronary boluses. Increasing doses of adenosine progressively 
decreased FFR values and increased the percentage of patients showing an FFR <0.75. In 
addition, lesion length and stenosis severity were independent angiographic determinants of 
FFR. 
Whether these theoretic concerns make a clinical difference requires more thorough 
validation of FFR in different coronary and microvascular physiological disease states. 
 
2.2 MULTIVESSEL DISEASE 
Although there are extensive validation studies for both FFR and CMR perfusion, there is less 
data available for diagnostic accuracy of the two tests specifically in multivessel disease.  This 
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assessment can be more complex due to the presence of raised and variable microvascular 
resistance and other co-morbidites and risk factors.  
 
2.2.1 CMR IN MULTIVESSEL DISEASE 
The diagnosis of functional significant coronary artery disease in patients with multi-vessel 
disease has traditionally been seen as a challenge for non-invasive imaging tests. 
Most previous studies specifically aimed at patients with multi-vessel disease have 
predominantly used SPECT as the non-invasive imaging test. In a study by Lima et al (88) in 
143 patients with proven angiographic 3–vessel CAD, myocardial perfusion imaging with 
SPECT demonstrated no significant perfusion defect or a single vessel pattern of disease in 
only 54% of patients. This may be due to the lower sensitivity of SPECT, which has been 
attributed to its relatively low spatial resolution(89) or to the well-recognised disparity 
between angiographic and functional information (90). The actual prevalence of true 
functional vs angiographic three vessel disease is low and in the FAME cohort of patients, 
only 14% of the angiographically classified 3- vessel disease group had functional 3- vessel 
disease(91). Additionally in the FAME 2 cohort of patients, only 3% of the patients had 3-
vessel disease by FFR. The low numbers make the characterisation and analysis of a true 
functional multivessel disease patient group more difficult. 
The data on CMR in multivessel disease is limited with most studies assessing multi-vessel 
disease only as a subgroup analysis in larger studies  
The CEMARC study, a large (728 pts) single centre study showed a sensitivity of 86% for CMR 
which was significantly superior to that of SPECT at 66.5%, although specificity was similar 
(5). Subgroup analysis for multivessel disease in the CEMARC trial resulted in good diagnostic 
accuracy (AUC of 0.91 vs 0.77 for SPECT), however the assessment was on a per patient basis 
only and anatomic stenosis severity rather than FFR was used as the reference standard. 
Subgroup analysis in the MR-IMPACT 2 study considering multi-vessel disease, by different 
gender and in patients without prior MI confirmed superior diagnostic accuracy(16). This was 
a multivendor trial in which 533 patients in which patients had SPECT, coronary angiography, 
and CMR in all patients. They demonstrated that the sensitivity of CMR to detect CAD was 
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superior to SPECT and the specificity was inferior to SPECT. A subgroup analysis was done of 
patients who had multivessel disease, and they demonstrated superiority of CMR to SPECT in 
patients with multi vessel disease. See Fig 2.2 
 
 . 
Figure 2.2: Diagnostic performance in the entire MR IMPACT II study population – ROC 
analyses. Diagnostic performance of perfusion-CMR and SPECT imaging compared by 
receiver operating characteristics curves (ROC) analyses for detection of CAD (per patient 
analysis). A). CMR performs superior to all SPECT studies in 1–3 vessel disease (1–3 VD) 
patients and is also superior to the gated-SPECT and ungated-SPECT groups. Difference in 
AUC between gated-SPECT and ungated-SPECT did not reach statistical significance. The dots 
on the ROC curve for CMR indicate the sensitivities and specificities for various thresholds 
(i.e. at summed gradings of 23 [dot on the left, 21 [middle dot], and 19 [dot on the right]) 
with + and – indicating superiority and inferiority vs SPECT, respectively, and = indicating 
non-inferiority versus SPECT for both, sensitivity and specificity, as defined as primary end-
point of the study B): Perfusion-CMR is superior to SPECT in multi-vessel disease patients. 
Sub-group analyses for gated-SPECT and ungated-SPECT yielded superiority for CMR, as well 
(adapted from(12) 
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 A comparative accuracy study done by Chung et al (92) compared SPECT and perfusion CMR 
in patients with angiographic three vessel disease and showed that CMR detected perfusion 
defects in all three vascular territories in 57% of patients vs only 11% with SPECT. 
Although this suggests that CMR performs better than SPECT in multivessel disease, there is 
still paucity of specific data on the accuracy of CMR in multivessel disease, in particular, the 
assessment of diagnostic accuracy on a per vessel basis (Fig 2.3).  Although the higher spatial 
resolution afforded by CMR should improve the diagnostic ability of CMR to accurately 
detect multivessel disease, further evidence is required before CMR can be recommended 
for guidance of revascularisation strategy in multi-vessel disease. 
 
 
Fig 2.3:  Example of CMR and angiographic images of patients with multivessel disease. In 
this case the LAD FFR was 0.7, the Cx was a CTO and the RCA FFR was 0.68. The CMR images 
show a mid ventricular slice demonstrating both an inferior and an anterior territory 
perfusion defect. A Cx artery defect is not well visualised and this may be due to the 
presence of collaterals. 
 
2.2.2 FFR IN MULTIVESSEL DISEASE 
The FAME trial (90) demonstrated that stenting in multivessel disease with FFR guidance 
results in fewer adverse events (death, non fatal MI and repeat revascularisation) than with 
angiography guidance. It has been suggested that this is likely to be due to a reduction in 
stent usage leading to a reduction in events, due to less side branch occlusion or 
embolisation and stent thrombosis. Although this suggests that an FFR guided strategy is 
superior to an angiography guided strategy the utility of stenting in multivessel disease needs 
to be examined more closely.  
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One of the advantages of FFR is that it allows precise localisation of the lesion causing 
ischaemia, which is thought to be superior to the spatial resolution of non-invasive imaging. 
Every artery or segment is analysed separately, and potential masking of one ischaemic area 
by another, more severely ischaemic zone is avoided. However, the utility of FFR to guide 
complete revascularisation  as  opposed  to  a  “targeted  revascularisation” approach needs to 
be considered. 
The COURAGE trial(67) failed to show a benefit for revascularisation when compared with 
optimal medical therapy, albeit in a low risk population with non-complex CAD. PCI was only 
beneficial in terms of ischaemia reduction in patients with significant ischaemia at the start. 
Thus there is an emerging concept that a favourable prognosis results from substantial 
ischaemia reduction rather than complete anatomical revascularisation. 
In the FAME trial (90), the main difference between the angiography and the FFR guided 
groups was a difference in the primary endpoint of mortality and myocardial infarction with 
no significant difference in angina reduction between the two groups (76% vs 80% free form 
angina at two years) (91).  
As alluded to earlier, the higher rate of death and myocardial infarction may be related to 
the increased number of stents used in the angiography guided vs FFR guided strategy (2.7 vs 
1.9 stents per patient respectively). Although there is clear demonstration that an FFR guided 
strategy is better than an angiographic strategy as it reduces the amount of excessive stent 
usage, there is no evidence that stenting in itself leads to symptomatic improvement or 
improved prognosis. 
Thus, it is possible that targeting revascularisation of lesions with a high ischaemic burden 
further, both within the multi-vessel and single vessel cohort could be beneficial in terms of 
symptom reduction as well as further reducing stent utilisation. Although ambitious, there is 
also the potential to aim for the elusive goal of prognostic benefit. 
The recent FAME 2 trial(30) does not provide any further clarification by essentially 
demonstrating that in FFR positive lesions, PCI is better than medical therapy as it reduces 
the need for urgent revascularisation driven by acute events. The impact on hard end-points 
such as mortality is not demonstrated due to the premature termination of the trial. 
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However, what the trial does allude to is a potential difference in outcomes related to 
different FFR values. The benefit of PCI seemed to be more pronounced among patients who 
had lesions with an FFR of less than 0.65 than among the patients who had only lesions with 
larger FFR values. This would be presumed to be due to a larger ischaemic burden associated 
with a lower FFR value. The mean FFR value in both groups was 0.68.  
This suggests that the extent of ischaemia reduction rather than the stenting of all FFR 
positive lesions is the important variable leading to patient benefit. With this in mind, a 
targeted approach dealing with the most severe lesion may be of more benefit than stenting 
all FFR positive lesions in a multivessel disease setting. The associated reduction in stent 
usage with this approach will no doubt be beneficial. 
In addition to FFR being used preferentially to target lesions causing more severe ischaemia, 
the accuracy of FFR measurement in multivessel disease also needs to be considered. This 
requirement for multivessel assessment can occur both within the context of stable and 
unstable CAD. 
In the elective setting, there is a paucity of data regarding the utility of FFR to guide 
revascularisation strategies. One concern is the presence of abnormal microvascular 
resistance, as discussed earlier, which is more likely to be prevalent in this cohort of patients 
with complex CAD. One small study (93) has demonstrated that elective target vessel PCI 
increases non-target vessel FFR due to an increase in remote coronary microvascular 
resistance in patients with normal microvascular function. This is thought to be due to 
generalised vaso-constriction mediated by the adrenergic system and should be taken into 
consideration when interpreting borderline FFR result in the diagnostic grey zone especially 
for FFR assessments that are planned immediately after initial stent implantation. 
 
2.3 MYOCARDIAL INFARCTION 
The assessment of ischaemia after myocardial infarction is more complex than that 
undertaken in an elective setting. There are additional issues to consider such as the 
assessment of bystander disease that is seen in up to 40% of patients, and the impact of 
myocardial scarring.  
    PhD Thesis: Shazia Hussain 
 52 
 
2.3.1 CMR IN MYOCARDIAL INFARCTION 
In the early phase after myocardial infarction, CMR is mainly used for the assessment of 
viability, residual ischaemia and also for the identification of any early mechanical 
complications.  
For the early assessment of bystander disease, adenosine stress CMR has been shown to be 
safe and feasible early after primary PCI and can reliably assess co-existing disease in non-
culprit arteries (94).  Additionally, there is data which shows that post PCI (3 days) CMR via 
visual assessment can identify perfusion defects with 96% sensitivity, 50% specificity, 97% 
positive predictive value, 43% negative predictive value(95). The low specificity in this study 
was explained by the high prevalence of diabetes (16%), hypertension (40%) and 
hypercholesterolemia (32%) causing microcirculatory dysfunction. In addition, the presence 
of acutely injured myocardium or variable amounts of scar was thought to have an 
unpredictable effect on the visual interpretation of myocardial perfusion. This is an 
interesting finding as it suggests that the presence of microvascular dysfunction in these 
patients may affect the CMR interpretation then it is likely to affect the FFR results also.  
One of the real strengths of CMR, however, is in demonstrating areas of scar in patients with 
chronic myocardial infarction. This has been demonstrated to be a well-validated and robust 
technique. The seminal paper by Kim et al (96) demonstrated that with delayed 
enhancement imaging it was possible to predict reversible myocardial injury, which would 
improve after revascularisation. In this study 50 patients had CMR before and after 
revascularisation. Contractility increased in 256 of 329 segments (78 percent) with no 
hyperenhancement before revascularisation, but in only 1 of 58 segments with 
hyperenhancement of more than 75 percent of tissue.  In particular, the identification of an 
epicardial rim of scar is not possible with any other forms of imaging and is important for 
both diagnostic and prognostic purposes. The performance of late gadolinium enhancement 
imaging CMR  (LGE) for the detection of MI has also been tested in an international 
multicentre trial(97). In total, 282 patients with acute and 284 with chronic first-time MI 
were scanned in 26 centres throughout the U.S., Europe, and South America. The study 
showed that the sensitivity of LGE increased with increasing gadolinium dose, reaching 99% 
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and 94% in acute and chronic MI.  Furthermore, when MI was identified, it was in the correct 
location in more than 97% of patients (i.e., the location of hyperenhancement matched the 
perfusion territory of the infarct-related artery). 
Although the interpretation of the extent of ischaemia could potentially be more problematic 
with a high scar burden (see fig 2.4), Plein et al(98) were able to demonstrate that it is 
possible to accurately measure the extent of ischaemia in the presence of scar.  Significantly 
different ischaemia: scar burden ratios were measured in patients with NSTEMI and those 
with STEMI. The ratio of scar to ischaemia was 3.5, 1.0 and 0.2 for Q-STEMI, Non-Q STEMI 
and NSTEMI, respectively.    
 
 
Fig 2.4: Angiographic images showing an occluded circumflex artery well collateralised from 
the RCA. Corresponding CMR images show a lateral perfusion defect that is consistent with 
the area of myocardial scarring demonstrated on the late gadolinium enhancement views. 
The perfusion defect does not extend beyond the area of scar suggesting that there in no 
peri-infarct ischaemia 
 
2.3.2 FFR IN MYOCARDIAL INFARCTION 
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There is a general consensus that in the acute phase of myocardial infarction (MI), FFR is 
neither reliable nor useful to assess the culprit lesions and should be deferred until after 
stabilisation. The main concern is that of raised microvascular resistance as a consequence of 
microvascular injury due to thromboemboli, platelet plugging, coronary vasospasm and 
endothelial dysfunction.  
There have been a number of studies testing the utility of FFR in the early days after acute 
myocardial infarction. Samady et al in one study (58), performed FFR measurements in 
patients in the infarct related artery early in the days after NSTEMI and STEMI and 
subsequently did myocardial contrast echocardiography (MCE) and single photon emission 
computed tomography (SPECT). They demonstrated that early into the infarct, an FFR of 
<0.75 reliably identified the presence of reversible ischaemia.  
De Bruyne et al (57) obtained FFR measurements and SPECT studies before and after PCI in 
57 patients 3.7 +/- 1.3 days after infarction also in the infarct related artery. To identify true 
reversibility, follow-up SPECT was performed 11 weeks after PCI. The sensitivity, specificity, 
and concordance of FFR ≤ 0.75 for detecting true reversibility on SPECT were 88%, 93%, and 
91% (chi-square p < 0.001) and for detecting reversibility on myocardial contrast echo were 
90%, 100%, and 93% (chi-square p < 0.001), respectively. The optimal FFR value for 
discriminating inducible ischaemia on non-invasive imaging was also 0.78, similar to findings 
by Samady et al (58). They concluded that that the 0.75 cut-off value of FFR to distinguish 
patients with positive from patients with negative SPECT imaging is valid after a myocardial 
infarction and that for a similar degree of stenosis, the value of FFR depends on the mass of 
viable myocardium. The diagnostic accuracy demonstrated in this study is commendable but 
correlating an FFR value done early in the days after infarction with a non-invasive imaging 
test done 11 weeks later does raise questions regarding the validity of the findings. In 
another study, McCLish et al (99) demonstrated that for angiographic lesions of matched 
lumen diameter and lesion length, FFR of vessels supplying recently infarcted myocardium is 
similar to FFR in non-infarcted myocardium in a control population. Additionally, the 
correlation between percent diameter stenosis and FFR and the slope of correlation is similar 
in recently infarcted and non-infarcted myocardium. This study was done 1 to 5 days after 
myocardial infarction and suggests that recent infarction and its accompanying microvascular 
injury may not significantly alter FFR measurements.  However, the study is limited by the 
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lack of visualisation of and correction for the extent of infarction. In addition, there was a 
significant difference in LV function between the two groups, which, may impact on 
differences in flow within the coronary arteries, and subsequent FFR results. Overall though, 
FFR assessment has been demonstrated to be a feasible method of assessment in the days 
after infarction. 
During the first few days after coronary occlusion, infarct volume can almost double, because 
of the addition of oedema and myocardial death. Subsequently, infarct volume may shrink to 
25% of its initial volume as necrotic muscle is replaced by scar over 4 to 6 weeks. The 
reduction in the total mass of functional myocardium supplied by a given stenosis in an 
infarct related artery will tend to decrease(57) and therefore, by definition, hyperaemic flow 
and thus hyperaemic gradient will both decrease as well and consequently FFR increases. It is 
argued that this does not mean that FFR underestimates lesion severity after myocardial 
infarction; it just reflects that the visual assessment of a stenotic segment does not 
necessarily reflect its functional importance. This principle is illustrated in Fig 2.5.  
 
Fig 2.5:  Schematic diagram demonstrating the FFR result in patients with myocardial scarring 
(Adapted from (57)) 
Thus, the mass of viable myocardium and also the microvascular resistance in the infarcted 
territory can affect the FFR.  
There has been conflicting data regarding the presence or absence of microvascular 
dysfunction in areas remote from the infarcted territory, with earlier studies suggesting that 
microvascular function would be abnormal in remote regions (100, 101). Recent data, 
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however, suggests that the hyperaemic myocardial resistance in viable myocardium even 
within the infarcted area remains normal (100). This study aimed to assess whether 
microvascular resistance in the infarct area is different from that in the reference area in 
patients with chronic myocardial infarction. In patients with chronic MI and a reduced 
ejection fraction, a good correlation was found between FFR measurements in the infarct 
related artery and RFR (the relative flow reserve) which is the ratio of myocardial blood flow 
in the stenotic area to blood flow in a normally perfused reference area, at maximal 
hyperaemia. The mean FFR and RFR values were 0.75 ± 0.16 and 0.74 ± 0.18, respectively. 
A significant correlation (r = 0.81; P <0.0001) was found between FFR and RFR. The authors 
concluded that microvascular resistance in the viable myocardium does not differ from that 
in the reference area. 
Thus, the data regarding the presence of raised microvascular resistance in patients with 
chronic myocardial infarction is not clear-cut and there is little direct evidence on the 
correlation and accuracy of FFR measurement within the context of chronic myocardial scar. 
Despite these limitations, the application of the established FFR cut-off value in the setting of 
partially infarcted territories appears to be accepted.  
 
2.4 SERIAL STENOSIS / DIFFUSE DISEASE  
With increasingly complex percutaneous interventional procedures being performed, the 
assessment of diffuse disease and serial stenoses also becomes important. For accurate FFR 
measurement interpretation an understanding of the mechanisms of pressure measurement 
is required so that the results may be interpreted correctly.  
As CMR assesses blood flow through the myocardium, the complexity of coronary disease is 
largely irrelevant to the interpretation of the presence of myocardial ischaemia. 
 
2.4.1 CMR IN SEQUENTIAL STENOSIS AND DIFFUSE DISEASE 
In the subgroup of patients, where the FFR measurement may be overestimated thus 
underestimating the severity of disease, CMR perfusion imaging is at an advantage as it does 
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not measure lesion or vessel severity. It assesses the impact on myocardial blood flow of the 
vessel as a whole.  
 
2.4.2 FFR IN THE ASSESSMENT OF SERIAL STENOSIS AND DIFFUSE DISEASE 
It is well recognised that atherosclerosis is diffuse in nature and the presence of diffuse 
disease is often associated with a progressive decrease in coronary pressure and flow or may 
manifest as a series of stenosis. The assessment of serial lesions and diffuse disease 
invasively by FFR is complex.  
Practically, in these cases the measurement of FFR involves the pressure wire being pulled 
back steadily from the distal to proximal vessel segment during continuous hyperaemia 
induced by intravenous adenosine. In the presence of a focal narrowing, there will be an 
abrupt change in distal pressure, whereas in diffuse disease there will a gradual increase.  
However, the very nature of diffuse disease means that even if the FFR reduces across an 
artery, there is no focal narrowing to stent.  To an untrained eye, it may seem that 
angiographically there is no significant disease. Such diffuse disease and its haemodynamic 
impact should always be kept in mind when performing functional measurements. 
In patients with diffuse disease with no focal stenosis, chest pain is often considered non-
coronary because no single focal stenosis is found, and the myocardial perfusion imaging is 
wrongly considered false positive. Both angiographic assessment and FFR measurement will 
be misleading in these circumstances. 
When several stenoses are present in the same artery, it is important to realise in such cases 
that each of several stenoses will influence hyperaemic blood flow and therefore FFR across 
the other one. When a second stenosis is present along the same epicardial vessel, flow 
through one stenosis will be submaximal because of the second stenosis, even during 
vasodilation of the microvasculature. It is, however, possible to assess the FFR value and the 
initial validation work for these measurements was undertaken in 5 dogs with 2 stenoses of 
varying severity(101).The influence of the distal lesion on the proximal  was found to be 
more important than the reverse. For 2 stenoses in series without intervening arterial 
branches the equation of FFR remains valid for determining the haemodynamic 
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consequences of both stenosis together. However, in the case of a normal side branch 
between sequential stenosis, diverting flow to the normal low-resistance branch during 
hyperaemia could reduce flow through the distal stenosis. This phenomenon is called branch 
steal and its quantification requires pressure and flow measurement or quantitative 
angiographic analysis of the entire coronary tree. 
After the initial animal validation work, these measurements were further validated in a 
human study also with 32 patients who had at least 2 serial stenosis in one coronary artery 
(102). Relevant pressures were measured before the intervention, after the treatment of one 
stenosis, and after the treatment of both stenoses, the true FFR of each stenosis (FFR true) 
was directly measured after the elimination of the other stenosis and compared with the 
value predicted (FFR pred) from the initial pressure measurements before treatment. FFRpred 
was close to FFRtrue in all patients (0.78±0.12 versus 0.78±0.11 mm Hg; r=0.92). The authors 
do concede, however, that one stenosis influences the haemodynamic effects of another in a 
sequence that may result in a mutual underestimation of the severity of each unless stenosis 
interaction is accounted for. The overestimation of FFR is more pronounced for the proximal 




Figure 2.6. Influence of the presence of 1 stenosis within a coronary artery on the 
haemodynamic effect of the other. The clear dot indicates patients in whom the proximal 
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stenosis was treated first; the solid dot, patients in whom the distal stenosis was treated 
first. A, with increasing severity of 1 stenosis, the underestimation of the haemodynamic 
severity of the other stenosis becomes more pronounced. The solid line is the line of identity, 
and the dashed line, the regression line for measured data. In B, the regression line almost 
coincides with the line of identity (and therefore is not visible).  
 
When calculating the FFR of each stenosis separately, a different equation needs to be used, 
requiring the pressure between both the stenoses to be measured separately. Realistically, 
however, the measurement of FFR between two stenoses is neither practical nor easy to 
perform and therefore not done routinely. Additionally to calculate the true FFR a wedge 
pressure also needs to be measured which adds to the complexity of the procedure. 
When faced with the scenario of sequential stenosis in the catheterisation laboratory, 
consideration needs to be given to the fact that this may lead to overestimation of FFR or 
underestimation of stenosis severity. It is important to realise that one stenosis influences 
the haemodynamic effects of another in a sequence that may result in an underestimation of 
the severity of each unless stenosis interaction is accounted for. 
A recently published paper by Yong et al (103) assessed the impact of a downstream stenosis 
on left main FFR assessment. In this study, variable stenoses were created in the left main 
arteries and downstream epicardial vessels in 6 anaesthetised male sheep using balloon 
catheters. A total of 220 pairs of FFR assessments of the left main stenosis were obtained, 
before and after the creation of a stenosis in a downstream epicardial vessel, by having a 
pressure wire sensor in the other non-stenosed downstream vessel. They found that the 
apparent left main FFR in the presence of a stenosis was significantly higher compared with 
the true FFR in the absence of downstream stenosis. (FFRtrue; 0.80±0.05 versus 0.76±0.05; 
estimate of the mean difference, 0.035; P<0.001). In all lesions where there was a difference, 
the epicardial lesion was in the proximal part of the stenosed vessel and the epicardial FFR 
(combined FFR of the left main and downstream stenosed vessel) was <0.50. It appears 
therefore that there is a clinically relevant effect on the FFR of the left main stem on the 
presence of a tight and proximal epicardial stenosis. 
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2.5 COLLATERALISATION AND CHRONIC TOTAL OCCLUSIONS 
Increasingly, there is interest in opening up chronic total occlusions percutaneously due to 
improved equipment and success rates. A recent meta- analysis (104) has documented 
benefits specific to successful chronic total occlusion (CTO) PCI with respect to improvement 
in symptoms, reduction in ischaemia, and even a suggestion of better outcomes. For  CTO’s  
the correct interpretation of ischaemia and viability to guide revascularisation is more 
important due the complex nature of the procedure and the increased associated risks of 
complications. 
 
2.5.1 CMR AND CHRONIC TOTAL OCCLUSIONS 
In   patients   with   CTO’s,   the   main   use   of   CMR   has   been   to   identify   areas   of   viability   or  
ischaemia in the territory to see if any benefit from revascularisation is likely to be derived. In 
CTO’s  the  evidence  for  revascularisation   is   less  robust  than  for  stable  angina  and  therefore  
ESC (2) guidelines recommend ischaemia directed revascularisation. 
Frequently, the presence of collaterals leads to a decision enforcing optimal medical therapy 
regardless of the presence of ischaemia. However, there is little data assessing the diagnostic 
accuracy of CMR perfusion imaging in   CTO’s,   and the potential discordance with invasive 
assessment especially in the presence of collaterals need to be understood in order to pursue 
the right management strategy.  
Patients  with  CTO’s have been studied previously by Aboul-Enein et al (105) who investigated 
the Rentrop angiographic grading of collaterals and myocardial perfusion imaging by SPECT, 
in   patients  with   single   vessel   CTO’s   and   no   prior   infarction.      The   stress   induced   perfusion  
defects did not differ between the groups with good or with poorly developed collaterals. 
However, there was a difference in resting perfusion suggesting that there may be some 
protective effects of collateralisation.  
Wright et al (106)  retrospectively compared the association between ischaemia  and 
myocardial perfusion imaging and the presence of collaterals on angiography with hard 
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cardiac   events   in   21   patients   with   CTO’s   treated   medically   over   a   mean   follow   up   of   23  
months.  They also demonstrated that the presence of collateralisation did not predict either 
ischaemia or hard cardiac events. 
Meuhling et al (107) performed CMR perfusion imaging in 30 patients with one occluded 
artery and no other flow limiting stenosis to assess the transmural extent of infarction, 
perfusion during rest and adenosine induced hyperaemia, and regional wall thickening in 
both collaterally dependent and antegradely perfused grade (0-3). They found that in 15 
patients with < 50 % LGE, perfusion was similar in antegradely and collateral dependent 
myocardium.  
In patients with greater than 50% LGE, perfusion was lower in collateral dependent than 
antegradely perfused myocardium, essentially demonstrating that in patients with scar, there 
is more contribution from antegrade perfusion than from collateral perfusion. 
From these small studies, it is difficult to come to any robust conclusion about the extent and 
effects of collateralisation on the assessment of ischaemia.  
 
2.5.2 FFR AND CHRONIC TOTAL OCCLUSIONS 
The utility of FFR in patients with a CTO is limited as it is not technically feasible to pass a 
pressure wire through an occluded artery. However, it is still possible to assess the remaining 
arteries with FFR and also to assess the extent of collateralisation in different grades of 
stenoses. 
 The concept of FFR can be extended to calculate separately myocardial, coronary, and 
collateral perfusion and it is possible to distinguish separately the contribution of coronary 
blood flow and collateral blood flow to myocardial blood flow (FFR myo is the maximum 
myocardial blood flow being maintained and equals FFRCoronary   and FFR Collaterals).  The FFR of 
the collaterals is also known as the collateral flow index (CFI). Recruitable collaterals can be 
assessed at coronary artery occlusion by the simultaneous measurement of mean arterial, 
coronary wedge and central venous pressure. CFI can be calculated as FFR coll = (Pw –Pv)/ 
(Pa-Pv) 
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Both pressure derived and doppler derived   CFI’s   have   been   clinically   validated. Pressure 
derived CFI was shown to have an excellent correlation with the extent and severity of a 
99Tc-sestamibi defect in the territory of an occluded artery during balloon angioplasty in the 
catheterisation laboratory (108). Doppler derived CFI has been shown to have excellent 
correlation with pressure derived CFI, and low values for both indexes were found to be 
highly predictive of ischaemic ST segment changes on electrocardiography during balloon 
occlusion. 
The study by Matsuo et al (108) showed that a close correlation is present between collateral 
fractional flow reserve, calculated from coronary pressure measurements, and the extent 
and severity of hypoperfusion of the territory supplied by the occluded artery in relation to 
normally perfused myocardium. 24 consecutive patients with stable angina and single LAD 
stenosis underwent simultaneous measurement of aortic pressure, coronary wedge 
pressure, and pressure during balloon inflation.  They found that the pressure-derived 
collateral indexes (Pw, Pw/Pa, and FFR coll) ranged widely but were closely correlated with 
the extent and severity scores of the nuclear occlusion images.  Of all parameters, FFR coll 
correlated best with the severity score at imaging (r = -0.88). 
Werner et al (109) demonstrate that in patients with a CTO, angiographically well-developed 
collaterals do not provide a sufficient functional supply to the occluded arterial segment. 107 
patients with a CTO and no prior myocardial infarction had invasive assessment of collateral 
function. Intracoronary doppler flow velocity and pressure recordings were obtained distal to 
the occlusion before the first balloon inflation and collateral function indices were calculated. 
Even in patients with normal regional LV function, collaterals provide a normal coronary flow 
reserve in less than 10%. Only 7% of patients had an increase in collateral flow reserve >2.0 
during pharmacological stress, whereas coronary steal occurred in one third independent of 
regional LV function. The  high  prevalence  of  coronary  steal   in  CTO’s   indicates  that  patients  
with even well collateralised CTO’s  may   benefit   from   revascularisation. This suggests that 
there may be significant ischaemia even in the presence of a good collateral circulation. 
The donor artery that is supplying the collaterals to the occluded artery can also be assessed 
by FFR but assessing and taking into account the extent of collateralisation is important. 
When providing collaterals to another territory, the size of the myocardial bed inevitably 
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increases. Therefore distal pressure will be low resulting in a larger pressure drop across a 
given stenosis. FFR measurement across the same stenosis would result in a lower pressure 
drop if the myocardial bed were smaller, i.e. in the absence of collaterals. There are reports 
in the literature, which support this phenomenon but this area has not been formally studied 
(110, 111). 
The FFR   measurement   is   thought   to   be   appropriate   as   it   “corrects”   for   the   size   of   the  
myocardial bed being supplied, as a larger myocardial area means that the benefit to be 
achieved from PCI would be greater than that of just a smaller territory. Although this may 
lead to an angiographic- functional mismatch with an angiographically mild stenosis having a 
significant FFR result, physiologically the stenosis is deemed significant. This should 
theoretically cause a perfusion defect in the area supplied by the donor artery, as this is the 
area  whereby  the  “coronary  steal” is occurring. 
If the stenosis of the artery being collateralised is relieved, the myocardial bed of the donor 
artery will reduce, resulting in an increase in the FFR result. 
This observation was demonstrated in a study by Leone et al(112) aiming to evaluate the 
influence of the amount of myocardium subtended by a stenosis on the FFR value. They 
studied 213 intermediate stenosis, in 184 patients and matched them with stenosis of similar 
type. The extent of myocardium was allocated according to jeopardy scores. They found that 
the stenosis that subtended a larger extent of myocardium had more significant FFR values. 
Interestingly, they also found that in the subanalysis of a proximal LAD lesion, the presence 
of a concomitant well-collateralised CTO is indeed associated with a significantly lower FFR. 
Taken together, these data suggest the importance of the functional assessment of stenoses 
in particular when located in proximal LAD, in the presence of collateralised CTO or in general 
when a large amount of myocardium is subtended by the index stenosis. However, this study 
was limited by the lack of imaging data to support the extent of ischaemic myocardium, using 
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2.6 SUMMARY  
From the literature, it appears that the measurement and interpretation of FFR and also of 
CMR images is not straightforward in patients with complex disease.  It does lead one to 
question the applicability of much of the validation work that was carried out in patients with 
single vessel disease. 
It is unclear whether increased microvascular resistance leads to abnormal perfusion 
detected by CMR perfusion imaging.  FFR may also underestimate the severity of a stenosis 
in patients with complex coronary disease, due to the concomitant presence but neglect of 
abnormalities in microvascular resistance. 
In multivessel disease, the evidence suggests that FFR does differentiate physiologically 
important lesions compared to invasive angiography. It remains to be seen whether a 
strategy of targeted revascularisation to the lesions causing most ischaemia is beneficial in 
terms of symptomatic improvement and prognostic benefit. The utility of CMR perfusion 
imaging to accurately guide decision-making in multi-vessel disease still needs to be 
assessed. 
With the potential of CMR scanning to assess scar size and the presence of ischaemia, an 
assessment of the correlation of the presence and extent of peri-infarct ischaemia with the 
FFR result is possible. 
In  diffuse  disease,  a  “step”  in  the  FFR  measurement  may  not  be  evident  and  this  may  suggest  
that there is no flow-limiting lesion. However, the overall impact of luminal reduction will be 
an impairment of flow that should manifest as a perfusion defect on CMR imaging. Similarly, 
the assessment of a stenosis in sequence may result in overestimation of FFR in the presence 
of a perfusion defect. 
Understanding the limitations of both techniques is important for the appropriate use of 
these valuable tools, especially in the setting of more complex coronary and myocardial 
disease.  
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CHAPTER 3: GENERAL METHODS – THE MR INFORM 
STUDY 
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Some of the patients used in the comparative studies between FFR and CMR were recruited 
to take part in the MR-INFORM clinical trial. 
(ClinicalTrials.gov Identifier:NCT01236807)  
 This is an international randomised controlled trial of FFR vs. CMR to guide the management 
of patients with coronary artery disease and is still currently recruiting. 
Currently there are over 600 patients recruited to this study, which aims to recruit 918 
patients.  
Analysis of subgroups where there is discordance between the two tests is part of the 
exploratory endpoints of the main trial. One of the disadvantages of using these patients is 
that the power calculations are based on the primary endpoint of the main clinical trial. 
However, these patients are a particularly interesting sub group as they have had both an 
invasive and non-invasive assessment of ischaemia. In addition, some patients were recruited 
from a second site, Porto in Portugal under the direction of Dr Nuno Bettencourt.  
In this chapter I will describe the general methods of the main MR-INFORM trial. My 
involvement in this study was writing the protocol, finalising the trial design including all 
important decisions on the nature of the trial, definition of end points, statistical power etc. 
Furthermore, I proceeded to get regulatory approval for the study, and set up enough sites 
to ensure adequate recruitment both nationally and internationally. Additionally, I recruited 
patients from our site and was responsible for the CMR scanning and follow up of these 
patients.  
The following chapter is adapted from the following publication: 
Hussain ST, Paul M, Plein S, McCann GP, Shah AM, Marber MS, et al. Design and rationale of 
the MR-INFORM study: stress perfusion cardiovascular magnetic resonance imaging to guide 
the management of patients with stable coronary artery disease. Journal of cardiovascular 
magnetic resonance : official journal of the Society for Cardiovascular Magnetic Resonance. 
2012;14:65(113) 
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3.1 BACKGROUND AND RATIONALE FOR STUDY 
Over the last few years, there have been a number of landmark trials questioning previously 
accepted management strategies for patients with stable coronary artery disease.  The 
COURAGE(67)  trial has shown no benefit of routine revascularisation both in terms of 
prognosis and long term symptom relief in patients with stable angina.  However, subgroup 
analysis of the COURAGE data(68), suggests that the prognosis of patients receiving optimal 
medical therapy (OMT) alone or percutaneous coronary intervention (PCI) and OMT is 
correlated to their ischaemic burden and the amount of ischaemia reduction achieved by 
therapy, as assessed by SPECT. The assessment of prognosis, however, was exploratory, and 
not associated with outcome when adjusted for treatment. 
There is evidence that the presence of stress-induced myocardial perfusion defects identified 
by non-invasive imaging tests such as SPECT have prognostic significance(114). An 
observational study of 10 627 patients with stable angina and evidence of ischaemia as 
measured by SPECT described a survival advantage for revascularisation (of which 52% was 
PCI) over medical therapy in patients with ischaemia of more than 10% of the myocardium 
(66). An alternative approach is the use of invasive FFR measurements to assess the 
functional significance of coronary stenoses. The FAME(115)  and DEFER(27) trials have 
demonstrated that patients in whom angioplasty is only performed on FFR positive stenoses 
have an improved outcome compared to those patients in whom the revascularisation 
decision is based on a visual estimate of angiographic severity alone. The 2-year follow-up of 
the FAME patients showed a significant reduction in major cardiac events (MACE) in patients 
guided by FFR. Thus, there is accumulating evidence dictating a shift away from a purely 
anatomical assessment for coronary artery disease to a functional assessment. These data 
are of specific importance as most studies so far have determined diagnostic accuracy, 
whereas FAME and DEFER are among the few studies, where different diagnostic strategies 
were used to guide further management and thus improve outcome.  
CMR perfusion is a well-established, non-invasive test with excellent accuracy for the 
detection of coronary artery stenosis(18) as well as abnormal FFR (31, 63). Multicentre data 
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has demonstrated non-inferiority of CMR myocardial perfusion imaging in comparison to 
SPECT for the assessment of myocardial ischaemia (15).  In a recent single centre study of 
750 patients the superiority of CMR perfusion in comparison to SPECT was shown mainly due 
to improved sensitivity (86.1% vs 65.5%) (5).  In addition, patients with a negative perfusion 
scan have a low likelihood (<1%) of a major cardiac event over the following two years (10) 
(116) (117). Thus, CMR perfusion seems well suited to guide the management of patients 
with stable coronary artery disease similar to invasive FFR measurements(1). 
Although treatment decisions are increasingly being based on the combination of symptoms 
and objective proof of ischaemia, there is insufficient evidence on the best management 
strategy for patients with stable angina(118) and comparative effectiveness. The aim of the 
MR-INFORM study, therefore, is to establish whether guiding the management of patients 
with a moderate to high risk of coronary artery disease by CMR perfusion is non-inferior to 
guiding the management of these patients by invasive angiography and FFR. 
 
3.2 STUDY DESIGN 
3.2.1 HYPOTHESIS 
The principal hypothesis is that selecting patients with stable angina for revascularisation and 
optimal medical therapy (OMT) or OMT alone based on CMR myocardial perfusion is non-
inferior to selecting patients based on routine coronary angiography and fractional flow 
reserve (FFR) in terms of subsequent major adverse cardiac events. 
3.2.2 STUDY CONDUCT AND RANDOMISATION 
MR-INFORM is a multi-centre, randomised controlled, non-inferiority trial. It is actively 
recruiting within the UK, Germany, Portugal and Australia. The study is performed in 
accordance with the principles of the Declaration of Helsinki; with all patients providing 
informed written consent prior to testing. The study protocol and other relevant 
documentation have been approved by the South London Ethics Committee (UK) and the 
relevant national ethics committees as well as registered on ClinicalTrials.gov identifier: 
NCT01236807: 
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(http://clinicaltrials.gov/ct2/show/NCT01236807?term=MR+INFORM&rank=1). Suitable 
patients are identified in the outpatient clinics and from the angiography and CMR waiting 
lists of the recruiting centres. If they meet the inclusion criteria and none of the exclusion 
criteria and provide written informed consent, they are enrolled into the study. 
Patients are electronically randomised prior to the baseline CMR scan via a web-based 
randomisation service into randomly varying block sizes of 2 and 4, stratified by study site 
and gender with an allocation ratio 1:1 to MR-INFORMED or FFR- INFORMED.  
3.2.3 FFR INFORMED GROUP 
Within the FFR-INFORMED group, the baseline CMR scan is blinded. This scan is not used to 
guide further management but will provide valuable additional scientific data that will be 
used in analyses specific to the sub studies (described below). All patients in this group are 
examined with invasive angiography, FFR is performed in all arteries >2.5 mm with a 
diameter stenosis >40%. FFR is attempted in all arteries up to a 99% stenosis, as long as 
patency is not compromised.  Although this strategy differs from clinical practice which tends 
to focus more on intermediate lesions, evidence from the FAME trial suggests that even in 
severe and mild stenosis the visual estimate can be inaccurate (29). 
The results of invasive angiography and the FFR result are used to guide further treatment. 
Any narrowing with an FFR of >0.8 is regarded as not haemodynamically significant, whereas 
a   narrowing   with   an   FFR   of   ≤0.8   or   a   total   occlusion   is   regarded   as   significant and 
revascularisation is indicated. The decision on the mode of revascularisation is left to the 
treating cardiologist and depends on local practice. In the case of repeat revascularisation, 
when symptoms are on-going, revascularisation will be guided according to either the FFR or 
CMR results depending on the group randomised. 
3.2.4 MR INFORMED GROUP 
Within the MR INFORMED group, further management is dictated by the results of the 
baseline CMR scan. A visual assessment of the significance of ischaemia and the territories 
involved is made (see investigation reporting below). Patients with significant perfusion 
defects are referred for angiography and revascularisation is guided by the ischaemic 
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territories identified on the CMR scan in combination with the results of the angiogram. FFR 





Fig 3.1: Study Flow diagram outlining the study design. *CXA = Coronary Angiography. 
 
3.2.5 PATIENT RECRUITMENT, INCLUSION AND EXCLUSION CRITERIA  
Patient Population 
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Patients recruited into the study have typical symptoms of angina (Canadian Class Symptoms 
CCS 2-3), and either a positive exercise/bicycle test or more than two cardiovascular risk 
factors. Exclusion criteria include contra-indications to CMR imaging or to adenosine, poor 
renal function (eGFR<30), LVEF <30%, PCI within the last 6 months, and previous Coronary 
artery bypass grafting (CABG). A prior myocardial infarction is not an exclusion criterion. The 
complete inclusion and exclusion criteria are listed in table 3.1. 
Table 3.1: Inclusion and Exclusion criteria 
 
All patients have a baseline stress perfusion CMR scan and further management will depend 
on whether they have been randomised to the MR-INFORMED or the FFR-INFORMED arm of 
the trial. In addition, all patients receive optimal medical therapy. 
 
3.3 ANALYSIS AND INTERPRETATION OF RESULTS 
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3.3.1 CMR IMAGING 
CMR imaging is performed on 1.5T scanners (various vendors); total scan duration is 
approximately one hour. See Figure 3.2. All images are acquired using phased array surface 
coils during mild expiration and electrocardiographic triggering. Cine images are acquired in 
the 4-, 3-, 2-chamber and contiguous short axis views using a steady state free precession 
(SSFP) sequence. For perfusion, a basal, midventricular, and apical short axis slice will be 
acquired during the first pass of 0.075ml/kg of a 1-molar gadolinium based contrast agent 
injected with a power injector at a flow rate of 4mls/s. The exact details of the sequence 
varies between different scanners used but will fulfil certain basic criteria, including high 
spatial resolution (< 3mm x 3mm), acquisition duration <180ms per slice, 90° saturation pre-
pulse, fixed pre-pulse delay and dual bolus contrast injection allowing semi-quantitative and 
fully quantitative analysis(119).  Hyperaemia is achieved by infusion of adenosine at 
140mcg/kg/min for 3-4 minutes. If there is neither a heart rate increase >10bpm nor a 
systolic blood pressure drop >10 mmHg from baseline nor symptoms the adenosine dose will 
be increased to 170mcg/kg/min after 2 minutes and to a maximum dose of 
210mcg/kg/min(120). All patients are asked to avoid caffeine, but to continue with their 
normal medication for 12 hours prior to the scan. For the perfusion measurements, contrast 
agent will be injected at the third minute of adequate adenosine stress using a dual bolus 
method. A dose of 0.075 mmol/kg of a 1-molar gadolinium-chelate (Gadobutrol, Gadovist®, 
Bayer, Germany) is injected for the main bolus preceded by the same volume of a 10% 
diluted contrast agent dose for a prebolus both flushed with 25ml of saline. Rest perfusion 
imaging is performed 10 min after stress perfusion to allow for clearance of most of the 
contrast agent. 
Late enhancement imaging is then carried out using an inversion recovery turbo gradient 
echo sequence. 
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Fig 3.2: MR-INFORM cardiac magnetic resonance protocol. 
 After individual patient planning using survey scans, intravenous adenosine is given 
according to the protocol. First pass stress perfusion imaging is done during stress visualising 
the first passage of a 0.75 mmol/kg contrast agent bolus through the myocardium. Short axis 
(SA) cine images are acquired. Rest perfusion images are acquired during an injection of a 
second bolus of 0.75mmol/kg contrast agent. 10 minutes after an additional injection of 0.05 
mmol/kg of contrast agent to increase the total dose of contrast agent to 0.2 mmol/kg. A 
modified Look-Locker inversion time scout is performed prior to late gadolinium 
enhancement imaging in short axis and long axis views. During the wait time after the last 
contrast agent injection long axis images in the 4 chamber, 3 chamber and the 2 chamber 
views are obtained.  
 
3.3.2 FFR MEASUREMENT 
In the FFR-INFORMED arm of the trial, all patients will have coronary angiography and FFR 
measurement as required. 
At angiography, any arteries with a diameter of >2.5mm and a diameter stenosis between 
40–99% will be assessed with FFR. A 0.014 guidewire (Radiwire, St. Jude Medical, St. Paul, 
MN, USA or Volcano, Volcano Corporation, San Diego, CA) will be introduced, calibrated and 
advanced into the coronary artery distal to the stenosis. An intravenous adenosine infusion 
(140mcg/kg/min) will be used to induce maximal hyperaemia. FFR is calculated as the ratio of 
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the mean distal coronary pressure measured by the guide-wire to mean aortic pressure 
measured by the guiding catheter. Revascularisation will be recommended in the FFR group 
if FFR is <0.80. In the case of a chronic total occlusion, FFR is regarded as positive and a 
default value of 0.5 is assigned to the chronically occluded vessel. In the case of triple vessel 
disease, an attempt should be made to do FFR in all three arteries.  
If there is more than one artery that needs to be revascularised, the PCI procedure can be 
staged. If this occurs, follow-up will begin after the first procedure, and the endpoints will 
include both procedures. 
Post-interventional FFR is useful but not mandated in order to keep the procedure as simple 
as possible. 
 
3.3.3 CMR ANALYSIS 
The local supervising CMR physician as per normal clinical practice will do the CMR analysis 
for the MR-INFORMED group.  
The following data are collected: 
1) Image quality (assessed on a grade of 1 to 4 – poor to excellent) 
2) Presence of scar tissue and transmurality (1=1-25%; 2=25-50%; 3=51-75%; 4=>75%) 
based on the AHA/ACC 17 segment model. 
3) Perfusion analysis at stress and rest scored as significant, insignificant or no defect 
based on the AHA/ACC 16 segment model (see below). 
4) Evidence of regional wall motion abnormalities (1=akinetic; 2=hypokinetic; 
3=dyskinetic) 
5) Quantitative analysis including end-diastolic and end-systolic volumes and ejection 
fraction  
The baseline CMR scan in the FFR-INFORMED group will remain blinded. 
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3.3.4 PERFUSION ANALYSIS 
The CMR perfusion images are interpreted visually and angiography recommended if the 
perfusion defect is classified as significant according to the presence of ischaemia in 2 
segments of a 32-segment model (see below) i.e.: 
• >60 degrees in either the basal or the midventricular slices or 
• >90 degrees in the apical slice or 
• Any transmural defect or 
• A defect across two adjacent slices. 
In the case of patients who have unexpected scar tissue evident on CMR, angiography will be 
recommended for all patients who have evidence of scar and peri-infarct ischaemia. When 
only scar is present, the management will be decided after an assessment of the 
transmurality of scar. In patients with transmural scar (>75%), and no additional ischaemia, 
angiography would not be recommended. In patients with partial transmurality (<75%) and 
no ischaemia, the need for angiography will be decided by the treating physician after an 
assessment  of  the  patient’s  symptoms  and  risk.  It  is  recommended,  however,  that the areas 
of ischaemia alone guide the subsequent revascularisation strategy. 
 
3.3.5 RATIONALE FOR SIGNIFICANT ISCHAEMIA THRESHOLD 
The rationale for the threshold at which ischaemia is deemed to be significant is based on 
data from Hachamovitch et al (66) who demonstrated that in patients with 10 – 12.5% 
ischaemic myocardium on SPECT, mortality is significantly higher if they are not 
revascularised in comparison to a revascularised group. The opposite is true in patients with 
less than 10% ischaemic myocardium. 
With the high spatial resolution of CMR perfusion (< 3mm x 3 mm) it is possible to distinguish 
endocardial, non-transmural, perfusion defects from transmural (>75% wall thickness) 
perfusion defects. Thus, the myocardium can be divided into the 16 AHA/ACC segments with 
a subdivision into an endocardial and an epicardial half resulting in a total of 32 segments. 
Each of these segments represents approximately 3% of the myocardium; two positive  
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segments represent approximately 6%. Since there is no data available providing a direct 
comparison between the ischaemic burden in SPECT and CMR perfusion this level is used as a 
conservative threshold to refer patients to invasive angiography. 
The criteria for interpretation of CMR scans, especially the differentiation between normal 
myocardium, non-transmural defects, and transmural defects, is discussed in detail with each 
site during the initiation visit using a set of example cases. In addition, CMR images will be 
periodically reviewed by the global coordinating investigator and selected coordinating 
investigators from participating countries who, in case of inconsistencies or differences in 
assessment, will contact the sites and consider specific training activities.  Each site can invite 
a second opinion from the global coordinating investigator or a coordinating investigator 
from a participating country (or one of their experienced co-workers) in unclear cases. 
 
3.4 OPTIMAL MEDICAL THERAPY AND FOLLOW UP VISITS 
 At baseline, 6 months and 12 months recommendations for therapy are made to the 
primary care physician in line with guidelines published by the Joint British Societies (121). 
See table 3.2 for the treatment targets. 









Risk factor Goals  
Blood Pressure BP 130/80 mmHg 
Diabetes Mellitus Fasting or pre-prandial glucose of 
4-6, or a HbA1C < 6.5% 
Lipids Total cholesterol less than 4mmol/l 
or an LDL <2.0mmol/l 
Smoking Smoking cessation 
Weight BMI<25 
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The goal of anti-hypertensive therapy is to achieve a blood pressure of less than 130/80 
mmHg. The choice of anti-hypertensive therapy will be left to the treating physician.  The aim 
of anti-lipid therapy is to achieve levels of LDL <2 mmol/l and total cholesterol <4 mmol/l. In 
the first instance, statin therapy will be initiated and then increased with the addition of a 
second agent if necessary. For patients with a BMI of > 25 kg/m2, the primary health care 
physicians are asked to refer the patient for dietary advice. Similarly, smokers are referred to 
the smoking cessation clinic. Recommendations for referral and for the continuation of 
therapy are made to the primary health care physician. 
In patients without diabetes, who have a raised random glucose, the primary health care 
physician is asked to repeat a fasting glucose to assess for sustained hyperglycaemia, in 
which case the appropriate dietary advice and/or diabetic treatment should be instituted. In 
the case of diabetics with a raised blood sugar, the primary health care physician is asked to 
measure HbA1c and  to  ensure  that  the  patients’  subsequent  therapy  is  tailored  to  achieve  a  
HbA1c of less than 6.5 mg/dl. All patients should be prescribed aspirin (clopidogrel if aspirin 
sensitive), statin therapy and an ACE Inhibitor (122). 
 
3.4.1 CLINICAL FOLLOW UP  
All patients undergo a thorough cardiovascular risk assessment at baseline with 
measurement of blood pressure, glucose levels, and body mass index, including measure of 
waist circumference, full lipid profile, the completion of a health questionnaire (EQ-5D) and a 
12 lead ECG. CCS and NYHA class records symptomatic status. Medical therapy is optimised 
in all patients and the risk factor assessments are repeated at 6 and 12 months to assess the 
impact of medical therapy. 
Furthermore, a 6 month follow-up CMR scan will be done in a subgroup of patients to assess 
for residual ischaemia, new scar formation and changes in left ventricular function and size 
after the initial therapy recommended after the baseline investigations.  The result of this 
CMR scan remains blinded. 
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3.5 REVASCULARISATION 
Revascularisation by either Percutaneous Coronary intervention (PCI) or coronary artery 
bypass grafting (CABG) will be guided by the ischaemic territories identified by either FFR or 
CMR perfusion, depending on the randomisation group. For example, if the CMR perfusion 
scan demonstrates a perfusion defect in the left anterior descending (LAD) territory and 
angiographically a narrowing is identified in the LAD and right coronary artery (RCA), only the 
LAD artery will be revascularised.  
In visual triple vessel disease, the FFR or CMR results will be used to guide the decision 
towards CABG or PCI. 
If there is more than one artery that needs to be revascularised, the PCI procedure can be 
staged. If this occurs, follow-up will begin after the first procedure, and the endpoints will 
include both procedures. 
Post-interventional FFR is useful but not mandated in order to keep the procedure as simple 
as possible. 
The specific revascularisation technique, i.e. type of stents used, staging of the procedure, 
PCI or CABG etc. will be decided by the treating interventionist and dictated by local 
guidelines.  This   is   to   reflect  “real   –world”  practice  and  to  acknowledge  that  practice  varies  
between centres and countries. Similarly, the cardiac surgeons will decide on the type of 
surgical revascularisation that they will undertake. 
In the case of patients who demonstrate scar and ischaemia on CMR perfusion subsequent 
revascularisation will be guided by areas of ischaemia alone rather than on the basis of scar. 
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LAD lesion 70% and 
RCA lesion 80% 
LAD FFR 0.75 
RCA FFR 0.85 
PCI to LAD alone 
CTO of LAD 
Circumflex(Cx) lesion 
50 % 
Assume LAD FFR 0.50 
Cx FFR 0.70 
Revasc of LAD and Cx 
Diffuse disease in LAD FFR < 0.80 on pullback Operator can decide 
not to stent 
Serial stenosis FFR <0.80 beyond all 
narrowings 
 
Stent most significant 
stenosis or one with 
the biggest pressure 
gradient 





3.6 RATIONALE FOR ENDPOINT SELECTION AND DEFINITION OF MACE 
 
3.6.1 PRIMARY ENDPOINT 
The primary endpoint is the occurrence of a Major Cardiac Event (MACE) at one year. This is 
a composite end-point of death, myocardial infarction, and repeat target vessel 
revascularisation. See table 3. 4 for detailed definitions of endpoints.  
 
    PhD Thesis: Shazia Hussain 
 80 
3.6.2 SECONDARY ENDPOINTS 
 Symptoms (angina score, NYHA class) within 1 year 
 Death, myocardial infarction and repeat revascularisation as individual components 
of     MACE 
 Cost-effectiveness of an MR vs FFR guided selection for revascularisation 
 Occurrence of new myocardial scar tissue 
 Ischaemia reduction in the FFR vs MR group after therapy 
 
Table 3.4: Detailed definition of end-points 
End Point  Definition 
Death  All cause mortality 
Myocardial 
Infarction 
Spontaneous Elevation of CK or Troponin 
above baseline with symptoms 
of ischaemia, ECG changes or 




CKMB>3X ULN- upper limit of 
normal (post PCI 12-24hrs) 
CKMB>5X ULN (post CABG 24-72 
hours) plus new Q waves or 
LBBB, new native vessel or graft 
occlusion, imaging evidence of 
loss of viable myocardium(123)  
Repeat  Repeat PCI or CABG of the target 







3.6.3 ENDPOINT SELECTION  
In a clinical trial, a primary endpoint is usually defined or specified as a measure that will be 
considered as the success of the therapy being tested. This can be a result, condition or 
event associated with individual study patients that is used to assess study treatments. The 
characteristics of endpoint measures are that they should be easy to diagnose, free of 
measurements error, internally and externally valid. Internal validity is demonstrated when 
the endpoint is directly linked to property of interest. External validity is demonstrated when 
an endpoint can be generalised to a wider population. They should also be clinically relevant. 
A trial might also define one or more secondary endpoints i.e. cost effectiveness, 
symptomatic improvement that will be measured and are expected to be met and also 
define exploratory endpoints that are less likely to be met. 
The MR-INFORM trial has been designed as a non-inferiority trial with the primary endpoint 
defined as death, myocardial infarction or repeat revascularisation.  Due to its non-inferiority 
design no difference between the two groups in reaching the endpoint is sought.  
Although MR- INFORM is a combined imaging and interventional trial, it essentially assesses 
two investigative strategies that guide therapy and therefore adopts endpoints that are 
usually reserved for interventional trials.  Interventional cardiology has a tradition of agreed 
upon clinical endpoint definitions and clinical trial methodologies (123, 124). This is to 
combat the variability in endpoint definitions that creates a barrier to the understanding of 
results across clinical trials or to the pooling of results. The endpoints used in MR-INFORM 
accurately reflect any improvement in survival by measuring death and myocardial infarction 
and also reflect the effectiveness of the revascularisation strategy by measuring repeat 
revascularisation. See table 3.5. All-cause mortality is the most unbiased method to report 
revascularisation lesion performed for restenosis 
or other complication of the 
target lesion (from 5mm 
proximal to 5mm distal to the 
stent) (124) 
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deaths in a clinical trial or observational study, even though it may be less specific than 
deaths adjudicated as cardiac in origin. 
Myocardial infarction during a clinical trial involving percutaneous intervention may occur 
during the immediate peri-procedural period as a result of the revascularisation procedure 
itself or long after the procedure as a result of spontaneous MI or late complication of the 
revascularisation procedure. 
Recent guidelines provide a universal definition for clinical as well as investigational trial use 
(93). The global task force recommends the establishment of criteria based on troponin or 
creatine kinase Mb (CKMB) but notes the preference for troponin in all cases. For either 
troponin or CKMB, the upper range limit is defined as the 99th percentile of the normal 
range. The peri-procedural period includes the first 48 hours after PCI and first 72 hours after 
coronary artery bypass grafting (CABG). 













Death (All cause) ++++ ++++ + +++ ++++ 
Myocardial 
infarction 
+++ +++ +++ +++ ++++ 
Repeat 
revascularisation 
++ ++ ++++ ++++ ++++ 
 
3.6.4 DATA COLLECTION AND MONITORING 
Patient demographic details, medical history and information on current medication use are 
collected. A 12 lead ECG will be performed at baseline and at 12 months. Blood tests will 
include a measurement of total cholesterol and full lipid profile, a random glucose 
measurement, and renal function (eGFR). These tests will be repeated at 6 and 12 months. A 
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full blood count will also be measured at baseline. Blood pressure, waist circumference 
measurement, and Body Mass Index will be determined at baseline, 6 and 12 months. 
At the time of revascularisation (PCI or CABG), baseline troponin is measured. This will then 
be repeated 6 hours post PCI or 12 hours post CABG. If the troponin is raised, then a CKMB 
will be done at 12-24 hours post PCI or 36-72 hours post CABG. The definition of myocardial 
infarction is based on CKMB. See table 3.4 for detailed definitions of endpoints. 
All study data is recorded via an electronic case report form (eCRF). Data is monitored at all 
sites for completeness and quality by the contract research organization (CRO). A full data-
monitoring schedule is established and an independent data monitor will verify the eCRF 
against the source data. 
Any adverse events or serious adverse events are recorded on the eCRF and forwarded to 
the sponsor and the CRO immediately. An independent Data Monitoring Committee reviews 
serious adverse events and any other trial safety issues.  
 
3.7 SAMPLE SIZE AND STATISTICAL ANALYSIS 
3.7.1 SAMPLE SIZE 
The sample size calculation is based on the primary endpoint of death, MI, and repeat 
revascularisation at one year. A 10% event rate in the FFR group and an equivalence margin 
of 6% were assumed based on the results of the FAME study. (125) A sample size of 826 
would be required to determine the non-inferiority of a CMR guided strategy compared to an 
FFR guided strategy with at least 80% power.  Allowing for a dropout rate of 10% a total 
sample size of 918 patients is necessary. The calculation was carried out using STATA 11SE. 
We do anticipate that there will be crossover between groups, most likely from the CMR 
group to the FFR group, when patients continue to experience symptoms and the CMR scan 
has been reported as negative. This will be taken into consideration during the statistical 
analysis which will be done on a per protocol and an intention to treat basis.  
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3.7.2 DATA ANALYSIS 
Primary analysis 
The main objective of this study is   to   assess   whether   an   “MR-INFORMED”   management  
strategy is non-inferior   to   an   “FFR   INFORMED”   strategy   for   the   clinical   management   of  
patients with angina who are at moderate to high risk of CAD. To satisfy this objective the 
study will test the following null-hypothesis 
H0: The difference in MACE incidence rates between MRI and FFR group is above or equal 
to    
The outcome will be primarily assessed on an intention to treat basis (mITT) and secondarily 
on a per protocol (PP) analysis. The null hypothesis H0 can be rejected and non-inferiority of 
the MR- guided strategy claimed, if the two-sided 95% confidence interval (CI) for the 
difference in incidence rates is completely below  in both the (mITT) and (PP) analysis.  A 
difference of 6%-points was regarded as clinically relevant.  Therefore the non-inferiority 
margin was set to 6%-points.  
In addition, absolute and relative frequencies will be given per group. An independent 
statistician will carry out all statistical analyses. A formal interim analysis is not planned in 
this study. 
For all secondary efficacy variables, descriptive statistics (n, mean, standard deviation, 
median, minimum, and maximum) will be calculated for each quantitative variable. Absolute 
and relative frequencies will be given for categorical data. 
 
3.7.3 COST-UTILITY ANALYSIS 
The economic analysis will compare the total costs and effectiveness within each arm of the 
treatment and provide incremental cost effectiveness ratio (ICER). It will be computed as 
incremental costs divided by increment quality adjusted life years (QALY). The total costs will 
include both the direct and indirect costs.  Costs will be computed by recording patient 
utilisation of all NHS services for the follow-up period of one year.  These include, for 
instance, the costs of the initial diagnostic procedures (MRI, coronary angiography and FFR), 
revascularisation (PCI or CABG), hospitalisation costs, pharmacy costs, optimal medical 
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therapy costs over the two years plus costs associated with any re-hospitalisation due cardiac 
events (MI, Repeat Revascularisation).  These costs will be assessed using the NHS reference 
costs.  Additional costs will be computed using patient diaries and will include direct health 
care expenditures plus total time off work (to compute lost income), travel time and any 
travel or work time costs incurred by home care givers (e.g. spouse, parent, etc.).  Quality of 
Life assessment will be carried out using the EQ5D questionnaire and will be administered at 
base line and every two months for up to 24 months. Bootstrap methods will be used to 
derive confidence intervals around the ICER and to derive the Cost Effectiveness 
Acceptability Curve (CEAC). 
  
3.8 SUMMARY 
MR–INFORM is an international, prospective, randomised controlled, non-inferiority 
outcome trial comparing the role of CMR perfusion to routine coronary angiography with 
invasive fractional flow measurements for guiding patients with stable angina and an 
intermediate to high likelihood of coronary artery disease. Non-inferiority of CMR perfusion 
imaging to the current invasive reference standard (FFR) would establish CMR perfusion 
imaging as an attractive, non-invasive, alternative to current diagnostic pathways. The results 
will help to inform national and international guidelines on the investigation and 
management of coronary artery disease, and ultimately lead to improved patient care. 
 
3.9 STUDY LIMITATIONS 
In this prospective outcome trial an important clinical question is addressed. There is 
currently insufficient evidence on the comparative effectiveness of different diagnostic 
strategies in patients with stable coronary artery disease and therefore the results of this 
trial will help to inform future guidelines.  
In order to achieve this objective, the trial has been  designed  to  reflect  “real-world  “  medical  
practice as closely as possible. This is important for the translation of its results into routine 
clinical practice. However, inevitably this leads to some limitations in the study design.  
    PhD Thesis: Shazia Hussain 
 86 
Although the aim is to optimise medical therapy in both groups, there are variations on what 
is deemed optimal in different health systems and the implementation of this is left to the 
primary care physician. The UK guidelines are followed to minimise variation as much as 
possible, the remaining variation reflects clinical practice.  
A critical point is the inclusion of peri-procedural myocardial infarction and target lesion 
revascularisation in the end-point. These endpoints are frequently used in interventional 
trials. The occurrence of peri-procedural myocardial infarction is an important end-point as it 
is associated with adverse outcome and may reflect better guidance by one technique or the 
other. However, as revascularisation is guided by objective proof of ischaemia in both arms, 
it is expected that all patients in the trial are guided towards fewer revascularisation 
procedures compared to angiography alone and that this will be reflected in low event rates 
in both arms. The rationale for using target lesion revascularisation is similar. 
It is difficult to predict the frequency of crossover from one arm to another that can be 
substantial (e.g. COURAGE trial). Although a high rate of crossover is not anticipated, the 
data monitoring committee will assess the occurrence of crossover and allow for adaptation 
of the randomisation scheme to account for this.  
 
3.9.1 TRIAL STATUS  
MR-INFORM is currently recruiting in the UK, Germany, Portugal and Australia. There are 
currently 9 sites active in the UK, one in Portugal, 5 in Germany and one in Australia. The 
number of patients recruited at the time of submission is 633. 
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CHAPTER 4: CORRELATION OF FFR WITH ISCHAEMIC 
BURDEN MEASURED BY CMR 
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4.1 INTRODUCTION 
In patients with stable coronary artery disease, international guidelines recommend 
assessment of ischaemia before revascularisation (2). This is based on an accumulating body 
of evidence showing improved outcome by guiding decisions on revascularisation based on 
the presence of ischaemia (29, 30, 66, 126). This can be done non-invasively with myocardial 
perfusion imaging or invasively in the catheterisation laboratory with the measurement of 
FFR. 
FFR is calculated as the ratio between aortic and distal coronary flow at hyperaemia and 
allows differentiation between flow limiting and non-flow limiting lesions. CMR perfusion 
imaging allows non-invasive assessment of ischaemia by visualising the first pass of a 
contrast agent bolus through the myocardium. It enables direct visualisation of a perfusion 
defect and therefore allows calculation of ischaemic burden as a percentage of the 
myocardium.  
In clinical practice a FFR cut-off value of 0.8 is used for guiding patient management. For 
perfusion studies most centres use a cut-off value of 10-12.5% ischaemic myocardium for 
SPECT and 2-3 (out of 32) myocardial segments for CMR. 
Several studies have compared the diagnostic accuracy of CMR perfusion imaging and FFR 
(31, 60, 63).  However, a direct comparison between the FFR value and the ischaemic burden 
measured by CMR has not previously been done. 
Therefore, in this study, we sought to determine the relationship between FFR and ischaemic 
burden measured by high resolution CMR imaging. 
 
4.2 METHODS  
A total of 49 patients with typical symptoms  (CCS class 1, 2 or 3) of angina were recruited 
into the study. They underwent CMR perfusion imaging and then angiography with FFR 
measurement within one month. The local research ethics committee approved the study 
and all patients gave written informed consent to participate.  
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Exclusion criteria were any contra-indications to CMR scanning (i.e. claustrophobia, metallic 
implant, pacemaker insertion), contra-indications to adenosine therapy, previous coronary 
artery bypass grafts (CABG), recent myocardial infarction (MI) (within 6 months) and left 
ventricular (LV) ejection fraction <30%.  
 
4.2.1 CMR ACQUISITION  
Data were acquired with a 1.5T scanner (Intera, Philips, Best, The Netherlands) using 32-
channel coils. Examinations included high-resolution perfusion, cine and scar imaging. 
Perfusion imaging consisted of 3 short axis slices acquired every heartbeat covering 16 of the 
standard myocardial segments (apex excluded)(11) first during adenosine stress 
(140g/kg/minute of adenosine administered intravenously for 4 minutes) followed by a 
short axis cine imaging stack and then rest imaging. Imaging parameters for perfusion 
imaging: k-t blast acceleration factor 5, SSFP sequence, shortest TE (range 1.35-1.54ms), 
shortest TR (range 2.64-3.12ms), 50° flip angle; 90° prepulse, 100ms prepulse delay and 
typical acquired resolution 1.7 x 1.9 x 10mm. A dual bolus(127) (equal volumes of 
0.0075mmol/kg followed by 0.075mmol/kg after a 20 second pause) of weight adjusted 
contrast agent (Gadobutrol/Gadovist, Bayer Healthcare, Germany) was injected at 4ml/s by a 
power injector for stress and rest imaging. The cine images were completed with a set of 
long axis views. Late Gadolinium enhancement (LGE) images were acquired after 10 minutes 
(Gadovist 0.2mmol/kg cumulative dose) using an inversion recovery sequence. 
 
4.2.2 CMR IMAGE ANALYSIS 
Two independent observers blinded to the angiographic data and clinical history analysed 
the CMR perfusion images.  
A perfusion defect was defined as reduced contrast uptake at stress persisting for ≥4 
consecutive dynamic time points but not present at rest. Each observer independently 
delineated LV endocardial and epicardial borders in all three slices to determine total 
myocardial area (Osirix software version 5.5.1 64 bit). The ischaemic area was delineated 
manually with the area of hypoperfusion defined as the area with the least signal intensity 
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(hypoenhancement) in the stress perfusion dynamic with the clearest delineation of a 
perfusion defect. In patients with single vessel disease and one perfusion defect, the 
ischaemic percentage was defined for that vessel as the area of hypoenhancement 
normalised to ventricular area in all three slice as calculated above. In multivessel disease, 
with two distinct perfusion defects it was possible to apply the same principle. In a confluent 
area, if it was difficult to distinguish two separate territories, then an arbitrary 50% division 
was applied to each. Designation of vascular territories was done according to American 
Heart Association (AHA) 16-segment classification(128).  
In the presence of scar identified as areas of hyperenhancement on late gadolinium imaging, 
the area of scar was quantified manually and subtracted from the area of hypoenhancement. 
Inter- observer variability was determined by the comparison of the results from the two 
observers. Repeating the analysis of 10 cases after an interval of two weeks assessed intra-
observer variability. 
 
4.2.3 CORONARY ANGIOGRAPHY AND FFR MEASUREMENT 
Standard   angiographic   views   using   a   Judkin’s   technique   were   obtained   and   patients   were  
anticoagulated with weight-adjusted dose of unfractionated heparin. 
Pressure measurements were obtained in all coronary arteries with a diameter >2.5mm and 
>40% stenosis by visual assessment using a 0.014-inch intracoronary pressure wire (Volcano 
Therapeutics, San Diego, CA, USA, or Pressure-Wire Certus, St Jude Medical Systems AB, 
Uppsala, Sweden), during hyperaemia (intravenous adenosine infused at 140g kg/min). FFR 
was calculated as Pd/Pa, where Pd and Pa are distal coronary and aortic pressure respectively. 
A FFR of ≤0.75   was   considered   significant.   Coronary   occlusions   or   lesions   of   ≥99%   were  
categorised as FFR-positive and a default FFR value of 0.5 was assigned. In cases of serial 
stenoses, the pressure sensor was positioned beyond the most distal lesion and if the FFR 
was positive, this was ascribed to the most proximal lesion 
 
4.2.4 ANGIOGRAPHIC ANALYSIS 
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Angiographic data was analysed offline at the end of the study. Coronary dominance was 
designated on the basis of the origin of the posterior descending artery. Quantitative 
assessment of coronary artery percent narrowing was performed with MDQM-QCA (Medcon 
Limited, Tel Aviv, Israel) software. Entirely smooth and occluded arteries were allocated 0% 
and 100% respectively. 
 
4.2.5 STATISTICAL ANALYSIS 
Data analysis was performed with SPSS version 20 (SPSS Inc., Chicago Illinois).  Continuous 
variables are presented as mean ±SD.  
Correlations between normally and non-normally distributed variables were tested by 
Pearson’s  and  Spearman’s  methods  respectively. Separate analyses were done, including and 
excluding the CTO data.  
Normality of distribution was tested by the Shapiro-Wilk test. 
Differences in means between multiple groups were compared using the ANOVA test for 
normally distributed populations and the Kruskal-Wallis test for non-normally distributed 
populations. 
Inter-observer agreement of perfusion analysis was calculated using the kappa coefficient. 




4.3.1 ANGIOGRAPHIC AND CLINICAL CHARACTERISTICS OF STUDY POPULATION 
The study protocol was successfully completed in all patients. Four scans had to be excluded 
from the CMR analysis due to uninterpretable CMR images, either due to the presence of 
artefact or the basal slice being too high to allow for accurate assessment of ischaemic 
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burden. The further analysis relates to the remaining patients. The demographic and clinical 
characteristics of these patients are listed in table 4.1.  
Table 4.1: Pt demographics and clinical characteristics 
Parameter  Number or mean ± SD 
Age (years) 61.9 ± 9.5 
Sex (male) (n) 37  
Height (m) 1.71 ± 0.10 
Weight (kg) 80.9±14.7 
Body Mass Index 27.8± 3.8 
CAD risk factors (%)  




Previous PCI 12.0% 
Previous myocardial infarction 7.8% 
Symptoms (%)  
CCS 1 5.9% 
CCS 2 85.3% 
CCS 3 8.8% 
CCS 4 0 








 Of all 147 arteries, 59 arteries had a stenosis >40% and were assessed with FFR. 8 vessels 
were occluded. For angiographic details see table 4.2 and details of the CMR stress perfusion 
imaging are given in table 4.3. 
 
Table 4.2: Angiographic Characteristics 
Parameter Number or mean±SD 
No of patients 49 
No  of  FFR  measurements  (incl  CTO’s) 59 
No  of  CTO’s 8 
Vessels with FFR >0.75 21 




Patients with FFR positive   
1- VD 23 
Drug therapy (%)  
Aspirin 82.0% 
Statin 71.4% 
B blocker 60.0% 
ACE I 30.0% 
    PhD Thesis: Shazia Hussain 
 94 
2- VD 7 
3-VD 2 
QCA in vessels with FFR >0.75 (% diameter 
stenosis) 
49.8± 33.1 
QCA in vessels with FFR <0.75 (% diameter 
stenosis) 
85.0± 24.6 
Abbreviations: SD – standard deviation: QCA – Quantitative Coronary Angiography 
 
Table 4.3: CMR Perfusion imaging – Haemodynamic parameters 
Parameter N=49 patients 
Heart Rate (bpm) Rest 64 
Stress 80 




Heart Rate Pressure 
Product 




4.3.2 COMPARISON OF FFR VALUES AND EXTENT OF ISCHAEMIA 
There was very good correlation between the FFR values and the extent of ischaemia in all 
territories. 
Analysis 1 (including occluded vessels): mean values: FFR 0.67±0.17; CMR 8.92±9.35%:  r= -
0.854, p<0.0005. See fig 4.1. 
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Analysis 2 (excluding occluded vessels): mean values: FFR 0.69± 0.17; CMR 8.39±9.49: r= -
0.849, p<0.005.  
 
Figure 4.1: Scatter Plot of FFR values and % ischaemia  (All values). The FFR values of each 
vessel have been plotted against the amount of ischaemic myocardium subtended by that 
vessel. The unfilled dots represent the chronically occluded arteries, which have been 
assigned a default value of 0.5.  
y = 304.16x3 - 595.75x2 + 326.97x - 34.24 
R² = 0.6125 (p=<0.0005) 























Figure 4.2: Scatter plot between FFR values 0.4-0.8. Scatter plot of FFR values compared to 
ischaemic burden of the corresponding vessel between the values of 0.4 and 0.8 
demonstrating a linear relationship (p<0.005).  The values for the occluded vessels have been 
removed and reference lines added to highlight the FFR values of 0.67 and 0.64 that 
correspond to the prognostically relevant ischaemic burden threshold of 10 to 12.5% 
respectively. 
 
4.3.3 ANALYSIS OF CORONARY ARTERIES  
When considering the different arterial territories individually, the correlation remained 
good: LAD r= -0.85 (p<0.005); CX r= -0.76 (p=0.80); RCA r= -0.81   (p<0.005). See Figure 4.3  
There was no significant difference between the mean values of the three groups: LAD FFR 
0.71 ± 0.15, CMR 7.66± 9.0; CX FFR 0.70± 0.21,CMR 9.6± 10.7; RCA FFR 0.61 ± 0.19, CMR 12.2 
±10.2: H =2.178, p=0.336.  See table 4.4 
When considering lesion location within the coronary arteries  (analysis done for LAD), mean 
values are as follows, Proximal LAD: FFR 0.65±0.11, CMR 10.3±8.78; Mid LAD FFR 0.68±0.20, 




4.3.4 ANALYSIS BY FFR SUBGROUPS 
At FFR values greater than 0.75, CMR showed no myocardial ischaemia in any patient. At 
values between 0.4–0.8 a linear relationship between FFR and CMR with very good 
correlation was found (r= -0.83, p<0.005). See figure 4.2.  
The FFR values that correspond to an ischaemic burden of between 10 – 12.5% are 0.67 and 
0.64 respectively and are demonstrated on figure 4.3. 
The amount of ischaemia by CMR reached a peak between FFR values of 0.5- 0.4 (mean value 
23.0±1.5%). For FFR values <0.4 less ischaemia was found by CMR (mean value 15.6 ±3.2%). 
There was a statistically significant difference between these three groups: H =35.141, 
p<0.005. See table 4. 4 
Table 4.4: Average CMR and FFR values per coronary territory and per FFR subgroup 




All arteries 0.67±0.17 8.92±9.35 
All arteries (- CTO’s) 0.69±0.17 8.39±9.49 
LAD All values 0.71 ±0.15 8.01±9.3 
Prox LAD (n=7) 0.65± 0.11 10.3±8.77 
Mid LAD (n=10) 0.68±0.20 8.1±10.4 
LAD in 1VD (n=19) 0.71± 0.13 6.5± 8.7 
LAD in 2-3 VD 
(n=10) 
0.71± 0.13 9.71±10.5 
RCA 0.61 ±0.19  12.16±10.3 
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CX 0.70 ±0.21 9.63±10.8 
FFR >0.75 0.81±0.07 0 
0.51-0.75 0.65±0.06 12.7±8.1 
0.4-0.5 0.46±0.02 23.02±1.53 





Figure 4.3: Scatter plot demonstrating the relationship between FFR value and percentage 
ischaemia for the different coronary territories * Too few data points to allow for regression 
line to be applied to the Cx data 
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There was good correlation between the two observers in the measurement of CMR 
ischaemia with a Kappa coefficient (k=0.826, p=0.048). 
Assessment of intra-observer variability demonstrated a co efficient of variation of 13% with 





Figure 4.4 b 
Figure 4.4: Image of angiographic stenosis (a) and corresponding stress CMR images (b). 
Figure 4.4a shows the angiographic images with a significant lesion in the circumflex artery. 
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The FFR value is 0.56. CMR perfusion images (Fig 4.4b) showing the apical, mid and basal 
slices during stress with a lateral perfusion defect. The endocardial and epicardial borders are 
delineated (green), the perfusion defect is segmented (red) and calculated as percentage of 
the total myocardial area.  In this case, the amount of ischaemia measured is 21.5%.  
 
4.4 DISCUSSION  
This study demonstrates a number of findings: 
1) FFR values between 0.75 and 0.4 correlate closely with the ischaemic burden as 
determined by CMR perfusion imaging. 
2) An FFR value of greater than 0.75 is associated with no myocardial ischaemia. 
3) The most extensive myocardial ischaemia is found for FFR values between 0.4 and 
0.5. 
4) The maximum amount of ischaemia caused by one artery is 25% of the myocardium. 
 
4.4.1 FFR AND ISCHAEMIC BURDEN 
FFR is an index of the physiological importance of a particular stenosis and its effect on flow 
within the artery and therefore indicates the presence of ischaemia(129). A significant FFR is 
currently used as a dichotomous variable signifying presence or absence of myocardial 
ischaemia. However, the relationship between FFR value and extent of myocardial ischaemia 
is poorly understood.  
In this analysis, it has been demonstrated for the first time, that there is good correlation 
between the severity of a narrowing and the extent of ischaemia. This is important for a 
number of reasons: firstly, it further validates the utility of FFR for the functional assessment 
of coronary lesions. Secondly, it demonstrates that the severity of FFR is related to the extent 
of myocardial ischaemia. A larger pressure drop across a coronary stenosis is indicative of 
greater flow limitation resulting in a lower FFR value. Our study confirms that this 
relationship translates into a larger ischaemic burden. Thirdly, it allows the development of 
FFR as a tool to assess ischaemic burden. 
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The maximum extent of ischaemia measured was 25% in patients with FFR values in the 
range of 0.4- 0.5. This seems to be the maximum myocardial area subtended by a single 
coronary artery. This observation was the same in all three arteries and is also observed in a 
recent 3D CMR perfusion study by Manka et al (65).  
Lesion location is also an important consideration and our results suggest greater ischaemia 
with a proximal LAD lesion than a mid LAD lesion despite similar FFR values. The complex 
inter-relationship between lesion location, FFR value and ischaemic burden is interesting to 
define, but requires much larger numbers of patients and is a potential subject for 
subanalysis once the MR-INFORM study is completed. 
A recent study by Leone et al also investigated the relationship between FFR and the amount 
of myocardium perfused (112). They analysed 213 intermediate stenoses (30- 80% visual 
estimate) in 184 patients and found that lesions located in the proximal LAD were related to 
significantly lower FFR values and to a higher rate of positive FFR than those in the distal LAD, 
CX and RCA.  However, this study is limited by lack of direct assessment of the amount of 
ischaemia caused which is calculated indirectly by myocardial jeopardy scores instead.  
FFR is also affected by diameter stenosis and minimal lumen area (130). It is noteworthy, that 
even in the absence of controlling for similar lesion location and arterial diameter, we have 
demonstrated good correlation, suggesting that the actual FFR value may be one of the more 
important variables affecting extent of ischaemia. 
For FFR values less than 0.4, a decrease in the extent of myocardial ischaemia was observed. 
This is unexpected and it is difficult to lay too much emphasis on this, as the numbers are 
small.  While we are unable to provide a clear understanding of this phenomenon it is 
interesting to postulate on the role of collaterals and pre-conditioning. 
 
4.4.2 CLINICAL IMPLICATIONS 
Data from SPECT (69, 126) and CMR increasingly supports the notion that revascularisation 
should be restricted to those patients with significant, rather than the pure presence of 
ischaemia. In the current data, significant ischaemia as defined by an ischaemic burden of 10-
12.5% (66) on the CMR perfusion scan only occurred at FFR values of approximately 0.63-
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0.67 (See Fig 2). Revascularisation could thus be targeted to these values but this relates to 
single vessel disease only. In patients with multivessel disease, revascularisation maybe 
targeted to the vessel with the lowest FFR result resulting in a greater reduction in ischaemic 
burden.  
This strategy is also supported by recent data from the FAME 2 trial (30), which suggests that 
the benefit in the PCI group may be related to the area of ischaemia associated with the FFR 
value. They demonstrated that the effects of PCI appeared to be more pronounced among 
patients who had lesions with an FFR of less than 0.65 than among patients who had only 
lesions with larger FFR values (p<0.01). This is the first time that the importance of the FFR 
value itself has been related to the endpoints of the trial. The data would suggest that the 
mean FFR value of 0.68 in the trial corresponds to prognostically significant ischaemic burden 
and thus would explain the benefit in the PCI group. However, whether this benefit 
translated into a reduction in hard endpoints remains unanswered due to the premature 
termination of the trial. Thus, future studies need to focus on further fine-tuning FFR to guide 
patients with mild ischaemia. 
 
4.4.3 STUDY LIMITATIONS 
This study has a number of limitations. The sample size in this study is modest.  
The polynomial fit has been used to include the values less than FFR 0.4 but caution has to be 
used in interpreting these, as the numbers are few. However, this is the first study of this 
kind and much larger sample sizes will be required to investigate how ischaemic burden 
varies with lesion location and vessel size as alluded to earlier in the text.  
The matching of angiographic coronary arteries with territories on non-invasive imaging can 
never be exact potentially leading to inaccuracies in assessment and allocation of ischaemic 
burden. Additionally, assessing the relative contribution of two coronary arteries to one large 
area of perfusion defect involving adjacent territories is very subjective. 
For this study, qualitative visual assessment was used to reflect normal clinical practice. Fully 
quantitative perfusion analysis measuring absolute myocardial perfusion is slowly becoming 
available and may allow more accurate assessment of ischaemic burden.  
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4.5 CONCLUSION  
There is good correlation between FFR values and the extent of myocardial ischaemia. FFR 
values above 0.75 are not associated with myocardial ischaemia and ischaemic burden 
increases linearly with smaller FFR values until a maximum ischaemia of 25% is found in 
myocardium subtended by arteries with FFR values between 0.4 and 0.5. This information 
could potentially be used to target revascularisation to a subgroup of patients with a positive 
FFR and high ischaemic burden. 
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CHAPTER 5: VALIDATION OF A FUNCTIONAL JEOPARDY 
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5.1 INTRODUCTION 
Functional information on the significance of a coronary artery stenosis is increasingly used 
to decide on the management of patients with coronary artery disease (CAD)(1). Using FFR to 
guide lesion revascularisation by percutaneous intervention (PCI) leads to a reduction of 
Major Adverse Cardiac Events (MACE)(131, 132). However, FFR only assesses whether the 
blood flow to a certain myocardial territory is sufficient, but does not provide any 
information on the myocardial volume subtended by the stenotic coronary artery. This 
information is important as only patients with >10-12.5% ischaemic myocardium profit from 
revascularisation(66).  
To overcome this limitation of invasive angiography several jeopardy scores have been 
developed and validated(70, 71). These scores are based on the location and anatomical 
severity of coronary lesions and do not directly incorporate the functional significance of a 
stenosis. The recently described functional Syntax score (133) integrates complex anatomical 
data that determines the classical syntax score with FFR assessment of the relevant vessels, 
providing a more accurate risk assessment of the angioplasty procedure. However, the 
Syntax score is complex to use, time consuming, has high inter-observer variability and 
provides information on risk of the procedure rather than ischaemic burden. Whether this 
same  principle  can  be  applied  to  classical   jeopardy  scores,   to  produce  “functional   jeopardy  
scores”   that   provide   a   more   accurate   assessment   of   the   myocardium   at   risk   by   the  
incorporation of FFR data, remains unknown. 
The aim of the current study is to combine functional and anatomical information obtained 
in the catheterisation laboratory to develop a functional jeopardy score and assess the 
anatomical (classical) as well as the physiological scores against ischaemic burden measured 
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5.2 METHODS 
5.2.1 PATIENT POPULATION 
The local research ethics committee approved the study and all patients gave written 
informed consent to participate. 45 patients with stable angina (CCS class 2 or 3) and two risk 
factors for CAD awaiting invasive angiography underwent CMR scanning followed by 
coronary angiography (CXA) and FFR measurement within one month.  
Exclusion criteria were contra-indications to CMR scanning or adenosine, previous CABG or 
recent PCI, renal failure with an eGFR<30, known LV ejection fraction <35% and unstable 
symptoms. 
 
5.2.2 CMR ACQUISITION  
Data were acquired with 1.5T scanners (Intera, Philips, Best, The Netherlands) using 32-
channel coils. Examinations included high-resolution perfusion, cine and scar imaging. 
Perfusion imaging consisted of 3 short axis slices acquired every heartbeat covering 16 of the 
standard myocardial segments (apex excluded)(11) first during adenosine stress 
(140g/kg/minute of adenosine administered intravenously for 3 minutes) followed by a 
short axis cine imaging stack and then rest imaging. Imaging parameters for perfusion 
imaging: k-t blast acceleration factor 5, SSFP sequence, shortest TE (range 1.35-1.54ms), 
shortest TR (range 2.64-3.12ms), 50° flip angle, 90° prepulse, 100ms prepulse delay and 
typical acquired resolution 1.7 x 1.9 x 10mm. A dual bolus(127) (equal volumes of 
0.0075mmol/kg followed by 0.075mmol/kg after a 20 second pause) of weight adjusted 
contrast agent (Gadobutrol/Gadovist, Bayer Healthcare, Germany) was injected at 4ml/s by a 
power injector for stress and rest imaging. The cine images were completed with a set of 
long axis views. Late Gadolinium enhancement (LGE) images were acquired after 10 minutes 
(Gadovist 0.2mmol/kg cumulative dose) using an inversion recovery sequence. 
 
5.2.3 CMR IMAGE ANALYSIS 
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Two independent observers blinded to the angiographic data and clinical history analysed 
CMR perfusion images. A perfusion defect was considered present if reduced contrast uptake 
was seen at stress, persisting for ≥ 4 consecutive dynamic time points, but not present at 
rest. Each observer independently delineated LV endocardial and epicardial borders to 
determine myocardial area (Osirix software v 5.5.1. Pixmeo, Switzerland). The ischaemic area 
was delineated manually with the area of hypoperfusion defined as the area with the least 
signal intensity (hypoenhancement) in the stress perfusion dynamic with the clearest 
delineation of a perfusion defect. The total ischaemic area was calculated by summation of 
the hypoperfused areas. In cases of scar, identified as areas of hyperenhancement on late 
gadolinium imaging, the perfusion defect including the scarred area was included in the 
analysis. Inter- observer variability was determined by the comparison of the results from the 
two observers. Repeating the analysis of 10 cases after an interval of two weeks assessed 
intra-observer variability. 
 
5.2.4 CORONARY ANGIOGRAPHY 
CXA was performed within one month of CMR scanning. Standard angiographic views using a 
Judkin’s  technique  were  obtained. 
Intra-coronary pressure measurements were obtained in all coronary arteries with a 
diameter >2mm and >50 % diameter stenosis by visual assessment using a 0.014-inch 
intracoronary pressure wire (Volcano Therapeutics, San Diego, CA, USA, or Pressure-Wire 
Certus, St Jude Medical Systems AB, Uppsala, Sweden). FFR was calculated as Pd/Pa during 
hyperaemia (intravenous adenosine infused at 140 micrograms kg/min), where Pd and Pa are 
distal coronary and aortic pressure respectively. A FFR of <0.75 was considered significant. 
Coronary occlusions   or   lesions   of   ≥99%   were   defined   as   FFR   positive.   In   cases   of   serial  
stenoses, the pressure sensor was positioned beyond the most distal lesion and if the FFR 
was positive, this was ascribed to the most proximal lesion 
 
5.2.5 ANGIOGRAPHIC ANALYSIS AND JEOPARDY SCORING 
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An experienced observer blinded to the CMR imaging and clinical data analysed the 
angiographic images. Quantitative coronary angiography (QCA) was performed with MDQM-
QCA (Medcon Limited, Tel Aviv, Israel) software. 
Jeopardy scores were calculated according to the Alberta provincial project for Outcome 
Assessment in Coronary Heart Disease Score (APPROACH) score(72) and the BCIS score (71, 
73). The APPROACH anatomical score divides the left ventricle into regions according to 
pathological studies in humans evaluating the relative proportion of myocardium perfused by 
each coronary artery. In the modified version, the vessel dominance, site of occlusion and 
size of the major branches of the infarct related artery are taken into consideration (Table 
5.1). 
The BCIS score is a contemporary score(71, 73), derived from the Duke score. The Duke 
Jeopardy score is calculated by dividing the coronary tree into six segments of nearly equal 
myocardial perfusion (i.e. left anterior descending artery, major septal perforator, major 
diagonal branch, circumflex artery, major obtuse marginal artery and posterior descending 
artery). A score of two is given for each significant lesion in a myocardial territory. The BCIS 
score allows for the classification of graft and left main stem disease by ascribing points to a 
left main lesion of >50% and to significant graft lesions. The total BCIS score was divided by 
12 to provide a percentage of ischaemia as required in the Bland Altman analysis etc.  
The jeopardy scores were calculated based on the QCA results using two accepted thresholds 
of luminal diameter reduction to define lesion significance: 70%  (APP70 and BCIS70) and 50% 
stenosis (APP50, and BCIS50).  
Table 5.1: Modified Angiographic APPROACH score. Results provided as a percentage of the 
left ventricular myocardium. Modified from Ortiz-Perez et al (134) 
Culprit 
lesion 
Infarct related artery 
side branches 
Diagonal for LAD occlusion only or 
posterolateral for all others 
Small/Absent Medium Large 
LAD (RD  Distal 13.75 14.8 15.9 
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or LAD) Mid 27.5 29.7 31.8 






Small/Absent 9.25 12.5 15.75 
Medium 15.25 18.5 21.75 





Small/Absent 23.5 28 32.5 
Medium 29.5 34 38.5 




PDA Small/Absent 9.25 12.5 15.75 
Medium 15.25 18.5 21.75 
Large 21.25 24.5 27.75 
Mid LCx 
(RD) 
 3.25 6.5 9.75 
Abbreviations: APPROACH score =Alberta provincial project for Outcome Assessment in 
Coronary Heart Disease Score: LAD = left anterior descending artery, LCX =left circumflex 
artery, LD=left dominant, RD=right dominant, RCA=right coronary artery, OM=obtuse 
marginal artery, PDA=posterior descending artery. 
 
5.2.6 FUNCTIONAL JEOPARDY SCORE 
The functional scores using the APPROACH (f-APP) and the BCIS (f-BCIS) jeopardy scores were 
calculated based on the FFR results alone. Additionally, a weighted functional- APPROACH 
score was calculated as the product of the APPROACH score and (1-FFR value). This allowed 
for a greater ischaemic burden to be calculated for lower FFR values and vice versa. 
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5.2.7 STATISTICAL ANALYSIS 
Statistical Analysis was performed using IBM SPSS Statistics (version 19 SPSS, Chicago, Illinois 
and Medcalc (v12.3.0, Mariakerke, Belgium). Continuous variables were expressed as mean 
+/- SD. Correlations between normally and non-normally distributed variables were tested by 
Pearson’s  and  Spearman’s  methods  respectively.  The  correlation  between  the  functional  and  
anatomical jeopardy scores and the extent of ischaemia measured by CMR was assessed. 
Agreement between the two tests was tested with the Bland-Altman analysis. Normality of 
distribution was tested by the Shapiro-Wilk test. The Fisher to z transformation was used to 
assess the significance of the change in correlations. Inter-observer variability of perfusion 
analysis was calculated using the kappa coefficient. 
Receiver-operating characteristic (ROC) analysis determined the accuracy of the f-APP and 
the f-BCIS scores to predict 12% ischaemia on CMR. Intra-observer variability was assessed 
by the use of the coefficient of variation from duplicate measurements. For all analyses 
P<0.05 was considered significant. 
 
5.3 RESULTS  
5.3.1 CLINICAL CHARACTERISTICS 
45 patients (mean +/- SD age, 62+/-10 yrs) were included in the analysis. For the 
demographic and clinical characteristics see table 5.2. 
Table 5.2: Patient demographics and clinical characteristics 
Parameter Number (%) or mean (SD) (n=45) 
Age (years) 61.9 (9.5) 
Sex (male) (n) 27 
Height (m) 1.72 (0.10) 
Weight (kg) 82.7 (14.71) 























Body Mass Index 27.8 (3.8) 
CAD risk factors (%)  




Previous PCI 11.7 
History of Previous myocardial 
infarction 
11.4 
Angina Symptoms (%)  
CCS 1 5.9 
CCS 2 85.3 
CCS 3 8.8 
CCS 4 0 
Drug therapy (%)  
Aspirin 91.1 
Statin 82.6 
B blocker 61.7 
ACE I 29.4 
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Abbreviations: PCI-percutaneous intervention: CCS- Canadian Class score: ACE – Angiotensin-
converting enzyme inhibitor 
 
5.3.2 ANGIOGRAPHIC AND FFR RESULTS  
Three patients had visually unobstructed arteries where no FFR measurement was done. On 
the basis of QCA measurements, 59 arteries had stenoses >50 % and 37 arteries had stenoses 
>70%.  
FFR was measured in 58 arteries (a pressure measurement was not performed in one artery 
due   to   technical   reasons   and   10   arteries   were   CTO’s   or   subtotal   occlusions).   Of   these,   26  
arteries had an FFR above 0.75 and 32 had a FFR <0.75 (table 5.3). 
Based on FFR measurements alone, 15 patients had no functional coronary disease, 15 
patients had single vessel disease, 4 patients had 2-vessel disease and 2 patients had 3-vessel 
disease.  
Table 5.3: Angiographic details  
Parameter Number 
No of patients 36 
No  of  FFR  classifications  (incl  CTO’s) 58 
Vessels with FFR >0.75 26 
Vessels with FFR <0.75 32 








One vessel disease 16 
Two vessel disease 4 
Three vessel disease 2 
 
5.3.3 CMR FINDINGS  
Three patients were excluded from the CMR data analysis due to poor image quality. Three 
patients had scar on LGE. The mean ischaemic burden measured on CMR was 11.21 +/-11% 
(table 5.4). 
Table 5.4: CMR data  
 Number or mean (SD) 
No of patients 36 
Rest HR 63.7 (12.0) 
Rest SBP 134 (21.3) 
Rest RPP 7089 
Stress HR 75.5 (21.3) 
Stress SBP 127 (24) 
Stress RPP 8353 
Ischaemia burden (%) 11.2 (11) 
 
Table 5.4: CMR data. Abbreviations: HR=heart rate: SBP= systolic blood pressure: RPP= rate 
pressure product 
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5.3.4 CORRELATION AND AGREEMENT BETWEEN CMR AND ANGIOGRAPHIC ASSESSMENT OF 
EXTENT OF ISCHAEMIA  
The mean score for APP50 was 40.36 +/- 26% and 33.81% +/-25% for APP70. The mean f -APP 
score was 23.97 +/- 23.4  (table 4) 
The mean score for BCIS50 was 4.4 +/- 3.1 and 3.73  +/- 3.17 for BCIS70. The f-BCIS score was 
2.78 +/-2.7 (table 5.5).   
The correlation between percentage ischaemia measured by CMR and the APP50 score 
(r=0.58 p=0.0001) was moderate. The correlation with the APP70 was r=0.66 (p=0.0001) with 
and r=0.82 (p=0.0001) with the f-APP (figure 5.1). The change in correlation between APP50 
and f-APP was significant z statistic=-2.04,p=0.04 whereas APP70 and f-APP did not differ 
significantly (z= -1.51, p=0.131).  
Bland Altman analysis reveals that in relation to CMR, the APP50 and APP70 overestimated the 
volume of ischaemic myocardium by 29.2% and 22.6% respectively, which was reduced to 
12.8 % after integrating functional data (table 5.5). An f-APP score of 26% corresponded to a 
CMR ischaemia threshold of 12%  (Fig 5.1c). 
The correlation between the BCIS50 score and CMR was r=0.48, p=0.0001 and r=0.63 
p=0.0001 with BCIS70 (fig 5.2). For the f-BCIS score r=0.82, p=0.0001. The change in 
correlation between BCIS50 and f-BCIS was significant (z statistic -2.63, p= 0.009), however, 
BCIS70 and f-BCIS did not differ (z statistic -1.51, p=0.13). 
An overestimation of ischaemic burden was demonstrated with the BCIS scores (mean bias: 
BCIS50: 25.2%, BCIS70: 19.9%, f-BCIS: 12%)(table 4). A f-BCIS score of 3 corresponded to a CMR 
ischaemia threshold of 12% (Fig 5.2c). 
Using the weighted APPROACH (APP X (1-FFR value)) score resulted in better agreement with 
a mean bias of 1.1%  (Fig 4). 
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APPROACH  APP50 40.37 
(26) 
0.58 p<0.05 29.9 
APP70 33.82 
(27.8) 
0.66 p<0.05 22.6 
f-APP 23.97 
(23.4) 
0.82 p<0.05 12.8 
BCIS BCIS50 4.37 
(3.1) 
0.48 p<0.05 25.2 
BCIS70 3.74 
(3.17) 
0.63 p<0.05 19.9 
f-BCIS 2.79 
(2.7) 
0.82 p<0.05 12.0 
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 Fig 5.1a             Fig 5.1d 
 
 
Fig 5.1b            Fig 5.1e 
 
Fig 5.1c           Fig 5.1f 
 
Figure 5.1:  Correlation and Agreement between CMR and the APPROACH jeopardy score. 
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Scatter plots illustrating the correlation between the extent of ischaemia measured by CMR 
compared to that assessed by the APPROACH jeopardy score based on thresholds of 50% 
(5.1a) and 70% (5.1b) for significance and on FFR (5.1c). Corresponding Bland Altman plots 
(5.1d-5.1f) with limits of agreement lines (2SDs). The prognostically important threshold of 
12% ischaemic burden is highlighted by the dashed vertical line (5.1c) and corresponds to a f-
APPROACH score of 26%. 
 
 
Fig 5.2a         Fig 5.2d 
 
Fig 5.2b        Fig 5.2c 
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Fig 5.2c             Fig 5.2f 
 
Figures 5.2:  Correlation and Agreement between CMR and the BCIS jeopardy score. 
Scatter plots illustrating the correlation between the extent of ischaemia measured by CMR 
compared to that assessed by the BCIS jeopardy score based on thresholds of 50% (5.2a) and 
70% (5.2b) for significance and on FFR (3c). Corresponding Bland Altman plots (5.2d-5.2f) 
with limits of agreement lines (2SDs). The prognostically important threshold of 12% 
ischaemic burden is highlighted by the dashed vertical line  (5.2c) and corresponds to a f-BCIS 
score of 3. 
 
 
Figure 5.3: Weighted APPROACH score  
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Bland Altman analysis demonstrating the agreement between the weighted APPROACH score 
and the extent of ischaemia demonstrated by CMR. The weighted APPROACH score is 
calculated as the product of 1- FFR value and the APPROACH score and demonstrates 
improved agreement with a mean bias of -1.1% 
  
5.3.5 DIAGNOSTIC ACCURACY OF THE FUNCTIONAL JEOPARDY SCORES TO DETECT ISCHAEMIA 
>12% 
The area under the ROC curve (AUC) for the f-APP and the f-BCIS scores to accurately predict 
ischaemia >12% is 0.893 (95%CI: 0.748-0.940) and 0.901 (95% CI: 0.757-0.974) respectively. 
An f-APP score of 26% results in a sensitivity of 62% and a specificity of 79% to detect a 
threshold of 12%. A f-BCIS score of 3 has a sensitivity of 55% and a specificity of 90% to 
detect this threshold  (Fig 5.4).  
 
5.4a      5.4b 
 
Figure 5.4: Receiver Operating Characteristic curve for f-APP and f-BCIS and Jeopardy Score 
to detect myocardial ischaemic  burden  ≥12%.   
A f-APP score (5.4a) of 3 detected this threshold with sensitivity 62% and specificity 79%. A f-
BCIS score  (5.4b) of 26% detected this threshold with a sensitivity of 55% and a specificity of 
90%.  
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5.3.6 REPRODUCIBILITY 
Inter-observer variability in the measurement of CMR ischaemia was good (k=0.826, 




Functional jeopardy scores correlate well with the ischaemic burden as determined by CMR 
perfusion imaging. There is significant overestimation of the ischaemic burden by anatomical 
jeopardy scores, which is reduced by adding the functional information. 
Since CXA is often performed without prior testing for ischaemic extent and severity, there is 
a need to assess the significance of ischaemia in the catheterisation laboratory. However, 
due to the disparity of functional and anatomical information (135) the accurate estimation 
of ischaemic extent by classical anatomical jeopardy scores is questionable. While functional 
measurements of stenosis significance by FFR are more predictive of outcome than the 
anatomical severity, FFR does not take the extent of the defect into account. For example, a 
positive FFR in an artery supplying a small territory may result in very little demonstrable 
ischaemia at a myocardial level.  
The novel functional jeopardy score proposed in this manuscript incorporates information on 
stenosis severity and the amount of myocardium subtended by the artery. This approach 
improves the estimate of ischaemic extent when compared to CMR as the reference 
















Figure 5.5: Case Example 
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Perfusion images of the apical, midventricular and basal slices with delineation of the 
endocardial and epicardial borders and measurement of ischaemic burden (Fig 5.5a). 
Hypoenhancement in the inferior wall is seen in all three slices, which would be consistent 
with ischaemia of the RCA. Additionally a small area is seen in the apical anterolateral wall 
that would be consistent with ischaemia in either the marginal or diagonal branches in which 
the FFR result is also positive. The amount of ischaemic myocardium is measured at 19%. 
Corresponding angiographic images (Fig 5.5b) demonstrating the significant lesions within 
the RCA as well as the LAD, and LCx arteries.  Lesions within the OM and diagonal branches 
are also seen. Fig 5.5c shows the FFR result in the vessels interrogated.  Based on the 
angiographic images, the APP score for area at risk is 89% and the BCIS score is 10 (Fig 5.5d). 
However, as the LAD and Cx arteries are FFR negative the score is reduced to 51% and to 4.  
 
      
Fig 5.5c      Fig 5.5d 
 
Previous comparative studies between CMR and FFR have assessed the diagnostic accuracy 
of CMR using FFR as the reference standard(63, 136) but CMR is now increasingly utilised to 




CMR ischaemia 19% 
APP score  89% 
BCIS score 10 
f-APP score 51% 
f- BCIS score 4 
Artery QCA  
(%) 
FFR 
LAD 72 0.79 
Diagonal 70 0.69 
Cx 67 0.93 
OM1 82 0.61 
RCA 80 0.30 
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analysis of CMR images(32) demonstrating good correlation with the Duke Jeopardy score 
(r=0.82).  Morton  et  al  showed  that  a  BCIS  score  ≥6  predicts  an  ischaemia threshold of 12% on 
CMR with high specificity(137). However, both of these studies have used an anatomical 
score, without correction for haemodynamic relevance.  
While confirming a good correlation, marked disagreement in the estimation of ischaemic 
volume is noted. This may be a consequence of underestimation by CMR, overestimation by 
the jeopardy scores, or a combination of both and could potentially be explained by 
limitations of jeopardy scoring.  
The APPROACH score is based on pathological post-mortem studies of hearts with occluded 
arteries(138, 139) and includes areas of infarction, risk zones and no reflow zones and thus 
will be significantly larger than areas of ischaemia in non-occluded arteries. This suggests 
that an overestimation by the angiographic scores may be responsible for the discordance. 
The extent of the area at risk has been compared previously in patients presenting with 
acute myocardial infarction. The Duke and the APPROACH score were both used by Berry et 
al who compared the extent of the area at risk with CMR T2 weighted imaging and 
angiographic scoring(140) demonstrating reasonable correlation (r=0.66, p<0.0001). 
Similarly, Fuernau et al also used the APPROACH score to compare the angiographic area at 
risk with the CMR area at risk (r=0.87, p<0.001) (141). Both studies showed an 
overestimation of T2 weighted area at risk in relation to angiographic area at risk by the 
APPROACH score due to inclusion of both the infarcted area and surrounding oedema. 
In patients with stable CAD, ischaemia may be the consequence of diffuse disease, for which 
the precise lesion responsible for ischaemia is harder to pinpoint, resulting in discrepant 
estimation. Furthermore, collaterals that develop during chronic ischaemia will reduce the 
ischaemic area. A recent study by Arnold et al (142) used the Bypass Angioplasty 
Revascularisation Investigation (BARI) myocardial jeopardy index and the DUKE score to 
assess angiographic disease burden in patients with multi-vessel CAD. Using fully quantitative 
analysis, hyperaemic blood flow was evaluated and ischaemic burden was quantified. They 
also found that relative to cardiovascular magnetic resonance, angiographic assessment 
overestimated disease burden at baseline (CMR 49.9±29.2% versus BARI 80.7±15.2% 
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[P<0.0001] and Duke 64.5±29.6% [P=0.0019]). This again may be a reflection of the limitation 
of using a jeopardy score and also of pure anatomical assessment. 
The BCIS score is derived from the Duke jeopardy score, which was developed based on the 
usual distribution of coronary arteries to more accurately define CAD than a simple 
classification into 1-, 2- or 3 vessel disease. As it is purely a weighted score its utility in 
estimating actual percentage ischaemic burden may be limited. Interestingly, however, when 
converted to a percentage, the amount of myocardium at risk is very similar to that 
measured by the APPROACH score (Figure 2) and the correlation and extent of ischaemia 
measured by the functional scores are almost identical (f-APPROACH r=0.82, isch  = 23%; f-
BCIS r=0.82, isch= 22%). 
Using a weighted APPROACH score that takes into account the FFR value assuming that the 
lower the FFR value the greater the ischaemic extent, results in almost perfect agreement. 
This suggests that value of FFR (when considered as a continuous variable) provides 
information on the severity of ischaemia, over and above the dichotomous classification that 
is currently used. Recent subanalysis data from the FAME 2 trial(30) also hints at this by 
demonstrating that in proximal lesions within large arteries, patients with an FFR value of 
less than 0.65 were more likely to benefit from PCI than lesions with an FFR value of greater 
than 0.65 (p =0.01). This is presumed to be due to a greater ischaemic burden.  Furthermore, 
it suggests that lesion location may not be the only variable that affects extent of ischaemia 
and this maybe one of the major limitations of jeopardy scores.  
 
5.4.1.CLINICAL IMPLICATIONS 
In principle, the f-BCIS score could be integrated into clinical standards due to its simplicity. 
However, a few areas of concern remain. 
1.) The mean estimates of ischaemic burden by the f-APPROACH score (24%) and the f-
BCIS (2.67 =23%) were twice the CMR estimate (11.2%). As such, 12% myocardial ischaemia 
by CMR (akin to 12% prognostically significant ischaemic threshold on SPECT) would be 
equivalent to a BCIS score of 3 or an APPROACH score of 26% (see figure 5.3).  
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2.) The specificity of a f-APP score >26% or a f-BCIS score of >3 is high and likely to be 
associated with a significant ischaemic burden supporting a decision to perform 
revascularisation. However the sensitivity for both these scores is modest, missing around a 
third of patients with significant ischaemia on the CMR scan. Further studies are therefore 
required to determine whether such a threshold has prognostic significance (see below) or 
how to further improve alignment of the two methods. 
 
5.4.2 FUTURE DEVELOPMENTS 
The estimation of ischaemic extent by CMR may be improved by fully quantitative perfusion 
analysis(20). There are currently novel developments to identify a perfusion threshold or 
absolute value for myocardial blood flow to allow a better estimation of ischaemic burden(4). 
 
5.4.3 LIMITATIONS  
One limitation of the study is using CMR as a reference standard when most of the data on 
ischaemic threshold is based on SPECT studies. We acknowledge that the 10-12.5% threshold 
for prognostically significant ischaemia may not apply to CMR but there is emerging evidence 
that the extent of ischaemia measured by the two modalities is similar (74). Another 
limitation is the consideration of the whole perfusion defect as the ischaemic area. This was 
done, as it can be difficult to accurately identify areas of peri-infarct ischaemia around scar. 
The number of patients with scar was small (n=3) therefore this is unlikely to have had an 
impact on the overall results. 
 
5.5 CONCLUSION 
The use of a functional jeopardy score integrates both anatomical and functional data from 
coronary angiography and FFR to provide an assessment of ischaemic burden. The functional 
jeopardy score can potentially be incorporated into interventional practice but further 
studies are required to see if this can be used to guide clinical decision-making. 
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CHAPTER 6. DIAGNOSTIC ACCURACY OF CMR IN 
MULTIVESSEL DISEASE. 




While there is a significant body of literature on the accuracy of both CMR and FFR for the 
detection of CAD, there are limited data on their comparability in defining ischaemic 
segments in patients with multi-vessel disease. Data comparing SPECT and FFR have shown 
fewer ischaemic territories with SPECT than FFR in patients with multi-vessel disease(143). It 
is well recognised, though, that the relatively low spatial resolution of SPECT may lead to 
underestimation of perfusion defects (89). 
While most literature on non-invasive assessment of ischaemia is based on single photon 
emission computed tomography (SPECT), cardiovascular magnetic resonance (CMR) has 
shown advantages such as higher spatial resolution (3, 63) and potentially better diagnostic 
accuracy (5). It is unknown, however, whether the use of a high-resolution perfusion 
technique such as CMR leads to improved concordance for the identification of ischaemic 
segments in multi-vessel disease in comparison with FFR. The aim of this study was to 
compare the extent of myocardial ischaemia based on CMR and FFR in patients with 
angiographically defined multi-vessel disease. 
 
6.2 METHODS 
The local research ethics committee approved the study and all patients gave written 
informed consent to participate. A total of 41 patients with stable 2- or 3-vessel disease 
designated on a visual basis by angiography (diameter stenosis >50%) were recruited. 
Individuals who consented for the study had coronary angiography with FFR measurement 
and CMR scans within 4 weeks of recruitment.  
Exclusion criteria were all contra-indications to CMR scanning (i.e. claustrophobia, metallic 
implant, pacemaker) contra-indications to adenosine therapy, previous coronary artery 
bypass graft (CABG), recent myocardial infarction (MI) within 6 months and left ventricular 
(LV) ejection fraction <30%.  
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6.2.1 CMR IMAGE ACQUISITION  
Data were acquired with a 1.5T scanner (Achieva, Philips, Best, The Netherlands) using 32-
channel coils. Examinations included high-resolution perfusion, cine and scar imaging. 
Perfusion imaging consisted of 3 short axis slices acquired every heartbeat covering 16 of the 
standard myocardial segments (apex excluded)(11) first during adenosine stress 
(140g/kg/minute of adenosine administered intravenously for 3≤ minutes) followed by a 
short axis cine imaging stack and then rest imaging. Imaging parameters for perfusion 
imaging: kt-blast acceleration factor 5 SSFP sequence, shortest TE (range 1.35-1.54ms), 
shortest TR (range 2.64-3.12ms), 50° flip angle; 90° prepulse, 100ms prepulse delay and 
typical acquired resolution 1.7 x 1.9 x 10mm. A dual bolus(127) (equal volumes of 
0.0075mmol/kg followed by 0.075mmol/kg after a 20 second pause) of weight adjusted 
contrast agent (Gadobutrol/Gadovist, Bayer Healthcare, Germany) was injected at 4ml/s by a 
power injector for stress and rest imaging. The cine images were completed with a set of 
long axis views. Late gadolinium enhancement (LGE) images were acquired after 10 minutes 
(Gadovist 0.2mmol/kg cumulative dose) using an inversion recovery sequence 
 
6.2.2 CMR IMAGE ANALYSIS 
CMR perfusion images were analysed by two experienced observers blinded to the 
angiographic data and clinical history (AC and SH). They reported all scans with consensus; 
any disagreement was arbitrated by a third reader (EN). 
A perfusion defect was defined as reduced contrast uptake at peak stress persisting for 5 
consecutive dynamic time points but not present at rest. Corresponding late gadolinium 
enhanced images were reviewed side by side with the perfusion data and enhanced 
myocardium was disregarded for ischaemia. 
Designation of vascular territories was done according to AHA 17 segment classification(128). 
Segments 1, 2, 7, 8, 13, 14, and 17 were assigned to the left anterior descending coronary 
artery (LAD). Segments 3, 4, 9, 10, and 15 were assigned to the right coronary artery (RCA). 
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Segments 5, 6, 11, 12, and 16 were assigned to the left circumflex artery (CX). This analysis 
was performed without knowledge of angiographic variation as per clinical practice. 
 
6.2.3 CORONARY ANGIOGRAPHY AND FFR MEASUREMENT 
After   obtaining   either   femoral   or   radial   access,   a   standard   Judkin’s   technique  was   used   to  
obtain angiographic views. Multiple projections of the coronary arteries were acquired, 
including at least 2 orthogonal views to assess stenosis severity.  
Pressure measurements were obtained in all vessels that showed a ≥40% diameter stenosis; 
lesser diameter stenoses were considered not significant. A 0.014-inch intracoronary 
pressure wire (Volcano Therapeutics, San Diego, CA, USA, or Pressure-Wire Certus, St Jude 
Medical Systems AB, Uppsala, Sweden) was inserted into the coronary artery. FFR was 
calculated during hyperaemia (intravenous adenosine infused at 140 micrograms kg/min for 
at least 90 seconds) as Pd/Pa, where Pd and Pa are distal coronary and aortic pressure 
respectively. In cases of serial stenoses or when there was diffuse disease, the pressure 
sensor was positioned beyond the most distal diseased segment and if the FFR was positive, 
this was ascribed to the most proximal lesion. A FFR of ≤0.75 was considered significant. 
Coronary   occlusions   or   lesions   of   ≥99%   were defined as FFR positive.  Arteries with focal 
lesions < 40% diameter stenosis were defined as FFR negative. 
 
6.2.4 ANGIOGRAPHIC ANALYSIS 
Angiographic data was analysed offline at the end of the study. Coronary dominance was 
designated on the basis of the origin of the posterior descending artery. Quantitative 
assessment of coronary artery percent narrowing was performed with MDQM-QCA (Medcon 
Limited, Tel Aviv, Israel) software. Entirely smooth and occluded arteries were allocated 0% 
and 100% respectively. 
 
6.2.5 STATISTICAL ANALYSIS 
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Data analysis was performed with SPSS version 20 (SPSS Inc., Chicago Illinois).  Continuous 
variables were presented as mean ± standard deviation (SD). The k statistic values were 
derived to investigate per-patient and per-vessel concordance between FFR and CMR derived 
evidence for ischaemia (a k statistic of +1 indicating perfect agreement, 0 indicating 
agreement as expected by chance, and -1 indicating complete disagreement). In groups 
where kappa statistics could not be performed (i.e. where the value in one group was 
constant) concordance was assessed by percentage agreement.  
Subgroup analyses according to arterial territories, FFR quartiles, single and multivessel 
disease were performed. Where possible the kappa statistic was used, otherwise percentage 
agreement was used and concordance was assessed.  
The Mann Whitney U test was used to compare the mean number of ischaemic territories 




All 41 patients (29 males, average age 62±9 years) and 123 territories were included in the 
analysis. Table 6.1 summarises the clinical characteristics of the patients and the 
angiographic features. Table 6.2 summarises the CMR perfusion data. Two patients had 
subendocardial scar, none had transmural scarring.  
 
Table 6.1:  Pt clinical characteristics and angiographic details 
Parameter  Number or mean (+/- SD) (n=41) 
Age (years) 62 (9) 
Sex (male) (n) 30  
Height (m) 1.71 (0.11) 
























Weight (kg) 81.0 (16.29) 
Body Mass Index 27.8 (4.1) 
CAD risk factors (%)  




Previous PCI (%) 18.5 
Previous myocardial infarction (%) 4.0 
Drug therapy (%)  
Aspirin 81.5 
Statin 80.0 
B blocker 61.3 
ACE I 29.6 
Angiographic details  
Vessels with FFR >0.75 (n) 72 
Vessels  with  FFR  ≤0.75 (n) 51 
QCA in vessels with FFR >0.75 (% 
diameter stenosis) 
55.8 (18.1) 
QCA   in   vessels   with   FFR   ≤0.75   (%  
diameter stenosis) 
81.3 (15.6) 














 Abbreviations: HR = heart rate, SBP= systolic blood pressure, RPP= rate pressure product 
 
6.3.1 COMPARISON OF CMR, FFR AND QCA 
CMR demonstrated no perfusion defect in 12 patients (29%), ischaemia in one territory in 20 
(49%) patients, two territories in 8 patients (20%) and 3 territories in one patient (2%). All 
cases were read with consensus between two readers with only two cases requiring a third 
observer. 
FFR results were negative in all vessels in 9 patients (22%), positive in 1 vessel in 16 patients 
(39%), in 2 vessels in 14 patients (34%) and 3 vessels in 2 patients (5%).  
Using quantitative coronary angiography (QCA) with an angiographic cut-off of 50% defining 
significant stenosis results in the classification of 34 patients with 2- vessel disease (83%) and 
7 patients with 3- vessel disease (17%). See figure 6.1. 
 Number or mean (+/- SD) 
No of patients 41 
Rest HR 63 (13.2) 
Rest SBP 132 (21.3) 
Rest RPP 8243 
Stress HR 80 (18) 
Stress SBP 129 (24) 
Stress RPP 9889 
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Using quantitative coronary angiography (QCA) with an angiographic cut-off of 70% defining 
significant stenosis results in the classification of 7 Patients with 0 vessel disease (17%), 9 
patients with 1- vessel disease (22%), 23 patients with 2- vessel disease (56%) and 3 patient 
with 3- vessel disease (7%). See figure 6.1. 





Figure 6.1: Respective proportion of number of vascular abnormalities as described by 
coronary angiography (based on a QCA cut off of 50% stenosis and 70% stenosis), CMR and 
FFR (CXA = coronary x-ray angiography) 
 
6.3.2 CONCORDANCE BETWEEN FFR AND CMR  
In 21 patients (51%), there was complete agreement as to the number of territories of 
ischaemia: mean no of territories 0.7±0.7 for both (p=1.0). Of these there was complete 
concordance in territories identified in 93 % of patients. 







CXA (50%) CXA (70%) FFR CMR
3VD2VD1VD0VD
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CMR showed fewer ischaemic territories than FFR. See table 6.3. 
The classification of 89 out of 143 territories (72%) was identical with CMR and FFR; of the 
discordant territories, in 20 (16%) CMR was negative and FFR positive and in 12 (10%) CMR 
was positive and FFR negative.  See Fig 6.2 and Fig 6.3. 
Overall, there was moderate concordance between the two methods on a per patient basis  
(k =0.555: 95% CI  0.179-0.753) and on a per vessel basis (k=0.416: 95% CI 0.248-0.573). See 
table 6.4. 
On a per patient basis, those with 0 or 1- vessel disease exhibited 72% agreement for the 
presence of any ischaemia, increasing to 88% in those patients with 2- or 3- vessel disease. 
 
Table 6.3: Concordance between CMR and FFR on a per patient basis according to number of 
significant FFR values and CMR perfusion defects. 
 FFR Result 
0 1 2 3 
CMR 
result 
0 7 2 2 1 
1 1 11 8 0 
2 1 3 3 1 








Figure 6.2: Case example of concordance between FFR value and CMR. 
Angiographic images and corresponding perfusion images of a patient with 2-vessel disease. 
The LAD has a proximal stenosis (FFR value 0.63) (see arrow) resulting in a perfusion defect in 
the anterior wall visible in the apical, mid and basal ventricular slice.  
The RCA has a distal stenosis (FFR value 0.62) (see arrow) resulting in a perfusion defect in 
the inferior wall visible in the basal and mid slice.  
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Fig 6.3. Case Example of discordance between the FFR value and CMR. 
Angiographic images and corresponding perfusion images of a patient with 2-vessel disease. 
The LAD has a distal stenosis (FFR value 0.7) (arrow) with no associated perfusion defect. 
The RCA has a proximally occluded artery (arrow) resulting in a perfusion defect in the 
inferior wall visible in all three slices. The combination of a distal lesion and a mildly positive 
FFR value results in no demonstrable ischaemia. 
 
Table 6.4: Per vessel and per patient concordance between CMR and FFR 
Concordance for the detection of ischaemia between CMR perfusion imaging and fractional 













6.3.3 CONCORDANCE OF FFR QUARTILES AND VASCULAR TERRITORIES 
Concordances between CMR and FFR for each territory: LAD artery concordance is poor: 
(k=0.159: 95% CI -0.104 – 0.423), CX artery concordance is moderate  (k= 0.478: 95% CI 0.175 
– 0.780), RCA artery concordance is also moderate (k=0.599: 95% CI  0.352 – 0.846). 
Percentage agreement for each FFR quartile: 1st quartile 0-0.25 - 100% agreement; 2nd 
quartile 0.25-0.49 = 100 % agreement; 3rd quartile 0.5 – 0.75 = 44% agreement; 4th quartile 
0.76 -1.0 = 84% agreement. 
The lowest percentage agreement (42%) was found with FFR values of 0.7-0.8, of which the 





 FFR Result 
Per vessel Per patient 
>0.75 ≤0.75 >0.75 ≤0.75 
Negative 61 23 7 5 
Positive 11 28 2 27 
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6.4 DISCUSSION 
The data presented in this chapter shows reasonable concordance between CMR and FFR for 
the identification of myocardial ischaemia in patients with angiographic multi-vessel disease. 
On a per vessel basis, 89 out of 123 territories demonstrated concordance between the CMR 
and FFR results (72%). On a per patient basis there was complete concordance of number 
and localisation of territories in 46% of patients. 
In one third of patients, CMR demonstrated a lower number of ischaemic territories than 
FFR. Agreement was best at the extremes of FFR (<0.5 and >0.75) but less strong for 
intermediate values. Concordance was best for RCA territory, followed by CX and worst for 
LAD. 
 
6.4.1 FUNCTIONAL ASSESSMENT IN MULTIVESSEL DISEASE 
Most previous studies specifically aimed at patients with multi-vessel disease have 
predominantly used SPECT as the non-invasive imaging test. In a study by Lima et al in 143 
patients with proven angiographic 3–vessel CAD, myocardial perfusion imaging with SPECT 
demonstrated no significant perfusion defect or a single vessel pattern of disease in 54% of 
patients(88). This may be due to the lower sensitivity of SPECT, which has been attributed to 
its relatively low spatial resolution(89) or to the well-recognised disparity between 
angiographic and functional information (90). In the FAME cohort of patients, only 14% of 
the angiographically classified 3- vessel disease group had functional 3- vessel disease(91). 
In a study by Melikian et al (143), the concordance between SPECT and FFR for the 
identification of ischaemic territories was poor (k=0.14 on a per patient and k=0.28 on a per 
vessel basis), which is interesting given that FFR was primarily validated against SPECT, albeit 
for the presence of ischaemia in single vessel disease (23). One of the limitations of this study 
was that 60% of the study cohort had either no or single vessel ischaemia when based on an 
FFR <0.8. Additionally, QCA measurement demonstrated an average stenosis severity of 50 - 
60%. Thus the study probably reflects a low risk population rather than a true multi-vessel 
cohort. An earlier study by Ragosta (144) compared the concordance between FFR (using 
<0.75 as the cut-off for significance) and SPECT demonstrating agreement in 69% of cases. In 
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the majority of the discordant cases SPECT identified one stenosis and failed to identify a 
second or third stenosis regarded as significant by FFR. The reasons for the disparity of the 
two studies remains unclear and is unlikely to be solely due to the different FFR cut off 
values. 
As mentioned earlier, the lower spatial resolution of SPECT may contribute to the lack of 
concordance. CMR perfusion imaging is an established imaging modality and the diagnostic 
accuracy of CMR has been assessed in multiple studies. A meta-analysis of 17, 901 patients 
showed an area under the curve (AUC) of 0.9055 for CMR (17), which was similar to PET and 
superior to SPECT imaging. In another meta-analysis, sensitivity, specificity and diagnostic 
accuracy were 0.91 and 0.81 respectively (18). Two recent studies have also shown results 
favourable for CMR. In the MR-IMPACT II trial, 533 patients underwent CXA, SPECT and CMR 
in 33 centres demonstrating a sensitivity of 75% which was superior to SPECT and a 
specificity of 59% which was inferior to SPECT (12). Additional subgroup analysis in multi-
vessel disease, by different gender and in patients without prior MI also confirmed superior 
diagnostic accuracy. The CEMARC study, a larger (728 pts) single centre study showed a 
sensitivity of 86% for CMR which was significantly superior to that of SPECT at 66.5%, 
although specificity was similar (5). Subgroup analysis for multivessel disease in the CEMARC 
trial resulted in good diagnostic accuracy (AUC of 0.91 vs 0.77 for SPECT), however the 
assessment was on a per patient basis only and anatomic stenosis severity rather than FFR 
was used as the reference standard. A comparative accuracy study done by Chung et al(92) 
compared SPECT and perfusion CMR in patients with angiographically proven three vessel 
disease and showed that CMR detected perfusion defects in all three vascular territories in 
57% of patients vs only 11% with SPECT. 
 
6.4.2 THE “TRUE” GOLD STANDARD FUNCTIONAL TEST 
Whilst trying to understand the causes of discrepancy between the two tests, it is worthwhile 
considering the applicability of FFR as a gold standard for ischaemia assessment. FFR is 
recognized to be a highly reproducible (26) and well-validated measure of ischaemia (23). 
The original validation, however, was against a number of non-invasive imaging modalities 
with a Bayesian statistical analysis involving a combination of all tests and demonstrating a 
    PhD Thesis: Shazia Hussain 
 140 
sensitivity of FFR in the identification of reversible ischaemia of 88% with a specificity of 
100%. However, a meta- analysis of FFR vs QCA and non-invasive imaging by Christou et al 
demonstrated a sensitivity and specificity of 76% and 76% of FFR compared with non-
invasive imaging (25). Compared to QCA, FFR had a sensitivity of 78% and a specificity of 
51%. The differences between the different tests reflect the differences of the physiological 
measures used. Currently, none of the techniques can be regarded as the diagnostic 
reference standard. 
CMR perfusion is also well validated against microspheres(7, 8), outcome (10, 11) as well as 
in large prospective studies (5, 12-14). In addition, recent work has focused on novel 
methods of quantitative perfusion analysis to improve diagnostic accuracy(4, 20). 
As both investigations have extensive supportive data further work is required to define the 
“gold  standard”  for  the  assessment  of  myocardial  ischaemia. 
 
6.4.3 DISCREPANCY BETWEEN CMR AND FFR RESULTS  
In this study, underestimation by CMR or overestimation by FFR is demonstrated in 33% of 
cases. This is similar to the two studies by Ragosta(144) and Melikian(143) discussed above.  
For   SPECT   and   PET,   the   concept   of   “balanced   ischaemia”   has   been   used   to   explain   this  
underestimation, whereby some patients with 3- vessel disease often do not manifest 
perfusion abnormalities in all ischaemic territories or may have normal results due to globally 
reduced flow, which results in no focal perfusion defect (89). 
There   are   a   number   of   reasons  why   the   concept   of   “balanced   ischaemia”  may   not   apply.  
Firstly, it is rare to have physiological 3- vessel disease based on FFR measurements. In the 
current study only two patients had 3- vessel disease based on FFR criteria. In the FAME 
study, it was found that only 14% of the anatomical multivessel population had functional 
multi-vessel disease (145). Secondly, the effect of physiological variables, i.e. length of vessel, 
length and severity of stenosis, area of myocardial bed, means that flow homogeneity in all 
territories is unlikely. Thirdly, the high spatial resolution of CMR means that the differences 
in flow between the three coronary territories and between the endo- and epicardium are 
more easily visualised (4).  
    PhD Thesis: Shazia Hussain 
 141 
Moreover, as alluded to by Ragosta et al(144), it is possible that the stenosis with the 
greatest ischaemia is more evident, leading to visual neglect of subtler perfusion 
abnormalities. In the majority of cases that were underestimated by CMR, the stenosis with 
the lowest FFR was identified correctly.  
As mentioned earlier, concordance of results can also vary according to the FFR value used to 
define a flow-limiting lesion. A cut-off of 0.75was used in line with clinical practice, however 
as the greatest disagreement occurs at values of 0.7-0.8, it is likely that concordance would 
improve using a lower threshold of 0.7. Moreover, the lower concordance demonstrated in 
the LAD territory could be due to the high number of values within the 0.7-0.8 range in this 
territory (46%) compared to only 7% in the CX and RCA territories.  
Any study that compares a non invasive with an invasive technique will be limited by the 
inability to define exact coronary territories by the 17 segment AHA model. Overlap of 
segments between the coronary arteries may lead to mis-assignment thus affecting 
concordance. Additionally in 2- vessel disease, depending on the functional severity of one 
stenosis compared with the other, it may be difficult to separate out two small areas of 
ischaemia from one larger more confluent area, again affecting concordance.  
Furthermore, FFR may overestimate CAD. There are many physiological variables that can 
affect FFR measurement i.e. presence of scar, collaterals, FFR in small diameter vessels, 
microvascular dysfunction etc. and these are more likely to be present in patients that have 
extensive CAD such as our patient population.  
While in general FFR is normalised for the perfusion area subtended by the interrogated 
vessel, a positive FFR in a small vessel may only lead to a small amount of myocardial 
ischaemia not detectable by CMR. Therefore, FFR may identify a greater amount of diseased 
vessels than ischaemic territories visualised on CMR.  
In the data presented in this chapter, the prevalence of myocardial scar was low. However, 
the presence of scar does result in a perfusion defect, although the FFR should again be 
normalised to the smaller perfusion territory subtended by the vessel. Given that collateral 
contribution is also incorporated in FFR (as it is with CMR perfusion) this is also unlikely to be 
a source of discrepancy.  
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In a different population of patients, the presence of microvascular disease could result in 
positive CMR result in the presence of a negative FFR(80). Severe endothelial dysfunction can 
also result in myocardial defects on SPECT in some patients (e.g. diabetic) who have no 
significant epicardial stenosis(146).  
 
6.4.4 REVASCULARISATION IN MULTIVESSEL DISEASE- CLINICAL IMPLICATIONS 
CMR has practical advantages including its non-invasive nature, independency from ionizing 
radiation   and   applicability   in   all   lesion   subsets   including   chronic   total   occlusions   (CTO’s),  
calcified lesions, and severely tortuous lesions, in which FFR assessment is difficult.  
 
6.5 CONCLUSION 
This study shows that CMR demonstrates reasonable concordance with FFR for the 
identification of perfusion defects in multi-vessel disease. However, some discrepancies 
remain. There is a general tendency that CMR perfusion shows fewer diseased vessels than 
FFR. At this stage it is unclear whether CMR underestimates or FFR overestimates the 
number of ischaemic segments in multi-vessel disease. 
 
6.6 LIMITATIONS 
The main limitation of this study is the use of qualitative visual analysis. Quantitative or semi-
quantitative perfusion analyses may further improve concordance and accuracy as recently 
shown in a study comparing visual and semi-quantitative CMR perfusion imaging versus 
invasive angiography in patients with known or suspected CAD (147). We have used visual 
analysis for the identification of perfusion defects as this is more applicable to clinical 
practice and our goal was the determination of similarities and differences between two 
clinically used tests. 
Consistent with clinical practice, FFR was only measured in vessels in which there was a visual 
stenosis, which may lead to the unlikely situation of missing a positive FFR. Similarly, FFR was 
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Coronary microvascular disease (CMD) is diagnosed invasively by exclusion in patients with 
signs of myocardial ischaemia and angiographically normal coronary arteries (148). 
However, the non-invasive differentiation of CMD from epicardial CAD remains a diagnostic 
dilemma. Positron emission tomography (PET), SPECT, CMR and echocardiography provide 
useful information on the presence of myocardial ischaemia. This is not sufficient however 
to differentiate reliably between CMD and multi-vessel CAD including left main (LM) stem 
disease as all these conditions may be characterised by the presence of extensive 
myocardial ischaemia, which on visual and quantitative analysis can have a similar 
appearance (149). Consequently, patients are subjected to the risks of invasive 
angiography to identify or exclude the presence of epicardial CAD and their quality of life 
can be significantly impaired due to frequent hospitalisations for angina and repeated 
catheterisation (150). 
Adenosine-stress first-pass perfusion CMR enables high spatial and temporal resolution 
perfusion data and has the potential to provide complementary information to visual and 
quantitative analysis for the study of coronary pathophysiology by the assessment of the 
spatio-temporal perfusion patterns(4, 151). Perfusion dephasing analysis is a novel strategy 
for the assessment of high spatio-temporal resolution CMR data that can provide new 
insights in the pathophysiological mechanisms underpinning the presence of myocardial 
ischaemia. 
The aim of this study is to test whether perfusion dephasing analysis can provide elements 
for the differential diagnosis of multivessel CAD and CMD, and to compare it with visual 
and quantitative perfusion analysis. 
 
7.2 METHODS 
7.2.1 STUDY POPULATION  
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Patients were retrospectively screened from the registries of clinical CMR scans performed 
between March 2010 and December 2012 at the Department of Cardiovascular Imaging, 
King’s  College  London  and  at  the  Cardiology  Department,  Centro  Hospitalar  de  Vila  Nova  de  
Gaia/Espinho, Portugal, accounting for 4,289 consecutive patients. Patients with previous 
coronary artery bypass grafting, hypertrophic cardiomyopathy, aortic stenosis or other 
primary myocardial or valvular disease were excluded. A total of 1,394 patients underwent 
CMR in the enrolment period (figure 7.1) and 756 were selected due to the presence of 
signs of ischaemia on CMR visual assessment. Results of invasive coronary angiography 
were available for 433 patients of these patients. Twenty-five had angiographically smooth 
coronary arteries and CMD was diagnosed by exclusion. These patients formed the CMD 
Group of the study. 
The remaining 408 subjects were found to have some degree of CAD on angiography, 
ranging from minor lesions to three-vessel disease or LM disease. In the group of patients 
with angiographically 2- or 3-vessel CAD, 20 patients had a complete haemodynamic 
assessment   of   all   lesions   ≥50%   stenosis   with   FFR and were found to have at least two 
vessels with haemodynamically relevant  stenosis,  indicated  by  FFR≤0.8.  These  patients,  as  
well   as   7   patients  with   ≥50%   stenosis   on   the   left  main   stem  were   enrolled   to   form   the  
Multivessel CAD Group. Patients with incomplete functional assessment or patients with 
functional single-vessel disease were excluded from this group.  
A control group including 12 healthy volunteers (Normal Group) recruited via university 
email was assessed by CMR using the same protocol used in patients. Exclusion criteria 
from this group were: known cardiac, respiratory, or renal disease or contraindications to 
CMR. 
Moreover, a registry of 64 consecutive patients with known or suspected CAD referred for 
CMR in the inclusion period and who underwent invasive coronary angiography and FFR on 
all coronary stenoses ≥50%  was   also   enrolled   (CAD   Registry  Group).   This   group   included  
patients with one haemodynamically significant coronary artery lesion, no 
haemodynamically significant lesions or only minor degrees of CAD. This study was 
performed in accordance with the standards set by the local ethics committee and all 
participants gave written informed consent. 
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Fig 7.1: Study Flow diagram 
7.2.3 CMR ACQUISITION. 
CMR was performed at 1.5-T (Philips Intera, Philips Medical Systems, Netherlands or 
Siemens Avanto, Siemens, Germany) or 3.0-T (Philips Achieva-TX, Philips Medical Systems) 
using standard acquisition protocols (152). Examinations included adenosine stress and 
rest perfusion, functional and scar imaging.  
Perfusion data were acquired in 3 left ventricular (LV) short-axis views covering 16 standard 
myocardial segments (153) during adenosine-induced hyperaemia over 3 minutes (140 μ
g/kg/min) and 15 min later at rest using 0.075 mmol/kg gadobutrol (Gadovist, Schering, 
Berlin, Germany) at 4 ml/s followed by a 20-ml saline flush. A dual bolus protocol for 
contrast agent injection was used(119).  
Perfusion imaging parameters at 1.5T: (Philips scanner): k-t blast acceleration factor 5, SSFP 
sequence, repetition time/echo time 3.1 ms/1.5 ms, flip angle 50°, 90° saturation pre-
pulse, 100-ms pre-pulse delay, spatial resolution 1.7x1.9x10 mm3; (Siemens scanner) 
gradient echo sequence (turbo fast low-angle shot), repetition time/echo time 1.5/0.99 ms, 
flip angle 12°, 90° saturation pre-pulse, 100-ms pre-pulse delay, spatial resolution 
1.7x2.6x10 mm.  Perfusion imaging parameters at 3T: k-t gradient echo method, repetition 
time/echo time 3.0 ms/1.0 ms, flip angle 15°, 90° saturation prepulse, 120-ms prepulse 
delay, spatial resolution 1.2x1.2x10 mm3.  
Functional data were acquired with steady state free precession cine sequences prescribed 
in short-axis and long-axis of the LV(152). Right and left ventricular volumes and function 
and LV mass were measured according to standard analysis criteria(154).  Late gadolinium 
enhancement (LGE) images were acquired after 15 min after injection of a top up bolus of 
contrast agent performed after rest perfusion imaging to a total dose of gadolinium of 0.2 
mEq/kg of body weight(152). 
 
7.2.4 VISUAL CMR ANALYSIS.  
Two blinded independent readers (NB, AS) visually assessed all CMR images. The scans 
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were judged positive for ischaemia in the presence of a stress-induced perfusion defect, 
defined as a delayed and reduced wash-in of contrast agent covering more than 60° 
circumferentially in the basal or mid slice or more than 90° circumferentially in the apical 
slice. In case of disagreement between the observers, the images were reviewed together, 
and a consensus was reached. Stress and rest scans and LGE images were viewed 
simultaneously, and areas of hypoperfusion were assigned to ventricular segments, using 
the standard 17-segment model, excluding the apex(153). 
7.2.5 QUANTITATIVE PERFUSION ANALYSIS. 
 Quantitative analysis was performed by an expert blinded to all other clinical and invasive 
data. After automated respiratory motion correction and image segmentation(155), 
perfusion was quantified in 16 standard American Heart Association segments(153), 
excluding the apex, by using dedicated ViewForum software (Philips, Netherlands) and the 
Fermi deconvolution method(7). Each cardiac segment was assigned to the appropriate 
perfusion territory, with segment 15 assigned to the dominant coronary artery (defined by 
the observer analysing the angiogram). Myocardial perfusion reserve (MPR) was defined as 
stress perfusion estimate divided by rest perfusion estimate and was calculated for each 
segment and perfusion territory. The average MPR of the 2 lowest scoring segments for 
each perfusion territory was used for further analysis(63).  
7.2.1 PERFUSION DEPHASING ANALYSIS.  
On visual analysis, abnormally perfused myocardium is apparent due to a reduced wash-in 
and the presence of transmural perfusion differences secondary to the increase of 
coronary resistance. (4, 151, 156) Both visual and quantitative perfusion analysis are based 
on the identification of abnormally reduced perfusion and cannot be used to differentiate 
multivessel CAD from CMD, as these both can be associated with extensive and diffusely 
abnormal perfusion patterns (149). 
Different pathophysiological mechanisms however underpin the presence of ischaemia in 
patients with CAD and CMD. CAD is characterised by the presence of flow-limiting stenoses 
in one or more branches of the epicardial coronary arteries. CMD is caused by 
abnormalities in the function and structure of the coronary microcirculation(149). It is 
hypothesised that analysing the spatio-temporal distribution of contrast agent wash-in 
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across the LV wall could hold supplementary disease-specific information to visual and 
quantitative perfusion analysis, thereby allowing the differential diagnosis between 
multivessel CAD and CMD.  
Perfusion dephasing analysis relies on the capability of CMR to acquire dynamic series of 
images with combined high temporal and spatial resolution, visualising the first-pass wash-
in of contrast agent through the myocardium. It is hypothesised that the presence of 
haemodynamically significant multivessel CAD results in a temporally heterogeneous wash 
in of contrast agent in the myocardium due to the different localisation of the lesions in the 
coronary tree and the varied functional severity of the lesions. Conversely, CMD is 
characterised by an unobstructed epicardial flow in combination with a generalised intra-
myocardial dysfunction resulting in a similar ischaemic burden but more homogeneous 
delay of the contrast agent wash-in across the LV myocardium (figure 7.2).  
Figure 7.2: Pathophysiology of ischaemia in multivessel CAD and CMD.  
Myocardial perfusion in a normal subject (left), in a patient with functionally significant 
three-vessel disease (centre) and in a patient with CMD (Upper row). The presence of 
haemodynamically significant multivessel CAD results in a temporally heterogeneous wash 
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in of contrast agent in the myocardium due to the varied localisation of the lesions and 
from the different severity of the stenoses. CMD is characterised by an unobstructed 
epicardial flow and by an intramyocardial delay of perfusion, evident with widespread 
subendocardial ischaemia but more homogeneous temporal distribution of the contrast 
agent across the left ventricular wall. (Lower row) In normal subjects, the upslope of 
myocardial signal intensity during first pass is relatively homogeneous in amplitude (normal 
perfusion dotted line) and temporal distribution (TTP range). In patients with multivessel 
CAD, myocardial perfusion is heterogeneous in absolute values and temporal distribution, 
whereas in patients with CMD myocardial perfusion is reduced in absolute values but 
homogeneous in the temporal direction. 
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Based on the same endo- and epicardial contours used for quantitative analysis a grid of 60 
angular positions located on chords perpendicular to the myocardial centreline was 
generated(157). Transmural SI curves were then extracted for each angular position. To 
accommodate for the noise present in the perfusion CMR series, the extracted SI curves were 
filtered in both the spatial and temporal domain using a binomial filter.  The temporal 
dephasing of LV perfusion was measured as variance or coefficient of variation of the time to 
peak myocardial signal intensity (TTPSI). The variance of TTPSI (VarTTP) is expressed in square 
seconds (s2). The coefficient of variation of the TTPSI is instead represented as a percentage. 
Both indices represent the temporal homogeneity of the TTPSI across the LV myocardium. 
Perfusion-dephasing analysis was performed by an observer blinded to clinical and invasive 
data using an in house programmed software (Labview, v2012SP1, National Instruments 
Corporation, TX, USA), relative to the onset of the main bolus arterial input function measured 
in the basal left ventricular slice. The analysis was repeated twice by the same operator and 
by a different blinded observer in order to measure the intra- and inter-observer variability. 
7.2.2 STATISTICAL ANALYSIS 
The Medcalc software (Medcalc, Belgium) and Analyse-it software (Analyse-it Software 
Limited, United Kingdom) were used. Data are presented as mean ± standard deviation. 
Shapiro-Wilk analysis defined when nonparametric tests were required. Intra- and inter 
observer reproducibility was determined by a coefficient of variation, defined as the ratio of 
the standard deviation of the differences divided by the mean, and by the Bland-Altman plot. 
Paired and independent t tests were used for comparison of paired and unpaired mean data, 
respectively. Receiver-operating characteristic (ROC) analysis determined the accuracy of 
visual and quantitative analysis in predicting the presence of multiple haemodynamically 
significant coronary artery stenoses and was used to compare these methods and perfusion-
dephasing analysis for the differential diagnosis of multivessel CAD and CMD. Optimal cut-offs 
were determined by the best sum of sensitivity and specificity. ROC curves were compared 
using the De Long test. Because three coronary artery territories were examined on per-vessel 
analysis, the intra-class correlation coefficient was calculated to determine the design effect 
and the need to adjust the data for clustering. 
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7.3 RESULTS 
A total of 129 subjects were included in the analysis groups. Baseline data and demographics for the enrolled population of patients and for each 
analysis subgroup are shown in table 7.1. 















Male Gender 90 (70%) 23 (85%) 15 (60%) 46 (71%) 5 (42%) 0.09 
Age 57±13 62±8 58±9 61±9 28±6 <0.001 
Hypertension 60 (47%) 15 (56%) 13 (52%) 32 (49%) 0 (0%) 0.008 
Dyslipideamia 75 (58%) 21 (78%) 8 (32%) 46 (71%) 0 (0%) <0.0001 
Diabetes 20 (16%) 4 (15%) 4 (16%) 12 (18%) 0 (0%) 0.449 
Current Smoker 19 (15%) 3 (11%) 0 (0%) 14 (22%) 2 (17%) 0.07 
Previous MI 18 (14%) 7 (26%) 0 (0%) 11 (21%) 0 (0%) 0.248 
Previous PCI 12 (9%) 2 (7%) 0 (0%) 10 (15%) 0 (0%) 0.08 
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Family history of  CAD 33 (26%) 11 (41%) 2 (8%) 20 (31%) 2 (17%) 0.096 
Body Surface Area (m2) 1.9±0.2 1.8±0.2 1.9±0.3 2±0.2 1.7±0.3 0.005 
 











Vessels FFR measured 107/351 (30%) 47/81 (58%) 0/75 (0%) 60/195 (31%) 
Vessels  FFR≤0.8 69/107 (65%) 45/47 (96%) - 21/60 (37%) 
Vessels FFR>0.8 38/107 (35%) 2/47 (4%) - 39/60 (63%) 
FFR positive vessels 0.6±0.14 0.61±0.14 - 0.57±0.13 
FFR negative vessels 0.9±0.06 0.92±0.10 - 0.9±0.06 
Vessels  with  FFR≤0.8     
LAD 35/107 (33%) 20/27 (74%) - 13/60 (22%) 
RCA 22/107 (21%) 16/27 (59%) - 6/60 (10%) 
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LCX 12/107 (11%) 9/27 (33%) - 2/60 (5%) 
Per-patient analysis 
Vessels FFR measured 1.7±0.7 2.1±0.5 - 1.5±0.7 
No significant CAD 69/117 (45%) 0/27 (0%) 25/25 (100%) 43/65 (66%) 
1-vessel CAD 21/117 (17%) 0/27 (0%) 0 (0%) 21/65 (34%) 
2-vessel CAD 17/117 (15%) 17/27 (63%) 0 (0%) 0/65 (0%) 
3-vessel CAD 3/117 (3%) 3/27 (11%) 0 (0%) 0/65 (0%) 
Left  main  stem  ≥50% 7/117 (6%) 7/27 (26%) 0 (0%) 0/65 (0%) 
 
Patients included in the CMD Group had normal epicardial coronary arteries by study design. Subjects in the Normal Group were not assessed by 
cardiac catheterisation.  
 
7.3.1 CORONARY ANGIOGRAPHY AND FFR 
Table 7.2 reports the angiographic and FFR findings. A total of 117 patients were evaluated with coronary angiography. Sixty-eight patients were 
judged not to have a significant CAD, 22 had functional single-vessel disease, 17 had functional two-vessel disease, 3 subjects had functional three-
vessel  disease  and  7  patients  had  a  ≥50%  stenosis  of  the  LM.  A  total  of  107  vessels  that  showed  a  stenosis  of  ≥50%  were  assessed by FFR. Sixty-nine 
    PhD Thesis: Shazia Hussain 
     157 
lesions  had  FFR≤0.8  (median  0.62),  38  lesions  had  FFR>0.8  (median  0.89). 
 7.3.2 PERFUSION CMR 
Table 7.3 reports the functional CMR and LGE findings. The technical quality of the scans was thought to be adequate for diagnostic purposes on all 
subjects included in the analysis. Detailed results of visual assessment and quantitative perfusion analysis are shown in table 7.4 and table 7.5 














LV EF (%) 78±15 65±7 65±8 59±9 61±6 0.333 
LV EDV (ml/m2) 31±11 71±16 74±8 77±14 92±13 0.260 
LV ESV (ml/m2) 75±16 25±8 26±7 32±12 36±8 0.187 
LV mass (g/m2) 60±17 69±21 72±26 54±11 58±9 <0.001 
RV EF (%) 62±8 61±7 67±7 62±8 64±4 0.151 
RV EDV (ml/m2) 75±16 77±19 67±10 74±15 86±15 0.030 
RV ESV (ml/m2) 29±10 31±10 43±9 32±12 31±7 0.123 
LA (cm2) 23±5 23±3 25±5 23±5 19±2 0.006 
    PhD Thesis: Shazia Hussain 
     158 
RA (cm2) 19±4 21±3 29±3 20±4 16±2 0.004 
LGE +ve patients 19/129 (15%) 7/27 (26%) 0/25 (0%) 11/65 (17%) 0/12 (0%) 0.02 
LGE  
+ve segments 
0.5±1.3 0.8±1.7 0 0.6±1.3 0 0.046 
Perfusion +ve patients 
(visual assessment) 
70/129 (54%) 27/27 (100%) 
25/25 
(100%) 
18/65 (28%) 0/12 (0%) <0.0001 
Perfusion +ve segments 
(visual assessment) 
4.5±5 (28%) 8.4±4(53%) 10±4(63%) 1.2±2(8%) 0 <0.001 
CAD – coronary artery disease; CMD – coronary microvascular disease; LBV- left ventricle; EF ejection fraction; EDV – end diastolic volume; ESV – end systolic 
volume; RV – right ventricle; LA – left atrium; RA – right atrium; LGE – late gadolinium enhancement ; RV – right ventricle; LA – left atrium; RA – right atrium; LGE – 
late gadolinium enhancement. 
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14 129 14 72 39 4 78 (52-93) 65 (55-74) 26(16-41) 95(86-98) 71(60-82) se 0.055 
Per-patient analysis 
 37 129 42 53 28 6 88 (74-95) 65(54-75) 60(48-71) 90(79-96) 
76(69-84) 
se 0.036 
EXCLUDING PATIENTS WITH CORONARY MICROVASCULAR DISEASE 
 CAD (%) n TP TN FP FN %Sensitivity %Specificity %PPV %NPV %Accuracy 
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Table 7.5– Results of perfusion quantitative analysis in predicting functionally significant CAD (FFR≤0.8) in all subjects and after excluding patients with 
coronary microvascular disease. 































42 53 3 6 88 (74-95) 95(84-99) 93(81-98) 90(79-96) 
91(85-
97)se 0.028 
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 37 129 40 53 28 8 83 (69-92) 65 (54-75) 59(46-70) 87(75-94) 
75(66-83) 
se 0.044 
EXCLUDING PATIENTS WITH CORONARY MICROVASCULAR DISEASE 
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7.3.3 PERFUSION VISUAL ASSESSMENT 
On visual assessment, areas of adenosine induced perfusion abnormalities were seen in 70 
patients. According to the study design, all patients included in the Multivessel CAD and CMD 
groups were positive on visual assessment. Eighteen patients in the CAD Registry Group were 
positive. All subjects included in the Normal Control Group were negative to visual analysis. 
Visual assessment allowed an accurate identification of the presence of functionally 
significant CAD defined by FFR (table 7.4). When all 129 enrolled subjects were analysed, the 
sensitivity, specificity and overall diagnostic accuracy were 78%, 66% and 72% on per-vessel 
analysis and 88%, 65% and 76% on per-patient analysis (table 7.4). 
When patients with CMD were excluded from the analysis, the sensitivity, specificity and 
overall diagnostic accuracy of visual assessment were 78%, 88% and 83% (p=0.003) on per-
vessel analysis and 88%, 95% and 91% (p=0.001) on per-patient analysis (n=104, table 7.4). 
7.3.4 QUANTITATIVE PERFUSION ASSESSMENT 
Fermi-deconvolution quantitative perfusion analysis also allowed an accurate identification 
of the presence of functionally significant CAD (table 7.5). The average MPR in the perfusion 
territories classified as positive on invasive assessment was 1.3±0.5. In the remaining 
territories MPR was 2.1±0.8 (p<0.0001).  
The sensitivity, specificity and diagnostic accuracy of quantitative perfusion analysis for the 
detection of haemodynamically significant CAD were 75%, 79% and 82%, respectively on per-
vessel analysis and 83%, 65% and 75%, respectively on per-patient analysis (table 7.5). 
When patients with diagnosis of CMD were excluded from the analysis, the sensitivity, 
specificity and overall diagnostic accuracy of quantitative assessment on the remaining 104 
subjects were 76%, 94% and 91% (p=0.003), respectively on per-vessel analysis and 83%, 88% 
and 90% (p=0.005), respectively on per-patient analysis (table 7.5). 





Quantitative perfusion assessment had similar diagnostic accuracy to visual perfusion 
assessment for the diagnosis of CAD on per-patient analysis (p=0.86), while it was 
significantly more accurate on per-vessel analysis (p=0.005). The same results were observed 
also after excluding patients of the CMD group from the analysis (p=0.81 and P=0.001, 
respectively). 
7.3.5 DIFFERENTIAL DIAGNOSIS OF MULTIVESSEL CAD AND CMD 
Visual assessment alone and quantitative analysis did not differentiate multivessel CAD from 
CMD (table 7.6). On average, the visual ischaemic burden was 0.5±1.3 positive segments per 
patient in the whole study population. This value was significantly higher in the Multivessel 
CAD Group (8.4±4 segments per patient; p<0.001) and in the CMD Group (10±4; p<0.001). 
However, no significant differences of the ischaemic burden were seen between the two 
latter groups (n=52; p=0.07). 
On quantitative analysis, the 2 lowest scoring segments had an MPR of 1.1±0.4 in the 
multivessel CAD Group and 1.1±0.5 in patients in the CMD Group. The overall diagnostic 
accuracy of quantitative analysis in differentiating multivessel CAD from CMD was 61% (43-
78%; p=0.09; table 7.6). 
 





Table 7.6 – Differential diagnosis of coronary microvascular disease from multivessel CAD 




















































































































Best cut-off for CMD: * > 12 positive segments; † MPR<1.09; ‡ Average TTPSI>13.9 s; § Variance TTPSI<2.1s2; # Coefficient of variation TTPSI <10. 
PERFUSION DEPHASING ANALYSIS 
The detailed results of perfusion dephasing analysis are shown in figure 7.3 and table 7.6. The average value of TTPSI increased in parallel with the 
extent of the ischaemic burden (p<0.001) and was significantly higher in patients with microvascular disease compared with all other groups 
(p<0.001 vs Normal Group; p<0.001 vs CAD Registry Group; p=0.011 vs Multivessel CAD group). TTPSI was significantly higher in patients with 
Multivessel CAD compared with normals (p=0.036).  
 






Figure 7.3 – Results of perfusion dephasing analysis.  
*   p=0.01   vs   CMD   Group   and   p=0.03   vs   Normal   Group;   †   p<0.001 vs Normal Group and CAD Registry Group; ** p<0.001 vs CMD Group and 
NormalGroup;  p=0.004  vs  CAD  Registry  Group;  ††  p=0.01  vs  CAD  Registry  Group;  ***  p<0.001  vs  CMD  Group;  p=0.01  vs  Normal  Group;  †††  p<0.001 
vs Normal Group and p=0.002 vs CAD Registry Group. 
 





Perfusion-dephasing results correlated instead with the extent and severity of functionally 
significant CAD rather than directly with the ischaemic burden. Patients in the multivessel 
CAD Group had the highest perfusion dephasing (VarTTPmultivesselCAD 6.2±4.3 s2; 
CovTTPmultivesselCAD 17%±8%) while patients with CMD showed very low perfusion dephasing, 
similar to normals (VarTTPCMD 1.8±1.7 s2 vs VarTTPNormals 2.5±1.8 s2; p>0.05) or even lower 
(CovTTPCMD7%±2% vs CovTTPNormals 13%±4%; p<0.001) depending on the index chosen. There 
was a significant difference in VarTTP and CovTTP between the multivessel CAD and CMD 
groups (p<0.001 for both indices), which demonstrates the presence of a significant 
difference in the temporal homogeneity of the LV myocardial perfusion during adenosine 
stress despite the presence of a similar extent and severity of adenosine-induced ischaemia 
on visual and quantitative assessment. 
The VarTTP was 89% accurate in the identification of multivessel CAD from CMD and has a 
significant added diagnostic value to both visual (p=0.0004) and quantitative analysis 
(p=0.007). The CovTTP was 96% accurate (p<0.0001 vs visual assessment and p=0.0003 vs 
quantitative analysis; table 7.6, figure 7.4).  
The coefficient of variation of inter-observer variability was 50% for VarTTP and 14% for 
CovTTP. Intraobserver variability was 35% for VarTTP and 11% for CovTTP.201 










This study was designed to assess the novel concept of perfusion-dephasing analysis for the 
differential diagnosis of multivessel CAD and CMD and significantly adds to the current 
literature in several aspects. 
1) Visual and quantitative assessment of CMR imaging allows an accurate diagnosis of 
functionally significant CAD as determined by FFR. Quantitative perfusion analysis is 
significantly superior to visual assessment for the detection of functionally significant CAD on 
a per-vessel analysis. The presence of patients with microvascular ischaemia however results 
in a number of false positive diagnoses against FFR, as ischaemia is found both in patients 
with CAD and with CMD. Visual and quantitative perfusion analysis cannot reliably 
differentiate between multivessel CAD and CMD.  





2) Multivessel CAD and CMD can be accurately distinguished using non-invasive CMR based 
on the novel concept of perfusion dephasing analysis, which analyses the spatio-temporal 
variability in the distribution of myocardial perfusion to the LV myocardium. 
 
Despite the well-defined link between CAD and myocardial ischaemia, a significant 
proportion of patients with angina are found to have normal epicardial coronary arteries. The 
non-invasive identification of these subjects is an important diagnostic dilemma, as CMD can 
present with signs of diffuse myocardial ischaemia similarly to multivessel CAD. The 
differential diagnosis therefore requires an anatomical assessment of the coronary arteries 
and CMD is usually diagnosed by exclusion (148, 149).  
CMD is an important medical problem that remains difficult to diagnose and treat. Its 
prevalence varies amongst published studies, mainly as a result of differences in the 
definition of normal coronary arteries(158) and ranges between 20% in the CASS 
Registry(159)and 50% in the Women Ischaemia Syndrome Evaluation (WISE) Study(160) . 
The prognostic significance of CMD is heavily debated. Data from the CASS Registry failed to 
demonstrate any prognostic implication of a positive ischaemic response in patients with 
normal coronary arteries (159), while in the WISE study the subgroup of women with chest 
pain and abnormal metabolism consistent with inducible myocardial ischaemia showed a 
significantly reduced event-free follow-up, similarly to patients with angiographic CAD(150).  
A systematic review including 1,694 patients with CMD from 16 different studies showed an 
incidence of a combined end-point of myocardial infarction, revascularisation and death of 
1.5% at 5 years(161). There is however agreement in the literature on the deleterious effects 
of CMD on the quality of life of patients. The recurrence of angina is as high as 55% at 5 years 
and it usually results in repeated coronary catheterisation(161) . 
The results of this study confirm that multivessel CAD and CMD are characterised by similar 
extent and severity of the LV ischaemia. This finding explains why non-invasive functional 
tests, based on the detection of the presence of ischaemia, cannot reliably differentiate 





between groups. CMD however is thought to be one of the main factors responsible for the 
low diagnostic yield of coronary angiography (162) and the availability of novel tools for the 
non-invasive stratification of patients would clearly have the potential to significantly 
improve the management of patients. 
Perfusion dephasing analysis is a novel technique of analysis complementary to visual or 
quantitative analysis and is based on a different and novel physiological principle, as it 
measures the spatio-temporal dephasing of LV wall perfusion rather than the presence of 
ischaemia. At the temporal resolution allowed by current CMR techniques (one frame/heart 
beat), normal myocardium has a relatively homogeneous perfusion, both in terms of 
absolute perfusion and temporal synchronisation. Functional multivessel CAD and CMD had a 
significantly larger ischaemic burden compared with patients with functional single-vessel 
disease, and in contrast to patients without significant CAD and normal volunteers, both on 
visual and quantitative assessment. This was reflected by the progressive increase of TTPSI in 
parallel to the extent of the ischaemic burden. When the data were analysed in the temporal 
direction however, only patients with CAD showed an increase of the spatio-temporal 
dephasing of LV perfusion in parallel with the severity of the epicardial CAD. Patients with 
CMD, despite an even slightly higher ischaemic burden in comparison with patients with 
multivessel CAD, did not show any additional temporal heterogeneity of the TTPSI across the 
LV wall in comparison with normal subjects. 
This study has demonstrated that perfusion dephasing analysis adds diagnostic value to both 
visual and quantitative perfusion analysis. We therefore propose an improved diagnostic 
algorithm of CMR, including the analysis of the CovTTP, the most accurate index for perfusion 
dephasing according to our results, for patients with 2 or 3 perfusion territories positive for 
ischaemia (figure 7.5). A CovTTP>10.1% allowed in our population a reliable identification of 
multivessel CAD, importantly with 100% sensitivity and negative predictive value (NPV), 
ensuring that no patients with prognostically relevant multivessel CAD were missed, at the 
cost of 1 undue coronary catheterisation in a patient with normal coronaries. Moreover, one 
patient with functionally single-vessel CAD and visually judged as positive in 2 perfusion 
territories was also identified positive by the perfusion dephasing analysis and, although not 





found to have functional multivessel CAD, the patient was correctly referred for coronary 
angiography. 
Perfusion dephasing analysis has several additional advantages. The inherently better spatio-
temporal resolution of CMR in comparison with other techniques makes perfusion dephasing 
possible regardless of the combination of CMR scanner, field strength and sequence. The 
algorithm is based on the detection of the TTPSI and not on its absolute value, making it very 
robust to signal dyshomogeneities as well as different data acquisition schemes. Moreover, 
perfusion dephasing does not require the administration of a dual bolus of contrast agent as 
performed in our patients to allow for MBF quantification.  
 
7.5 CONCLUSION 
In conclusion, perfusion dephasing analysis, a novel method to measure temporal differences 
of myocardial perfusion, is highly accurate in distinguishing patients with functionally 
significant multivessel CAD from patients with CMD and can easily be added to the current 
diagnostic protocol for perfusion CMR. 
 
7.6 LIMITATIONS 
This study included highly selected populations of patients with multivessel CAD or CMD. 
Perfusion-dephasing analysis will need to be tested on larger, multicentre and less selected 
populations of patients in the future, and the diagnostic criteria identified in this study 
independently validated. 
The CAD registry group was enrolled retrospectively from the registry of CMR scans and FFR 
performed in the enrolment period. Since the indications for FFR were based on clinical 
grounds, a bias in this group towards a higher prevalence of intermediate lesions is likely. 
Conflicting results on the presence of ischaemia in CMD patients are reported in the 
literature(80, 81, 83, 85). However, this study was not designed to address the dilemma of 





the presence or absence of myocardial perfusion abnormalities in the subgroup of patients 
with coronary syndrome X, but solely to provide a tool to differentiate epicardial coronary 
artery disease and CMD in patients with a positive perfusion scan. The subjects enrolled in 
this study in the CMD Group were selected on the basis of positive CMR findings and showed 
a relatively high prevalence of coronary risk factors and LV mass and are thus more likely to 
represent a group of patients with CMD secondary to LVH. Similarly, patients with HCM were 
excluded to avoid the confounding effect of the variable geometry of the LV wall in the 
analysis of perfusion-dephasing data. 
Perfusion-dephasing analysis is not suitable to assess microvascular impairment in cases of 
CMD secondary to obstructive CAD(149).  However, these cases are likely to present with a 
degree of CMD directly dependent on the severity of the epicardial lesions and therefore 
following the spatio-temporal pattern of CAD. In these cases, perfusion-dephasing analysis 
would indicate the need for coronary angiography and missing these patients is therefore 
unlikely. 











Figure 7.5:  Revised diagnostic algorithm for the differential diagnosis of multivessel CAD and 
coronary microvascular dysfunction including the Coefficient of Variation of the Time to Peak 
Signal Intensity (CovTTP). 
The best threshold of 10.1% identified from ROC analysis was used. 





CHAPTER 8. SUMMARY 
8.1 AIMS OF ORIGINAL WORK 
This work was carried out with the main aim of enhancing our understanding of ischaemia 
assessment by CMR and FFR. 
In particular, two areas of comparison between CMR and FFR have been assessed: 
1) Investigating the relationship between the invasive assessment of stenosis severity and 
FFR measurement and ischaemic burden. This involves a novel development of the functional 
jeopardy score to provide a simple method of assessing ischaemic burden with FFR. 
2) To investigate if there is a discrepancy in ischaemia assessment in multivessel disease. A 
novel CMR method to differentiate between multivessel disease and microvascular disease is 
developed and tested.  
In this chapter, the extent to which these aims have been achieved, the limitations, the 
implications for the clinical management of these patients and future research in this area 
will be discussed.  
 
8.2 MEASURES OF ISCHAEMIC BURDEN  
As discussed in the introductory chapters, current guidelines stress the importance of 
physiological assessment of ischaemia for the guidance of revascularisation.  There is 
particular research interest in the measurement of ischaemic burden and its reduction as a 
therapeutic goal. 
This body of work contributes to the notion that the FFR value itself can be used as a marker 
of the extent of ischaemia. This work demonstrates a strong correlation between FFR values 
and the extent of ischaemia with the lower FFR values associated with greater ischaemia. The 
amount of ischaemia demonstrated by CMR reached a peak between FFR values of 0.5 – 0.4. 





Furthermore, the lack of ischaemia demonstrated at FFR values >0.75 does lead one to 
question the benefit of revascularisation in the group with FFR values 0.75 – 0.8. 
In particular, centres that do not have access to advanced imaging techniques such as CMR 
perfusion to guide revascularisation, could use the FFR value itself as an invasive marker 
indicating the extent of ischaemia. Findings from the landmark COURAGE trial have 
questioned the utility of PCI in patients with stable CAD.  It is foreseeable, that in time, 
revascularisation guided by the FFR value itself may be related to prognostic benefit. If so, 
this could result in a shift in management with a reduction in unnecessary stenting 
procedures and the associated risks. 
The limitations of modest numbers, especially in the values with very low FFR (<0.4) are 
acknowledged and it is difficult to know whether these values do actually represent a 
significant decline in ischaemic extent. The findings therefore need to be confirmed with 
larger scale studies and if established are potentially very exciting.  
In chapter 5, the functional jeopardy score is described and it’s potential to assess the extent 
of ischaemia invasively. There are limitations to this score that have been acknowledged, 
namely the significant overestimation when compared to the CMR assessment of ischaemia, 
and there is considerable variability in the estimation of CMR defined ischaemic burden.  
However, its correction by the severity of the FFR value in a weighted jeopardy score again 
lends importance to the FFR value itself as a major variable in the assessment of ischaemia.  
One of the limitation’s precluding the routine use of a jeopardy score is that it is an 
additional step in assessment during the procedure usually in busy catheterisation 
laboratories. More established scores such as the syntax score and the functional syntax 
score still remain in the realm of the research arena. 
Although difficult to argue a true clinical value of the functional jeopardy score, the findings 
of both studies mentioned above do reinforce the concept of lesion location and FFR value as 
important markers of extensive ischaemia and lend weight to the strategy of 
revascularisation targeted to lesions causing the most ischaemia. 





8.3 AREAS OF DISCREPANCY  
Chapters 6 and 7 focused on the areas of discrepancy between the two tests. Although the 
high diagnostic accuracy of CMR has been confirmed in many studies, the accurate 
assessment of patients with multivessel disease is more problematic.  
Chapter 7 highlights that although there is reasonable concordance, CMR does not correctly 
identify all ischaemic territories when compared to FFR. It is unclear whether this is related 
to underestimation by CMR, overestimation by FFR or a combination of both. The question 
then arises, of whether FFR is truly the gold standard especially as FFR was primarily 
validated against non-invasive imaging tests in patients with single vessel disease.  
However, it is apparent from the data that the perfusion defects usually identified are those 
with the lowest FFR value. If, as we have ascertained, it is the lesion with the lowest FFR 
value that causes the most ischaemia then this throws the whole concept of multi-vessel 
revascularisation into the arena of debate. There is an argument, therefore, for reassessing a 
patient’s symptoms and extent of ischaemia after targeted revascularisation to the lesion 
causing the most ischaemia. 
At this stage, it is also important to mention the role of semi- and absolute quantification of 
myocardial perfusion. The CMR analysis used for chapters 4,5 and 6 was qualitative visual 
analysis. Full myocardial quantification was attempted, hence the use of the dual bolus 
method of contrast administration. However, the data was noisy and the quantification 
results did not correspond with the findings on visual analysis. It is difficult to know the exact 
reason for this but it is likely to be due to a combination of reasons. The dual bolus 
administration of contrast is complex and prone to errors. Additionally, with the small 
numbers of study patients, the presence of artefacts in even a small number of patients 
becomes more problematic. Furthermore the comparison with PET(20), the non-invasive 
reference standard had mixed results. Much of this is in contrast to visual analysis of 
perfusion, which is now a routine clinical tool.  There are only a number of clinical situations 
where it is anticipated that quantification will be advantageous although to date data to 
support this are very limited. 





In chapter 7, testing a novel quantitative method requires the comparison with more 
established quantitative measures i.e. Fermi deconvolution and thus the results are 
presented in this chapter.   
Another diagnostic dilemma that is faced by the cardiologist interpreting multiple perfusion 
defects on a CMR scan is the differentiation between multi-vessel and microvascular disease. 
Currently there is no method of non-invasive differentiation of these two pathologies 
resulting in patients with microvascular disease being exposed unnecessarily to the risks of 
coronary angiography. 
The novel concept of perfusion dephasing analysis, which analyses the spatio-temporal 
variability of myocardial perfusion to the LV myocardium, is introduced in chapter 7. The 
demonstration of reduced temporal homogeneity in patients with microvascular dysfunction 
compared to patients with multi-vessel disease could have a significant impact on 
management algorithms.  
This method also appears to be more robust than absolute quantification as it is not limited 
by errors associated with the dual-bolus technique. 
However, there are significant limitations to this retrospective data, with an obvious referral 
bias in those patients referred for catheterisation based on the standard CMR indices for 
perfusion. There is also a selection bias within the CAD group undergoing FFR evaluation as 
not all arteries are interrogated by FFR. 
This concept is novel and therefore does require prospective outcome data in order to assess 
its clinical relevance. However, if its utility is proven, then it is foreseeable that dephasing 
analysis could potentially result in fewer diagnostic angiograms.  At this stage, however, the 
majority of patients with a perfusion defect on CMR perfusion imaging would still be referred 
for coronary angiography. 
 
8.4 AREAS OF FUTURE RESEARCH  





The studies presented in this thesis raise some interesting questions, but firstly the results 
need to be confirmed with larger scale outcome studies.  
As mentioned already, the incorporation of the functional jeopardy score in routine clinical 
practice is unlikely although there maybe a role in randomised clinical trials evaluating new 
therapeutic interventions with definition of the extent of the ischaemic burden as a 
normalising factor. 
The use of the FFR value itself as an important variable in measuring the extent of ischaemia 
requires confirmation with larger scale studies.  It could potentially be of great clinical 
relevance and may aid with decision-making regarding revascularisation in patients with 
multivessel disease, currently there appears to be no data available on which technique is 
best in describing ischaemia, and whether one tool over or under estimates the other in 
predicting the best strategy to guide revascularisation; therefore highlighting the importance 
of further research and larger clinical trials with long term follow-up. However, the low 
prevalence of patients with physiologically significant 3VD makes further research in this area 
challenging. 
The major drawback of the dephasing study is that the data is retrospective and highly 
selected. The best test of this approach would therefore be a prospectively collected data set 
to determine which patients require invasive angiography and would truly test the diagnostic 
algorithm. 
Some of the data used for the studies above is obtained from the MR-INFORM trial, which, 
once completed should provide extensive data to further explore the findings of this thesis. 
The MR-INFORM study however is not powered to test these specific end-points and so 
further outcome studies would be required to test the prognostic implications of some of the 
findings in this thesis.  
No interim analysis is planned and so it is unclear what the final outcome will be. In the event 
of non-inferiority of CMR being demonstrated, CMR will be regarded as an equivalent to FFR 
for ischaemia testing without the inherent risks of an invasive procedure. Although 
establishing equivalence is the aim of the trial, this thesis emphasises the point that the type 





of test used should be according to the clinical situation, and the real role for each modality 
is not in competition, but complementary to each other. 
The results of the ISCHEMIA trial (https://www.ischemiatrial.org) are also eagerly awaited. 
This multinational comparative effectiveness trial aiming to recruit in excess of 8000 patients 
is currently recruiting. In this study, patients with moderate ischaemia on SPECT, stress echo 
or CMR (>12% ischaemia) will be randomised to either coronary angiography and subsequent 
revascularisation or optimal medical therapy. The primary objective of the trial is to see 
whether an invasive or conservative strategy leads to a reduction in the composite end-point 
of cardiovascular death or non-fatal myocardial infarction. This trial will again answer 




In conclusion, the work in this thesis contributes to an enhanced understanding of the 
overlapping roles of two very different methods of ischaemia assessment. 
FFR can be used to estimate ischaemic burden, traditionally the realm of the non-invasive 
imaging test, either directly via the use of the value itself or indirectly via the use of a 
functional jeopardy score. 
CMR can be used to differentiate between microvascular and multivessel disease, previously 
only possible with invasive angiography.  
The increasing use of CMR and the merging of boundaries between these tests can only be 
beneficial for patients provided that there is a good understanding of the differences and 
therefore appropriate referral. 
Results from the on-going large multi-centre trials should further contribute to this area of 
research.
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